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Abstract 
Bone cell differentiation and remodelling are controlled by hormones, growth factors 
and specific transcriptional regulators. This thesis aims to investigate the role of two 
transcription factors, c-Fos/AP-1 and Msx-1/2 in osteoclast and osteoblast differentia- 
tion using in vivo and in vitro approaches. 
c-Fos has been shown previously to be essential for osteoclast differentiation and is 
overexpressed in osteoclasts of Paget's disease. To investigate the role of c-Fos in 
osteoclasts, transgenic mice were generated where c-fos was overexpressed in osteo- 
clasts using the TRAP promoter. Several TRAP-e-josLTR transgenic founders were 
generated which developed severe bone remodelling lesions with eventual tumour for- 
mation. Histological and in situ expression studies showed abundant osteoclasts within 
these lesions which expressed c-Fos, in addition to the anti-apoptotic gene Bel-2. These 
features are reminiscent of Pagetic osteoclasts and suggest that these mice are useful for 
studying bone remodelling disorders. 
The effects of c-Fos on osteoblasts was next investigated in vitro using a well- 
defined inducible expression system. Stable MC3T3-EI osteoblastic subclones ex- 
pressing a tetracycline-regulatable c-fos gene demonstrated that exogenous c-Fos ap- 
peared to augment the proliferation induced by BMP-2, and inhibited BUIP-2-induced 
alkaline phosphatase activity during differentiation. Moreover, ectopic c-Fos expression 
in these cells stimulated apoptosis induced by serum withdrawal and Etoposide. This 
apoptosis was not effectively blocked by the caspase inhibitors Z-VAD-fink and DEVD- 
CHO, but was blocked by the cell cycle dependent kinase (CDK) inhibitor, Roscovitine, 
and ectopic BcI-2 or p2l WAFI. CIPI, SDII expression. These results may provide a novel link 
between growth control and apoptosis in osteoblasts, such that under environmental 
stress, c-Fos may drive cell cycle progression and render the cell susceptible to apopto- 
sis. 
Finally, the regulation of Msx2 by osteotropic factors using two reporter gene con- 
structs was analysed in osteoblastic cells. PTH showed no regulation of Msx2 expres- 
sion, however, small increases were observed with BMPs. The expression of Msx] 
2 
during bone development was also analysed in tissues from Msxl-lacZ transgenic mice. 
LacZ expression was detected in mineralising tissues of the foetus and neonate, but no 
LacZ expression was observed after birth. 
Taken together, these data further delineate the functional roles of these transcrip- 
tion factors in bone development and bone disease. Importantly, these studies provide a 
role for c-Fos in osteoblast apoptosis and osteoclast function, and may serve as a model 
for c-Fos overexpression in Paget's disease. 
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Bone is a dense, specialised form of connective tissue comprised of highly specialised 
cells, mineralised and unmineralised connective tissue matrix, and spaces that include 
the bone marrow cavity, vascular canals, canaliculi, and lacunae. The bony skeleton 
performs a number of fife supporting functions including a physical support, an aid in 
locomotion, protection of vital organs and bone marrow, and a metabolic role as a 
source for mineral ions, Eke calcium and phosphate. In addition, bone helps to maintain 
the blood ion concentration and acts as a reservoir for growth factors, which can be 
released as required by osteoclasts, the bone resorbing cells (Marks and Hermey, 1996). 
The extracellular matrix makes up the major constituent of the skeletal system 
which is primarily composed of collagen fibres, calcium phosphate crystals (hydroXY- 
apatite) and a ground substance made up of proteoglycans, glycoproteins and other 
non-collagenous proteins. In addition, bone consists of several cell types: the morpho- 
logically distinct and specialised bone specific supporting cells (osteoblasts, osteoclasts, 
bone lining cells and osteocytes) responsible for bone metabolic activity and other cel- 
lular components including the nerves and the vascular elements which help to supply 
essential nutrients (reviewed in Marks and Hermey, 1996; Baron, 1999). 
For all its rigidity, adult bone is by no means a permanent and immutable tissue. 
Rather, it is a highly active tissue which remodels and repairs itself throughout life. 
During development and growth, the skeleton is sculpted to produce its shape and size 
by the removal of bone from one site and deposition at another; a process termed mod- 
elling. In contrast, the mature, adult bone regeneration continues with the periodic 
replacement of old bone with new at the same location. This remodelling is a continu- 
ous turnover process, which is tightly regulated and coupled by systemic hormones and 
by local factors which affect osteoblast and osteoclast proliferation and differentiation. 
Furthermore, the structural formation of a bone is a complex, muhi-stage process and 
the sequence of events that give rise to the skeleton must be temporally and spatially 




Thus, skeletal development, growth and horneostasis are all tightly controlled proc- 
esses, defects in which can give rise to skeletal abnormalities and metabolic bone dis- 
eases such as osteoporosis, osteopetrosis, osteosclerosis and Paget's disease. 
1.2 Bone structure 
Anatomically, the skeletal system contains two basic types of bone. There are long 
bones which include the tibia, femur and humerus, and flat bones such as the skull bones 
and the ileum. Furthermore, in the mature skeleton there are two types of bone struc- 
ture that can be observed macroscopically which have structural and functional differ- 
ences, although microscopically they contain the same cells and the same matrix ele- 
ment: 1) cancellous bone (spongy or trabccular) is located in the vertebrae, in the ma- 
jority of the flat bones, and in the ends of the long bones and comprises only 15% of the 
skeleton. This bone is made up of a network of fine interlacing plates and columns, 
called the trabeculae. 2) A larger proportion (85%) of bone is made up of hard, com- 
pact or cortical bone, which is located largely in the shafts of the long bones that sur- 
round the marrow cavities, and in bones of the skull, and performs mainly a mechanical 
and protective function (Baron, 1999). 
Two types of bone, larnellar and woven bone, can also be found according to the 
organisation of collagen fibres. The lamellar, or secondary bone is a form of mature 
bone found in normal cortical bone and cancellous bone after birth. It contains collagen 
fibres, organised into parallel layers or sheets which are uniformly mineralised. The 
lamellae may be arranged concentrically around a central vascular channel forming the 
"Haversian systenf' or the "osteone" (Marks and Hermey, 1996). Prior to the forma- 
tion of lamellar bone, primary, immature woven bone is produced such as during the 
formation of the embryonic skeleton and in a fracture callus. The collagen fibrils in 
woven bone interweave in all spatial directions, with irregular mineralisation. This type 
of bone is also found in pathological situations such as fracture healing, Paget's disease 
and osteogenesis imperfecta. Woven bone is remodelled and replaced by the lamellar 
bone to form mature bone. 
External examination of a long bone shows two outer extremities (the epiphyses), 
an almost cylindrical tube in the middle (the midshaft or diaphysis), and a developmental 
14 
1. Introduction 
zone between them (the metaphysis). In a growing long bone, the epiphysis and the 
metaphysis, are separated by a layer of cartilage, the epiphysial cartilage or the 'growth 
plate' which is comprised of proliferative chondrocytes; and cartilage matrix and is re- 
sponsible for the longitudinal growth of bones. Finally, the bone surfaces at the epiphy- 
ses that help to make up the joint are covered with a layer of articular cartilage that does 
not calcify (Baron, 1999). The layer of cells that surround the bone, the periosteum, 
covers the entire outer surface except for the synovial joints. The periosteum consists 
of an inner osteogenic layer of osteoprogenitor cells which is important for appositional 
bone formation, and a dense fibrous outer layer. Similarly, the internal surface (the 
endosteum) is lined with layers of osteogenic cells (Baron, 1999). 
The bone extracellular matrix is composed of organic matrix which is synthesised 
locally by bone cells, consisting mainly of collagen and noncollagenous proteins such as 
osteocalcin and bone sialoprotein, various inorganic salts, primarily hydroxyapatite, and 
cellular material and water. Type I collagen is the most abundant organic component 
which accounts for approximately 90% of total bone protein. Whereas, the noncollage- 
nous proteins account for 10-15% of the total bone protein content and are thought to 
lend the unique properties to bone tissue. Most of these proteins are synthesised by 
osteoblasts, such as osteocalcin, osteopontin, bone sialoprotein and osteonectin (see 
section 1.3.2) (for review, see Tem-dne and Gehron Robey, 1996; Gehron Robey, 1996; 
Duey and Karsenty, 1996). 
1.3 The cells of bone 
Bone formation, remodelling, repair and mineral homeostasis are carried out by the co- 
ordinated actions of a number of specialised cells found in bone. Both during embry- 
onic development and in the maintenance of bone structure of the adult, these events are 
dependent on the tightly regulated differentiation, function and interaction of these cell 
types. Three major cell types contribute to the skeleton: osteoclasts which resorb bone, 
osteoblasts which form the bone matrix and chondroblasts which form cartilage. In 
addition, there are osteocytes and bone lining cells, and also cells of the mono- 
cyte/macrophage lineage. The cells of the osteoclast and osteoblast lineages are de- 
scribed in more detail below. 
15 
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1.3.1 Osteoclasts and bone resorption 
Osteoclasts are large, multinucleated cells derived from the fusion of mononuclear hae- 
matopoietic precursor cells belonging to the monocyte/macrophage lineage (Udagawa 
et al, 1990; Chambers et al, 1993; Kurihara et al, 1990; Hattersley et al, 1991; reviewed 
by Roodman, 1996). Early studies showed that injection of normal spleen cells into 
osteopetrotic mice rescued this phenotype which was characterised by increased bone 
mass that, by definition, is caused by osteoclast dysfimction (Walker et al, 1973). Os- 
teoclast precursors are recruited to the bone via circulating blood, where they prolifer- 
ate and differentiate into osteoclasts through cell-to-cell interaction with osteoblastic 
stromal cells. Early myeloid precursors can differentiate along the osteoclastic lineage 
or the macrophage lineage and have a high proliferative potential. Commitment to the 
osteoclast lineage results in osteoclasts gradually losing their proliferative capacity. As 
the mononuclear cells proceed down the osteoclast lineage, they become further differ- 
entiated and eventually fuse to form immature osteoclasts. This is followed by activa- 
tion where osteoclasts polarise on bone and in doing so form a ruffled membrane, 
whereby they resorb bone (Suda et al, 1996) (Figure 1.1). 
Osteoclasts are highly motile cells and are usually rare in bone with only two to 
three per ýLn?, where they can be located on most bone surfaces including endosteal 
bone, within the Haversian system, on trabecular bone, and occasionally on the perios- 
teat surface beneath the periosteum. Osteoclast number increases at sites of active bone 
turnover, such as the metaphysis of growing bone or in pathological situations, includ- 
ing Paget's disease, osteoporosis, and hypercalcaemia of malignancy (Roodman, 1996). 
Osteoclasts can possess up to 100 nuclei per cell, but tend to contain between 10 
and 20 per cell, which are often highly variable in shape (Roodman, 1996). An ultra- 
structural feature of the osteoclast is its ruffled border. This is adjacent to the bone 
surface and is surrounded by the filamentous actin-rich sealing zone, the latter attaching 
tightly to the bone surface via integrins. Resorption and degradation of mineralised 
bone matrix occur beneath the ruffled border due to the release of proteolytic enzymes 
and hydrogen ions across the ruffled border into the sealing zone. Osteoclasts transport 
resorbed material through their cytoplasm to the extracellular environment, where it is 
removed by macrophages (reviewed in Boyce et al, 1999). Osteoclasts can be identified 
16 
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by their phenotypic markers which include calcitonin receptors, band 5 isozyme of tar- 
trate resistant acid phosphatase (TRAP), cathepsin K, carbonic anhydrase 11, and the 
integrin(X, P3 (Suda el al, 1996). 
RANKL 
MITF avP Cathepsin K 
Pu. 1 WCSF c-Fos C-Sf r, CA 11 
NFKBIr2 TRAM H4. -ATPase 





B- and T-cells 
Gramlocytes 
Figure 1.1 - Factors regulating osteoclast differentiation and function. Line- 
age diagram showing the basic stages of osteoclast differentiation from myeloid precur- 
sor to polarised, functional osteoclast capable of resorbing bone. The positioning of 
factors known to control this sequence of events, such as PU. 1, M-CSF, RANKL, and 
c-Fos, are based on gene knockout studies (see section 1.3.1.1 for details). (Adapted 
from Teitelbaum, 2000). 
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1.3.1.1 Factors regulating osteoclast differentiation and function 
Osteoclast proliferation, differentiation and activity are regulated by transcription fac- 
tors, local cytokines and systemic hormones. Over recent years, several mouse knock- 
out genetic studies into the phenotype of osteopetrotic mice have revealed a genetic 
cascade of signalling molecules regulating different stages of osteoclastogenesis and 
osteoclast function (Figure 1.1). These molecules include the transcription factors 
PUA, c-Fos, nuclear factor icB (NF-icB) and N (microphthalmia), as well as the cyto- 
kine M-CSF and the tyrosine kinase c-Src (Tondravi et al, 1997; Grigoriadis et al, 
1994; Franzoso et al, 1997; Iotsova et al, 1997; Hodgkinson et al, 1993; Yoshida et al, 
1990; Wiktor-Jedrzejczak et al, 1990; Soriano et al, 1991; reviewed by Suda et al, 
1996; discussed below). Also, two very important regulators of osteoclastogenesis, 
RANK (receptor activator of NF-icB) ligand (RANKL) and osteoprotegerin (OPG), 
have been found recently, and act in antagonistic mode to regulate bone resorption (Si- 
monet et al, 1997; Tsuda et at, 1997; Lacey et al, 1998; Yasuda et al, 1998; Hofbauer 
et al, 2000; see below and Figure 1.3). 
Of particular interest for this thesis, osteoclast commitment and differentiation are 
dependent on the expression of c-Fos, since c-Fos deficient mice show an early arrest in 
osteoclast differentiation and have increased numbers of macrophages (Wang et al, 
1992; Johnson et al, 1992; also see section 1.6.3 below). Interestingly, the osteope- 
trotic phenotype in c-Fos knockout mice can be rescued by marrow transplantation as 
well as other Fos proteins, but most efficiently by Fra-l (Grigoriadis et al, 1994; Ma- 
tsuo et al, 2000; Fleischmann et al, 2000). Fra-1, although dispensable for osteoclast 
differentiation, enhances the differentiation of osteoclasts in vitro (Owens et al, 1999; 
Matsuo, et al, 2000; Schreiber et al, 2000; Jochurn et al, 2000; reviewed by Jochurn et 
al, 2001). Furthermore, RANK activation by RANKL results in increased expression of 
c-Fos, and has been shown to stimulate Fra-l expression in osteoclast precursors in a 
process dependent on c-Fos (Matsuo et al, 2000). This suggests that Fra-1 is located 
downstream of c-Fos in the genetic cascade controlling osteoclast differentiation. With 
regard to other AP- I family members, macrophages which over-express a mutated form 
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of c-jun that cannot be activated by the kinase JNK, also show a block in osteoclasto- 
genesis (David et al, 1999). 
Similar to c-Fos, mouse knockouts of both the p5O and p52 subunits of the tran- 
scription factor NF-1cB are also osteopetrotic due to the absence of osteoclasts (lotsova 
et al, 1997). Mice with natural heterozygous mutations at the microphthalmia. locus 
(milmi) develop osteopetrosis, because they fail to form multinucleated osteoclasts, a 
ruffled border and are defective in bone resorption (Hodgkinson et al, 1993). The Ets 
family transcription factor, PU. I is indispensable for the development of all myeloid 
cells since mice deficient in PUA lack both macrophages and osteoclasts (Tondravi et 
al, 1997). The oplop osteopetrosis mouse model is deficient in osteoclasts as a result of 
a lack of circulating macrophage colony stimulatory factor (M-CSF) produced by stro- 
mal. cells. M-CSF promotes osteoclast proliferation, differentiation, migration, cherno- 
taxis and survival (Wiktor-Jedrzejczak et al, 1990; Yoshida et al, 1990; Lagasse and 
Weissman, 1997; reviewed by Suda et al, 1996). In addition, the non-receptor tyrosine 
kinase c-Src has been shown to have a role in ruffled border formation since osteoclasts 
from these c-Src knockout mice are incapable of resorption (Lowe et al, 1993; Boyce et 
al, 1992). 
The recent discovery of the RANKL (also referred to as OPGL, TRANCE, ODF) 
and OPG families of osteoclast regulating factors has opened up a new era of molecular 
mechanism of the paracrine control of osteoclast development and function. OPG was 
found to be identical to osteoclastogenesis inhibitory factor (OCIF) cloned by Tsuda et 
al (1997) and is a soluble decoy receptor for RANKL. Targeted over-expression of 
Opg under the control of a fiver-specific promoter in transgenic mice, resulted in an 
osteopetrotic phenotype owing to the arrest of terminal osteoclast differentiation. In 
contrast, targeted deletion of the Opg gene in mice leads to severe osteoporosis caused 
by increased number of functional osteoclasts (Bucay et al, 1998). 
The figand for OPG was later discovered revealing the molecular mechanism of 
OPG activity. The OPG ligand (OPGL/ODF) was found to be identical to RANKL, a 
TNF-fike molecule, shown to bind the transmembrane receptor RANK. Similarly 
RANKL was also identified and termed TNF-related activation-induced cytokine 
(TRANCE) and osteoclast differentiation factor (ODF) by other groups (Yasuda et A 
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1998; Wong et al, 1997). RANKL, synthesised by osteoblasts and stromal cells, is 
found in both soluble and transmembrane forms. RANKL, in conjunction with M-CSF, 
acts as a potent activator of osteoclasto genesis and of osteoclast function and survival 
in vivo and in vitro, and bypasses the need for stromal cells and 1,25-(OH)2D3 to induce 
osteoclast differentiation (Lacey et al, 1998; Yasuda et al, 1998; Quinn et al, 1998; 
Fuller et al, 1998; Burgess et al, 1999; Lacey et al, 2000). Moreover, injection of the 
soluble form of RANKL into mice leads to a significant increase in bone resorption 
(Lacey et al, 1998). As expected, RANKL knockout mice lack functional osteoclasts 
and develop severe osteopetrosis (Kong et al, 1999). Thus, the secretion of RANKL by 
activated T cells is thought to act as a systemic activator of bone resorption, leading to 
initiation of osteoclastogenesis and subsequent bone loss and joint destruction in autom 
imrnune disorders (Kong et al, 1999). 
Mice deficient in RANK, the receptor for RANKL, are devoid of osteoclasts and 
develop severe osteopetrosis (Dougall et al, 1999), and interestingly, an activating mu- 
tation in the human RANK gene has been found in patients with familial expansile oste- 
olysis, a condition characterised. by increased bone resorption (Hughes et al, 2000). 
1.3.2 The osteoblast, functions and origin 
Osteoblasts are the cells which not only produce bone but also act as central co- 
ordinators to maintain bone metabolism (Karsenty, 2000). Osteoblasts are mononu- 
clear, cuboidal, post-mitotic cells found in contact with the bone surfaces (reviewed by 
Lian, 1999). Osteoblasts are polarised and have a prominent, well developed Golgi 
apparatus and rough endoplasmic reticulum, which indicates high metabolic activity, 
predominantly for the production of new bone matrix or osteoid. This osteoid is subse- 
quently calcified by the process of mineralisation. Osteoblasts express high alkaline 
phosphatase activity and synthesise bone matrix proteins such as osteopontin, bone 
sialoprotein (BSP), and most predominantly osteocalcin, which is the only osteoblast- 
specific gene identified to date (Figure 1.2). Osteopontin expression appears earlier than 
many other matrix proteins including BSP and osteocalcin. During this stage of differ- 
entiation the expression pattern correlates with the ordered deposition of hydroxyapa- 
tite, and leads to the increased expression of other genes such as BSP and osteocalcin. 
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However, in the late mineralisation phase, alkaline phosphatase, osteopontin and osteo- 
calcin appear to be down-regulated. Osteonecth in contrast, is an osteoblast marker 
that can be detected early in progenitor cells and will continue to be expressed until as 
late as in the osteocyte stage. Characteristically, another marker of the differentiated 
osteoblast phenotype, is the binding of PTH (parathyroid hormone) to the PTH/PTHrp 
receptors and subsequent activation of adenylate cyclase, resulting in increased cAW 
production. Thus, the identification of these proteins in cells is a useful tool to identify 
osteoblasts biochemically (reviewed by Aubin and Liu, 1996). 
Osteoblasts originate from pluripotent mesenchymal stem cells of the bone marrow, 
whereby cells become committed to osteoprogenitor cells then further differentiate into 
mature osteoblasts, bone fining cells or osteocytes (Figure 1.2; Owen, 1970; Frieden- 
stein, 1976; Aubin et al, 1993; Aubin and Liu, 1996; Aubin, 1998). Isolated bone mar- 
row cells give rise to colonies of fibroblastic cells (colony-forming unit-fibroblast [CFU- 
F] or colony-forn-dng cell fibroblast [CFC-F]) that, under different conditions have the 
potential to differentiate into a range of differentiated, connective tissue cell types in- 
cluding muscle, fat, cartilage and bone (e. g., Owen, 1988; Grigoriadis et al, 1988; Ya- 
maguchi and Kahn, 1991; Bennett et al, 1991; Owen, 1985; see review by Triffitt, 
1996). 
Prcosteoblasts He near bone-forming surfaces where active mature osteoblasts are 
synthesising bone and, unlike mature osteoblasts and osteocytes, have a limited capacity 
to proliferate. Levels of alkaline phosphatase are lower in preosteoblasts than in mature 
osteoblasts and they have not yet acquired many of the protein synthesising characteris- 
tics as evidenced by a lack of a developed rough endoplasn-ýc reticulum. An osteoblast 
becomes My mature when it reaches the surface of the bone. Bone lining cells are 
members of the osteoblastic lineage representing a state of terminal differentiation. 
They are flattened cells located on the surface of bone during stages when there is no 
bone deposition or osteoclast resorption occurring (reviewed in Manolagas, 2000). 
Osteoblasts that have become terminally differentiated and encased in their own pro- 
duction of matrix, that has been calcified, are known as osteocytes. Osteocytes reside in 
lacunae and have many long cell processes which form a network of thin canaliculi, 
permeating the entire bone matrix and forming contacts or gap junctions with the cell 
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processes of other osteocytes, bone lining cells and active osteoblasts (reviewed in No- 
ble and Reeve, 2000). Although the function of the osteocytes is debatable, they may 
regulate bone mass, acting as mechanoreceptor-transducers and may signal to osteo- 
clasts to replace bone at the sites of bone which have undergone micro-damage (Noble 
and Reeve, 2000). 
The transition from early progenitors to a fufly-functional matrix synthesising os- 
teoblast is a gradual process controlled by sequential pattern of gene expression (see 
below). The differences in level of expression of osteoblast-associated products and 
different combinations of several of the osteoblast properties is used to characterise cells 
at certain developmental or maturational stages (Figure 1.2). Analysis of osteoblasts in 
vivo or progression of osteoblast differentiation in model systems in vitro, has deter- 
mined the levels of some of these osteoblast products at particular stages (reviewed in 
Aubin and Liu, 1996). Biochemical responses of osteoblasts to systemic hormones and 
growth factors have provided an indication of the osteoblastic potential in some cells. 
At present, there is a lack of early osteoblast stage specific markers, with most of the 
available ones biased towards the more differentiated osteoblast and osteocytes. How- 
ever, certain discrepancies have been found both in vivo and in vitro which may reflect 
the functional and spatial heterogeneity of the osteoblast (Aubin et al, 1993; Stein and 
Lian, 1993; Aubin and Liu, 1996; Aubin, 1998). 
1.3.2.1 Factors regulating osteoblast differentiation 
Although the specific regulatory mechanisms that control the differentiation from osteo- 
progenitor to mature osteoblast have not been defined, the responsiveness to a series of 
known transcription factors, such as Runx2 and growth factors, including BUTs, have 
been demonstrated. Genetic mouse models, either transgenic or knockout mice, have 
been used to determine the role of these factors in osteoblast differentiation. 
Runx2, previously known as PEBP2AI/Osf2/Cbfal, is an essential transcription 
factor for osteoblastic differentiation and bone formation (Ducy et al, 1997; Komori el 
al, 1997; Otto et al, 1997), being the earliest and most specific marker, and thus a mas- 
ter controller in bone formation. Runx2 was found to map to the same location as Ccd 
(Cleidocranial dysplasia; Otto et al, 1997) and is mutated in certain human cases af- 
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fected with CCD (Lee et al, 1997; Mundlos et al, 1997). Of the defects in this condi- 
tion, the defects in skeletal patterning and growth imply that the gene responsible is 
necessary for correct skeletal patterning and growth. Indeed, homozygous Runx2 mu- 
tant mice completely lack osteoblasts, implying that Runx2 is essential for osteoblast 
diffierentiation during embryonic difTerentiation (Komori et al, 1997; Otto et al, 1997). 
Ducy et al (1999) also demonstrated that Runx2 was required for post-natal bone for- 
mation by differentiated osteoblasts and was shown to regulate bone matrix deposition 
and induce the expression of osteohlast-related genes such as osteocalcin and osteopon- 
tin (Ducy et al, 1999). 
The transcription factors that act upstream or downstrearn of Runx2 remain to be 
identified and may not be osteoblast specific (Karsenty, 2000). BMPs enhance expres- 
sion of Runx2 in MC3T3-EI cells (e. g., Ducy et al, 1997; Tsuji et A 1998), whereas 
PTH was reported to suppress expression of Runx2 and of its target gene, collagenase 3 
(Winchester et al, 2000; Hess et al, 2001). Furthermore, several other transcription 
factors such as Hox-a2, Msx2, BapxI, have been shown to regulate Runx2 expression 
(Triboli and Lufkin, 1999; Kanzler et al, 1998). 
Several other transcription factors have been identified as important regulators of 
osteoblast differentiation such as members of the helix-loop-helix (HLH) family of tran- 
scription factors, Twist, Id and Scleraxis (PoUard et al, 1995; Harris et al, 1995; Liu et 
al, 1997; Cseýesi et al, 1995 and Murray et al, 1992). These transcription factors can 
be regulated by osteotropic factors such as l, 25-(0H)2D3,, glucocorticoids, TGF-P and 
BMPs (Kawaguchi et al, 1992; Ogata and Noda, 1991; Ogata, 1993; Liu et al, 1997). 
Additional1y, homeobox proteins such as Dlx5 and Dlx6, and the leucine zipper and zinc 
finger proteins, human X-box binding protein I (h XBP-1) and Egr-I (Krox-24, zif268), 
respectively can affect osteoblast differentiation (Simeone et al, 1994; Clauss et al, 
1993 and McMahon et al, 1990). Moreover, inactivation of the homeobox gene, MSX2, 
causes a severe skeletal phenotype (Satakota et al, 2000; explained in more detail in 
section 1.7.1 below). The expression of the proto-oncogenes c-Myc, c-Jun, c-Fos, and 
related AP-1 family members (e. g AFosB and Fra-1) have been implicated in the regula- 
tion of bone cell function (see section 1.6 below; and reviewed in Stein and Lian, 1995; 




















































Figure 1.2 - Regulation of osteoblast lineage and differentiation. The mor- 
phological characteristics, developmental steps and many of the markers of the differen- 
tiating osteoblast are shown on the left. The factors that induce the differentiation of 
precursors and transcription factors which act as key regulators of bone formation are 
illustrated on the right. See section 1.3.2 for details. Alk Phos: Alkaline phosphatase, 
BSP: Bone sialoprotein. (Adapted from Lian et al, 1999). 
Members of all the major families of growth factors, including BMPs, TGF-P, 
IGFs, Indian hedgehog (Ihh) and the hormones PTH, 1,25-(OH)2D3 and oestrogen have 
been implicated in the control of osteoblast differentiation. Bone morphogenetic pro- 
teins (BMPs) are glycoproteins, which are members of the TGF-P superfamily of 
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growth factors, capable of inducing new bone formation in vivo (Urist et al, 1984; re- 
viewed by Wozney, 1993; Hogan, 1996). BMP: s have been shown to promote cell pro- 
liferation in bone organ cultures (Canalis et al, 1985) and induce ectopic cartilage and 
bone formation at non-skeletal sites (Wozney et al, 1988; Sampath et al, 1990). The 
mechanisms of BM? induction of de novo bone formation are unclear, however BMPs 
are known to act on uncommitted multipotential stem cells to promote their passage 
into the chondrogenic or osteogenic lineage (Yamaguchi et al, 1991; Girable et al, 
1995). Alternatively, the BMPs may stimulate cells already committed to the chondro- 
genic and osteogenic: lineages (Katagiri et al, 1994). Several BMPs have been isolated, 
all of which show structural similarity to TGF-P (Wozney et al, 1998; Celeste et al, 
1990), most of which can individually cause bone morphogenesis (Wang et al, 1988; 
Wozney et al, 1988; Celeste et al, 1990). 
The in vitro response to exogenous BW is dependent on the cell system used and 
is also stage-specific, with suggestions that less differentiated osteoprogenitor cells 
respond to lower concentrations of BMP with greater increases in differentiation (Li et 
al, 1996). In certain pluripotent cell lines, BMTs can induce the cells to differentiate 
down the adipocytic lineages in addition to the osteoblastic and chondrocytic lineages 
depending on the concentration of BMP used (Ahrens et al, 1993, Wang et A 1993, 
Asahina et al, 1996). Mostly, BMPs induce differentiation whilst inhibiting prolifera- 
tion, but a minority of cell types experience accelerated proliferation. Studies on osteo- 
blasts and chondroblast cell lines or primary cultures showed that BMPs can stimulate 
the expression of alkaline phosphatase, and osteocalcin, promote collagen synthesis, 
produce a PTH response, induce the formation of mineralised nodules and indirectly 
induce Runx2 expression (Vukicevic et al, 1989; Sampath et al, 1992; Theis et al, 1992; 
Asahina et al, 1993). Not all BMPs induce an osteoblast phenototype in vitro, for ex- 
ample BMP- 12 and - 13 only induce myoblast differentiation in C2C 12 cells (Inada et al, 
1996). In addition, BMP-2 has been shown to have a stimulatory effect on osteoclast 
differentiation and resorption, although this may occur by indirect stimulation via stro- 
mal cells (Kanatani et al, 1995). 
TGF-P can control the steady state level of osteoblast differentiation in vivo and 
has been shown to inhibit Runx2 expression in cultured osteoblasts (reviewed in Ducy, 
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2000). However, the mechanism of how TGF-P regulates osteoblast differentiation is 
debatable. TGF-P can promote the expression of most differentiated phenotypes, such 
as alkaline phosphatase expression and extracellular matrix synthesis (reviewed in 
Bonewald, 1996), and is also known to stimulate bone formation when injected in vivo 
(Noda and Camilliere, 1989). TGF-P may regulate the further differentiation of corn- 
mitted precursors cells, suggested by its ability to induce cartilage and bone formation 
when it is administered under the periosteum (Joyce et al, 1990), but not in the de novo 
production of bone at non-skeletal sites (Centrella et al, 1994). 
1.3.2.2 Model systems of the osteoblast phenotype and osteogenesis. 
In vitro models of osteogenesis have been developed whereby long-term culture of bone 
marrow stromal cells or calvarial cells in the presence of ascorbic acid and 0- 
glycerophosphate results in the production of mineralised bone-like nodules (e. g., 
Beresford et al, 1993). Nodule formation allows the complete study of the distinct 
stages of proliferation, extracellular matrix development and maturation and finally min- 
eralisation. Primary marrow cell culture also allows the evaluation of gene expression 
related to comn-dtment of stem cells to the osteoblast lineage (reviewed by Aubin et al, 
1998). In addition, a number of osteoblast-like cell lines have been derived from nor- 
mal bone. For example, rat (RCJ) and mouse (MCM-El) calvarial cell lines have been 
shown to develop mineralised nodules and express osteoblast markers sirnilar to osteo- 
blast from primary calvarial cultures (Grigoriadis et al, 1988; Sudo et al, 1983). 
As an alternative to using primary cells, the immortalisation of cells of the osteo- 
blast lineage either by derivation of clonal cell lines from spontaneous tumours or the 
introduction of various adenoviruses have allowed the study of particular stages of os- 
teoblast differentiation. For example, the most widely used osteosarcoma osteoblast- 
like cell lines, UMR-106, ROS 17/2, ROS 17/2.8, SaOS, TE-85, MG-63 demonstrate a 
varied osteoblast phenotype including PTH-responsiveness, expression of osteoblastic 
markers and formation of n-dneralised tissue in vivo (see review by Majeska, 1996). Rat 
calvaria or human bone cells have also been immortalised by transfection with large T 
antigen of SV-40, e. g., RCT-1 or RCT-3 and HOBIT, respectively and also show os- 
teoblastic properties. Similarly the hFOB cell line was derived by inunortalisation of 
26 
1. Introduction 
human fetal bone cells using a temperature sensitive mutant of the SV-40 T antigen and 
selectively supports proliferation or post-proliferative phenotypic gene expression 
(Majeska, 1996). 
1.3.3 Formation of the skeleton and bone remodelling 
The process of bone formation in embryonic development occurs by two different 
mechanisms. Bones of the craniofacial skeleton, as well as clavicles, derive directly 
from intramembranous ossification. Whereas, bones of the axial and appendicular 
skeleton derive from an indirect process of endochondral ossification. 
The process of intramembranous ossification occurs when mesenchymal cells 
within a well polarised region of the embryo differentiate directly into pre-osteoblasts 
and then mature osteoblasts (see section 1.3.2). These cells synthesise a woven bone 
matrix and at the periphery of this bone a population of mesenchymal cells keep differ- 
entiating into precursors of osteoblasts to allow what is known as appositional growth 
of bone. Haernatopoietic bone marrow is formed as blood vessels are incorporated into 
the woven bone; and later this bone is gradually resorbed and replaced in the adult by 
lamellar bone (Baron, 1999). 
The essential difference between endochondral ossification and intramembranous 
ossification, is the presence of a cartilage template, which is best exemplified in long 
bone development. A population of mesenchymal cells, derived from the sclerotome 
and lateral plate mesoderm, first undergo division and differentiation into pre- 
chondroblasts which then mature into chondroblasts capable of secreting collagenous 
matrix (Olsen, 2000). Chondroblasts become chondrocytes as they are embedded 
within the gel-like cartilage matrix, where they continue to grow via interstitial growth. 
The chondrocytes within the cartilage become progressively larger, a process known as 
hypertrophy, after which they die off as the cartilage becomes calcified. 
Following calcification, the cartilage is partially resorbed by selective resorption 
carried out by osteoclasts. Osteoblasts are recruited in to form a collar of woven bone 
by intramembranous ossification in the future mid-shaft area of long bones, under the 
perichondrium, which is then calcified. Selective osteoclastic: resorption allows forma- 
tion of the future haematopoietic bone marrow by facilitating the vascular invasion of 
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both this newly formed bone and the previously avascular embryonic cartilage. A layer 
of woven bone is produced by osteoblasts on top of the cartilaginous remnants, which is 
termed primary spongiosa. Later this woven bone is further resorbed and replaced with 
lamellar bone, reaching the mature state known as the secondary spongiosa (Baron, 
1999). 
1.3.3.1 Bone remodelling 
Bone remodelling in the adult is a turnover mechanism, replacing the old bone with new 
and thus allowing control of mineral homeostasis (Mundy, 1999). It is a complex, dy- 
namic process involving a number of cellular functions controlling the resorption and 
formation of new bone so that bone mass is maintained constant throughout adult life. 
The first remodelling of bone takes place during embryogenesis and is known as the first 
activation-resorption-formation (ARF) sequence. Once the shape of each bone is 
formed during ernbryogenesis and modelled throughout bone growth, the activity of 
osteoblasts and osteoclasts is co-ordinatcd, in a process known as coupling, to ensure 
the maintenance of a mineralised bone matrix in the adult bone. 
Bone remodelling basically consists of two phases: bone resorption by osteoclasts 
followed by formation by osteoblasts, and generally, bone formation only occurs where 
resorption has taken place. As explained above, the signal to resorb bone is received 
and processed by the osteoblast, which then expresses M-CSF and RANKL to recruit 
and stimulate the activity of osteoclasts (Suda, 1999). In the adult bone, osteoblasts 
play a pivotal role in directing both when and where bone resorption will occur and 
require osteoclastic resorption to occur for their activation and subsequent bone forma- 
tion. During the ARF sequence, osteoclasts are recruited to the site of remodelling, and 
become activated to resorb the bone. An intermediate phase between resorption and 
formation, known as the reversal phase, is distinguished by the presence of a cement line 
marking the limit of resorption and acts to cement together the old and the new bone. 
Following the n-dneralisation of new bone some osteoblasts become inactive bone lining 
cells and the bone surface enters a resting phase (Mundy, 1999). 
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1.3.3.2 Factors regulating bone formation and remodelling 
Bone remodelling is regulated by a number of systemic hormones including PTH, 1,25- 
(OH)2D3,, glucocorticoids,, gonadal steroids, and insulin, in addition to regulation at the 
local level by autocrine and paracrine factors (reviewed by Mundy, 1999; Karsenty, 
2000). To achieve the balanced control of bone turnover, the above hormones and 
factors directly affect the proliferation of undifferentiated cells, the recruitment of cells 
and the differentiated function of the cells involved. 
In particular, PTH and 1,25-(011)2D3 are the two principle hormones of the cal- 
ciurn homeostatic system, and maintain this through the stimulation of osteoclast devel- 
opment and regulation of calcium absorption and excretion from the intestine and kid- 
ney, respectively. PTH has a complex effect on bone formation being responsible for 
both the stimulation and inhibition of bone formation, depending on the continuous 
presence of the hormone and its association with IGF-I (Canalis, 1989; Dempster el al, 
1993). 
The effects of PTII are mediated via the activation of transmembrane PTII/PTH 
related protein (PT1IrP) receptor. The PTH receptor type 1 (PTHRI) mediates signal- 
ling in osteoblasts and classical second messenger pathways such as adenylate cyclase 
and phospholipase C. Several studies have shown that the receptor expression is asso- 
ciated with specific stages of differentiation, with greatest levels found in active osteo- 
blasts fining trabecular bone. 
PTH controls the resorption of bone indirectly by stimulating the osteoblast or 
stromal cells to increase the generation of osteoclast precursors and osteoclast matura- 
tion and fusion. PTH also stimulates the production of collagenase and plasminogen 
activator (Otsuka et al, 1984; Cowen et al, 1985; Hamilton et al, 1985), both of which 
are thought to control bone resorption. PTH also functions by mediating ion and amino 
acid transport. In osteoblasts and stromal cells, PTH (and 1,25'(OH)2D3) regulates the 
synthesis of collagen and alkaline phosphatase activity (Canalis et al, 1989; Kream el al, 
1986; Donahue et al, 1988) and various cytokines such as IL-6 and IL- II and adhesion 
molecules (reviewed by Manolagas et al, 1996). Although controversial, PTHRI ex- 
pression has been found in osteoclasts, and direct effects of PTH on osteoclast differen- 
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tiation and resorption have been reported. However, the effects on mature osteoclasts 
may be mediated through cells of osteoblast lineage (reviewed by Roodman, 1996). 
The overall effects of PTH on bone are dependent on the mode of administration, 
which has important therapeutic implications, such as in the treatment of osteoporosis. 
Continuous treatment of PTH in vitro was shown to inhibit collagen synthesis, but in- 
termittent exposure stimulated collagen synthesis via local production of IGF-I and 
hence inhibition of osteoblast apoptosis (Canalis et al, 1989). 
1,25-(OH)2D3 has complex effects on bone formation and osteoclast function. Vi- 
tamin D receptor (VDR) deficient mice develop rickets. Their osteoclast differentiation 
is normal, indicating that 1,25-(011)2D3 is not necessary for osteoclast differentiation in 
vivo (Balsan et al, 1986; Li et al, 1997; Yoshizawa et al, 1997). The effects of 1,25- 
(011)2D3 on osteoblast differentiation is controversial. In VDR deficient mice osteo- 
blast differentiation is normal. V&Ust in vitro treatment of 1,25-(OH)2D3 can inhibit 
osteoblast differentiation and inhibit expression of Runx2, alkaline phosphatase activity 
and collagen synthesis (Ducy et al, 1997). In other studies, 1,25-(OM2D3 induced os- 
teoblast differentiation and stimulated the synthesis of osteocalcin, collagen and alkaline 
phosphatase (Fritsch et al, 1985; Manolagas et al, 1981; Beresford et al, 1984). How- 
ever, the complex response of the osteoblast to 1,25-(OH)2D3 is thought to be due to 
species differences, cell density and the proliferation/differentiation stage of the cells. 
Recently, leptin has been identified as a hormone important in controlling bone re- 
modelling. Leptin is synthesised by adipocytes and acts to signal to the hypothalamus to 
control starvation and adiposity. Interestingly, mice deficient in leptin (oblob) mice or 
its receptor (dbldh) have an increased bone mass (Ducy et al, 2000). Leptin indirectly 
inhibits bone formation through actions on the hypothalamus, to inhibit the mature os- 
teoblasts which have already differentiated, with no effects observed on osteoblast num- 
ber or on osteoclast differentiation or function. This highlights a central regulatory con- 
trol for bone remodelling. 
Local factors, paracrine or autocrine, are also involved in the process of bone re- 
modelling. These are best represented by the growth factors embedded in bone by os- 
teoblasts, which are released to influence these cells at a later time. In addition to fac- 
tors previously described, TGF-P is found in large quantities in bone and can stimulate 
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or inhibit osteoblast proliferation depending on its concentration in vitro and cell density 
(Centrella et al, 1987). TGF-P has been shown to inhibit proliferation and alkaline 
phosphatase production in osteoblastic cell lines in response to PTH (Noda and Rodan 
et al, 1987; Elford et al, 1987). TGF-P has diverse effects on osteoclasts: via the 
stimulation of osteoblasts. TGF-P can reduce osteoclast formation and stimulate apop- 
tosis, and inhibit the effect of TGF-cc which is itself known to promote the proliferation 
of committed osteoclast precursors in combination with EGF (Lorenzo et al, 1986; 
Takahashi et al, 1986); in contrast, the release of TGF-P from osteoblasts, osteoclasts, 
or the bone matrix, can also directly augment osteoclast formation and survival in the 
presence of RANKL (Fuller et al, 2000). Similarly, epidennal growth factor (EGF) has 
been shown to cause proliferation of osteoblasts in vitro (Ng et al, 1983) and various 
prostaglandins secreted by osteoblasts cause differentiation of osteoblastic cells (Hakeda 
et al, 1987). However, both EGF and prostaglandins, are also stimulators of osteoclast 
resorption. In addition, IGF-I and IGF-II which have been shown to stimulate both 
proliferation and differentiation of osteoblasts (Hock et al, 1988). To this end, the ma- 
jority of paracrine and autocrine activity demonstrated by these factors is particularly 
important in the process of controlling osteoblast differentiation. 
Most of the factors known to stimulate osteoclast differentiation, such as PTH, and 
1,2540H)A. prostaglandins, interleukins (IL-1,6,11), leukaemia inhibitory factor 
(LIF), oncostatin M, tumour necrosis factor (TNF)-cc and -0, and TGF-a were always 
thought to do so by binding to receptors on stromal cells or osteoblasts, and to stimu- 
late the release of osteoclast stimulatory factors, rather than directly via receptors on 
osteoclast precursors (reviewed in Suda et al, 1999). The discovery of RANKL and 
previous knowledge with M-CSF provided this signalling link between osteoblast and 
osteoclast. Some of the aforementioned factors mediate their signalling through three 
signal transduction pathways in stromal/osteoblastic cells (Figure 1.3): cAW, gpl30-, 
and 1,25-(OH)2D3-receptor mediated pathways (reviewed in Suda. et al, 1996; Suda et 
al, 1999). Signals mediated by cAMP are transduced by bone resorbing factors such as 
PTH, PGE2, and IL- 1, although the effect of IL- 1 is mediated by a mechanism involving 
PGE2. Cytokines such as IL-I 1, LIF, and oncostatin. M, and a complex of a soluble IL- 
6 receptor (slL-6R) and IL-6, stimulate osteoclast formation through a gp130-mediated 
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signal transduction pathway involving Janus family of tyrosine kinases (JAK) and signal 
transducers and activators of transcription (STAT) family of transcription factors to 
activate cytokine responsive gene transcription (reviewed in Manolagas, 2000). How- 
ever, osteoclasts are produced in gp130-deficient mice possibly as a result of functional 
redundancy (Kawasaki et al, 1997). Osteoclast. formation induced by 1,25-(OH)2D3 is 
independent of the mechanism involving cAM[P and gp130, being mediated through the 
VDR (Suda et al, 1999). 
IL-6 has attracted much attention because of its involvement in several disease 
states characterised by increased bone remodelling and excessive focal or systemic bone 
resorption such as multiple myeloma, post-menopausal osteoporosis, Paget's disease, 
and rheumatoid arthritis. Cytokines and growth factors, such as IL-1, TNF, PDGF, and 
IGF-11 stimulate the production of IL-6 in stromal/osteoblastic cells (reviewed in Ma- 
nolagas, 2000). The excess production of IL-6 is not sufficient to induce osteoclastic 
resorption and the production of sIL-6R is indispensable for IL-6-induced osteoclast 
bone resorption in the above conditions. 
In contrast, factors which show inhibitory effects on osteoclastic development and 
activity and promote osteoclast apoptosis include calcitonin, IL-4, IL-10, IL-18, inter- 
feron-1, TGF-P and nitric oxide. Some evidence suggests that many of these hormones 
and cytokines act indirectly through osteoblasts (reviewed by Roodman, 1996; Suda, 
1997). Oestrogen has also been shown to have an inhibitory effect on osteoclast devel- 
opmcnt which is thought to involve indirect stimulation of osteoclast apoptosis via 
TGF-P (Hughes et al, 1996) and indirectly induces OPG synthesis with a decrease in 
RANK and M-CSF production, possibly through production of IL-1 and TNF-a (re- 






























Figure 1.3 - Factors controlling osteoclast differentiation. Osteotropic factors 
including 1,25-(OH)2D3. PTH and IL- II stimulate osteoclast formation via different 
signalling pathways mediated by VDR, PTH/PTHrP receptor, and gp130, respectively, 
on osteoblasts/stromal cells. Osteoblasts/stromal cells express RANKL in response to 
1,25-(OH)2D3, PTH and IL- 11. Osteoclast progenitors of the monocyte-macrophage 
lineage recognise RANKL on osteoblasts/stromal cells through cell-to-cell interaction, 
then differentiate into osteoclasts. M-CSF produced by osteoblasts/stromal cells is a 
prerequisite for both proliferation and differentiation of osteoclast progenitors. Osteo- 
blasts/stromal cells also synthesise OPG, a process which can be inhibited by osteotropic 
factors, which can antagonise osteoclast formation by competing with RANK for bind- 
ing to RANKL. (Adapted from Suda, 1999). HSC: haernatopoietic stem cell. 
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Furthermore, a lack of hormones such as in the case of oestrogen, can stimulate the 
production and activity of osteoclasts. Oestrogen deficiency after menopause and in 
elderly men and women is associated with the development of osteoporosis and seems 
to be mediated by an increase in cytokines that mediate osteoclast development and 
hihibit apoptosis such as IL-1, IL-6, IL-11, RANKL, M-CSF, PGE-2 and TNF 
(Horowitz, 1993; Rodan and Martin, 2000). 
In addition to the paracrine, autocrine and endocrine signals described above, cell- 
to-cell and cell-matrix interactions are also important for osteoclast development 
through adhesion molecules expressed on cell surface of osteoclast precursors and 
stromal/ostcoblastic cells. Adhesion molecules also facilitate migration of these cells 
from the bone marrow to sites of bone remodelling, cellular polarisation and the initia- 
tion and termination of bone resorption, as well as apoptosis (reviewed by Roodman, 
1996). 
Finally, the inherent mass/architecture of bone is influenced by the changing me- 
chanical enviromnent associated with nonnal function and during skeletal growth and 
development. Bone modelling and remodelling allows bone to adapt to functional load- 
ing without damage and depends on local feedback signalling, known as the 'mechano- 
stat' mechanism, to bone cells at each bone site. 11igh levels of functional load bearing 
results in accumulation of bone tissue. In contrast, reduction of load bearing, for exam- 
ple with prolonged skeletal disuse results in marked osteopenia. The diminished ability 
to maintain bone strength in postmenopausal osteoporosis; despite continued exercise is 
considered to be a failure of the mechanostat mechanism (reviewed by Lanyon and 
Skerry, 2001). Osteoblasts, osteocytes, and lining cells immediately respond to strain 
(and/or one or more of its derivatives such as fluid flow) and influence modelling and 
remodelling by influencing osteoblast proliferation, bone formation and the release of 
osteogenic factors such as those described above. Osteoclasts and their precursors are 
not well located to respond directly to strain in bone tissue, but their activity during 
remodelling is likely to be controUed indirectly osteoblasts, osteocytes, and Uning cells 
(reviewed by Basso and Heersche, 2002). 
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1.4 Cell cycle regulation 
The proliferation of normal cells is controlled by multiple growth-regulatory pathways 
that act together to ensure proper growth regulation. Disruption of normal cell cycle 
control is one of the most frequent alterations in tumour cells, which contributes to 
uncontrolled cell proliferation during turnour development. Tumour cells have to ac- 
quire multiple genetic changes before they display a fully transformed phenotype. Cells 
respond to a variety of extracellular signals, including growth factors, mitogen antago- 
nists and differentiation-inducing factors, which together dictate cellular behaviour, 
including the decision to grow, differentiate, or undergo apoptosis. Cancer cells ignore 
many of these signals due to mutations in genes that control either growth-promoting 
(proto-oncogenes) or growth-inhibitory pathways (tumour-suppressor genes). 
The eukaryotic cell cycle is divided into four phases (reviewed by Sherr and Rob- 
erts, 1995; Figure 1.4). During two of these phases, cells execute the two basic events 
in cell division: generation of a single copy of its genetic material (the synthetic or S 
phase) and partitioning of all the cellular components between two identical daughter 
cells (mitosis or M phase). The two other phases of the cycle - G, and G2 - represent 
'gap'periods, during which cells prepare themselves for the successful completion of the 
S and M phases, respectively. When cells cease proliferation, either due to specific anti- 
mitogenic signals or the absence of proper mitogenic signalling, they exit the cycle and 
enter a non-dividing, quiescent state known as Go. To ensure proper progression 
through the cell cycle, cells have developed a series of checkpoints that prevent them 
from entering into a new phase until they have successfully completed the previous one. 
It is likely that newly divided or quiescent cells must also pass certain checkpoints be- 
fore they can enter the cycle. 
1.4.1 Gene expression and cell cycle control 
Cell cycle progression during the mammalian cell division cycle are controlled by several 
classes of cyclin-dependent kinases (CDKs). The activities of these CDKs are regulated 
by various mechanisms including association with cyclins, phosphoryla- 
tion/dephosphorylation events, as well as association with two families of CDK inhibi- 
tors (CKIs) which prevent activation of the kinases and uncontrolled replication (re- 
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viewed by Muller, 1995; Sherr and Roberts, 1995; Sherr and Roberts, 1999; Figure 
1.4). CDKs are constitutively expressed serine/threonine kinases which phosphorylate 
key substrates to facilitate cell cycle progression by the association with a specific cy- 
clin. For example, CDK4 or CDK6 associate with D-type cyclins and CDK2 associate 
with cyclins E or A. Cyclins function as positive activators of the kinase activity of 
specific CDKs and their levels oscillate throughout the cell cycle: Cyclin D family 
members are expressed in GI phase, cyclin E at GI-S phase, cyclin A in late GI-S phase 
and G2-M phase, and cyclin B in S and G2 phases. The sequential activation, with sub- 
sequcnt inactivation, of these cyclin-CDK complexes governs the progression through 
the cell cycle. 
The classification of CKI families are based on their structure and CDK targets. 
The Cip/Kip (p2l, p27, p57) famfly bind to all Gi-cyclin/CDK complexes, whereas the 
INK4 (p15, p16, p18, pl. 9) family only bind to CDK4 and CDK6 (Sherr and Roberts, 
1995). CKIs play key roles in the response of cells to growth-inhibitory signals, such as 
induction of differentiation, p53 activation (e. g. in response to DNA damage), TGFP 
treatment, contact-inhibition, and senescence (Sherr and Roberts, 1995). 
Cyclin-CDK complexes phosphorylate a number of specific targets, the most well- 
characterised being the retinoblastoma family proteins, pRB, p107 and p130 (Lipinski 
and Jacks, 1999). pRB becomes progressively more phosphorylated as cells progress 
through the G, phase allowing pRB to dissociate from the E2F family members (Figure 
1.4). The active E2F transcription factor is then free to regulate the expression of genes 
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Figure 1.4 - Factors regulating cell cycle progression. The cell cycle is con- 
trolled by several classes of cyclin-dependent kinases (CDKs), which are themselves 
regulated by various mechanisms such as the association with cyclins and the association 
with two farnifies of CDK inhibitors (CKIs): Cip/Kip (p2l, p27, p57) and INK4 (05, 
p 16, p 18, p 19). Cyclin-CDK complexes phosphorylate a number of specific targets, for 
example the retinoblastoma family protein, pRB, which acts as a negative regulator of 
cell growth. pRB becomes phosphorylated as cells progress through the Gi phase 
which leads to E2F dissociation. The active E2F transcription factor then regulates the 
expression of genes required for G, to S phase progression (see section 1.4 for details; 
adapted from Sherr and Roberts, 1995). 
1.5 Apoptosis 
In the past decade, there has been extensive interest in the processes of apoptosis or 
programmed cell death. Apoptosis is a form of cell death in which the dying cell plays 
an active role in its own fate under tightly controlled circumstances (Kerr et al, 1972) 
and is associated with a progressive series of morphological and biochemical changes in 
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the cell. Apoptosis provides a means of eliminating cells that acquire chromosomal 
damage or have dysregulated ceU cycles, thus preventing possible malignant progression 
(for review, see Reed, 2000; Hengartner, 2000; Wyllie, 1996; Hale et al, 1996). 
Morphologically, apoptosis is characterised by chromatin condensation and nuclear 
fragmentation (pyknosis), plasma membrane blebbing, and cell shrinkage. Eventually 
the cell breaks into small membrane-surrounded fragments (apoptotic bodies). These 
are subsequently cleared by phagocytosis by either neighbouring cells or by phagocytes 
without inciting an acute irdlammatory response (reviewed by Savill and Fadok, 2000). 
The mean duration of the histological stages of apoptosis is approximately three hours 
(Bursch et al, 1990). Biochemically, apoptosis can also be characterised by the appear- 
ance of phosphatidyl serine on the cell surface, the cleavage of numerous intracellular 
proteins and DNA digestion at internucleosomal sites producing small double-stranded 
fragments of DNA that are multiples of 180-200 base pairs, identified as a DNA ladder 
pattern using agarose gel electrophoresis (reviewed by Walker and Sikorska, 1997). In 
addition, cells undergoing apoptosis also show elevated levels of cytochrome c in the 
cytosol and a corresponding decrease in the mitochondria (Yang et al, 1997; Offenius et 
al, 1997). 
More recently, apoptosis has been defined as "the process of cell death associated 
with caspase activation or caspase-mediated cell deatW' and presumes that caspases 
represent its final common mechanistic pathway (Hock et al, 2001). In the presence of 
caspase inhibitors or in the total absence of caspases death is delayed (Figure 1.5) and 
this 'Slow cell death' may display many of the above apoptotic morphological features, 
suggesting that nuclear fragmentation, DNA degradation, cell shrinkage, membrane 
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Figure 1.5 -Schematic of the different pathways of cell death. Apoptosis may 
be stimulated by the activation of cell surface death receptors or of mitochondria. The 
activation of decoy death receptors or survival factors such as in serum may inhibit 
these processes. In the absence of the caspase cascade, slow death may results as a 
consequence of cytotoxic stimulus or mitochondrial activation. (Adapted from Hock et 
al, 2001). 
The above criteria distinguish apoptotic cefl death from necrosis, which is ceU death 
that occurs usually in response to physical injury. Necrosis is characterised by swelling 
of the cells and breaking of their plasma membranes to release proinflammatory material 
from the cell interior into the extracellular space. At the tissue level necrosis triggers an 
inflanunatory response and may be an ultrafast process activated within hours, before the 
onset of any caspase activity. 
Apoptosis plays critical roles in a wide variety of physiological processes during 
development including embryogenesis, organogenesis, and tissue morphogenesis (Meier 
et al, 2000) and in adult tissue homeostasis, including that of bone. Apoptosis needs to 
be tightly regulated, otherwise various diseases evolve because of hyperactivation of 
apoptosis (impaired development, neurodegenerative diseases, immunodeficiency, is- 
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chaemia-reperfusion injury) or suppression of apoptosis (cancer, autoimmune disor- 
ders) (Reed, 2000). 
The regulation of apoptosis is extremely complex involving a large number of gene 
products which act through various different pathways. Factors which induce apoptosis 
include hormones such as glucocorticoids, growth factor withdrawal, cytokines and 
growth factors such as TGF-P, chernotherapeutics, free radicals, oncoproteins and tu- 
mour suppressor proteins (e. g., c-Myc and p53), pro-apoptotic Bcl-2 family members 
and cysteine proteases. In addition the pathways may be inhibited by certain growth 
factors (e. g., IGF-I), most interleukins, NF-icB, anti-apoptotic Bcl-2 family members, 
cysteine protease inhibitors (e. g., ICE inhibitors, pox viral protein CrmA), calcium 
channel antagonists, viral proteins (e. g., adenovirus EIB) and calpain inhibitors (for 
review, see Hale et al, 1996; White, 1996). 
Apoptosis may occur through one or more key pathways; the two most common 
are the mitochondria-activated pathway, resulting in the release of cytochrome c from 
the n-dtochondria (Figure 1.6; see section 1.5.3), and the activation of one of niany death 
receptors, such as the TNF receptor superfamily, leading to the activation of a parallel 
apoptotic cascade (Figure 1.7; see section 1.5.4). Pro-apoptotic agents such as growth 
factor withdrawal, the activation of p53, irradiation, activated oxygen, and cytotoxic 
drugs induce their effects through the mitochondrial pathway (reviewed in Green and 
Reed, 1998; Wang, 2001). 
1.5.1 Caspases 
The morphological and biochen-dcal changes associated with apoptosis are caused by 
caspases, which are a family of intracellular cysteine proteases, that cleave their sub- 
strates at specific sites (reviewed in Eamshaw et al, 1999; Hengartner, 2000). Caspases 
are either involved in the initiation and propagation of apoptosis (e. g., caspase-2, -3, -6, 
-7, -8, -9, and -10; classed as homologues of C elegans, Ced-3) or are involved in 
proteolytic activation (e. g., caspase- 1, -4, -5; caspases related to caspase- I [Interleukin- 
I converting enzyme]). Also, caspases are subclassed as initiators (e. g., caspase-2, -8, - 
9, -10) or effectors or 'executioners' (e. g., caspase-3, -6, -7). Initiator caspases cleave 
and activate the executioner caspases as well as a variety of key proteins to irreversibly 
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alter cell function. For example, they interact with signalling adaptor molecules (e. g., 
FADD) through caspase recruitment domains (CARDs) or through death effector do- 
mains (DED) during death receptor apoptosis (Figure 1.7). The executioner caspases 
target substrates that induce the morphological features and DNA fragmentation of 
apoptosis, such as poly ADP ribose polymerase (PARP) and structural proteins for 
cytoplasmic and nuclear membranes (Earnshaw et al, 1999; Hengartner, 2000). 
1.5.2 Mitochondrial-activated death pathway 
In many tissues, the mitochondrial pathway (Figure 1.6) can be activated directly by 
apoptogens or indirectly by activation of caspase enzymes, such that mitochondrial 
membrane permeability transition is induced and cytochrome c is subsequently released 
(reviewed by Wang, 2001). The Bcl-2 family are important regulators of this process. 
Bcl-2 and its closely related anti-apoptotic homologues, such as Bc1-X, exert control of 
mitochondrial permeability and prevent cytochrome c release. In contrast, the similarly 
structured pro-apoptotic members ofthe Bcl-2 family of proteins, such as Bax and Bak, 
can combine and promote mitochondrial permeability via their direct effects on the mi- 
tochondria or through the inhibition of Bcl-2 (reviewed in Adams and Cory, 1998; Chao 
and Korsmeyer, 1998; Gross et al, 1999; Tsujimoto and Shimizu, 2000). Bax can ho- 
modimerise, as well as form heterodimers with Bcl-2, and the ratio of Bcl-2 to Bax is 
one determinant of the fate of the cell following apoptotic stimulus (Oltvai et al, 1993). 
Once released, cytochrome c interacts with the cytoplasmic adaptor protein Apaf- I 
(apoptosis activating factor) and procaspase-9 to form the apoptosome complex, which 
promotes the processing and cleavage of an initiator caspase, such as procaspase-9 (re- 
viewed by Chinnaiyan, 1999). Caspase-9 then activates caspase-3, a point where this 
pathway converges with the death-receptor pathway (see below). The formation of the 
apoptosome and caspase-3 activation can be blocked by inhibitors of activation of 
caspases (IAPs), such as MAP proteins (Figure 1.6), which themselves may be inhibited 
by the Smac protein (second mitochondrial activator of caspases [SMAC/DIABLOI) 
released from rnitochondria (Hengartner, 2000). 
A third type of Bcl-2 protein, the pro-apoptotic protein BID, provides cross-talk 
and integration between the mitochondrial and death-receptor pathways. BID is 
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cleaved by activated caspase-8 and can promote cytochrome c release (reviewed in 
Hengartner, 2000). Furthermore, pro-apoptotic factors exist, such as apoptosis- 
inducing factor (AIF), that are present in the mitochondria and released upon induction 
of apoptosis via caspase-independent effects, which may be necessary to ensure a swift 
and certain death (Susin et al, 1999; Wang, 200 1). 
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Figure 1.6 - The mitochondrial pathway of apoptosis. The formation of the 
apoptosome is necessary for the activation of procaspase-9 into caspase-9. Multiple 
feedback loops and intervention points exist to control the progression of apoptosis, for 
example Bcl-2 may inhibit the effect of Bax on the mitochondrial membrane. Cross-talk 
between the mitochondrial. and death-receptor pathway is provided by Bid, a pro- 
apoptotic Bcl-2 family member, which causes cytochrome c (cyt c) release from the 
mitochondrial. (Adapted from Hock el al, 2001). 
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1.5.3 Death receptor-activated death 
A parallel pathway of death induction is the activation of at least five different cell death 
receptors, all members of the TNF receptor superfan-ffly (reviewed in Ashkenazi and 
Dixit, 1998). RANK/RANKL/OPG are included in this family of ligands and receptors 
and are emerging as important regulators of apoptosis in skeletal development (Hock el 
al, 2001). The two well characterised pathways are Fas/CD95 and type I TNF receptor 
pathways. For example when bound with TNF, death receptors bind secondary adaptor 
proteins such as FADD (Fas-associated death domain) via interactions with their cyto- 
plasmic death domain (1313). This complex may cleave and activate one or more initia- 
tor procaspases (caspase-8 and caspase-10), which, in turn, cleave and activate execu- 
tioner caspases (reviewed by Reed, 2000). 
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Figure 1.7 - The death-receptor pathway of apoptosis. The binding of ligands 
of the death-receptor superfamily, such as TNF, induce receptor clustering and forma- 
tion of a death-inducing signalling complex. This recruits adaptor molecules to the death 
domain (DD), which then binds DED-containing pro-caspases particularly, pro-caspase- 
8 molecules, resulting in caspase-8 activation. This pathway may be blocked before 
ligand receptor binding by a decoy receptor or during intracellular steps by pathways 
activated to ensure cell survival. (Adapted from Hock et al, 2001). 
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1.5.4 Cell proliferation and apoptosis 
Recent evidence has clearly demonstrated a link between growth and cell death. Many 
oncogenes and growth factors, such as c-Myc, E2F-1, and EIA, can induce prolifera- 
tion and promote cellular survival, but can also induce growth arrest and apoptosis (re- 
viewed by Evan and Littlewood, 1998). 
c-myc was one of the first proto-oncogenes found to regulate proliferation but also 
induce apoptosis, such as under conditions of serum deprivation (Evan et al, 1992; 
reviewed by Prendergast, 1999). This apoptosis could be blocked by certain growth 
factors such as IGF-I and PDGF (Harrington et al, 1994). Many mitogenic oncogenes 
such as c-Myc, c-Fos, E2F and EIA activate apoptosis via induction of p53 through 
P19ARF-dependent degradation of MDM2. This in turn leads to p53 stabilisation and 
apoptosis possibly by caspase-9 and Apaf-I activation (Hermeking and Eick, 1994; 
Soengas et al, 1999; reviewed by Blagosklomy, 1999). 
Cells also respond to DNA damage signals by activating cell cycle checkpoints 
which arrest the cell cycle in both G, and G2 phases or by inducing apoptosis (reviewed 
by Rich et al, 2000). p53 has a role in DNA repair, cell cycle arrest, as well as in the 
induction of apoptosis especially for turnour suppression (reviewed by Oren, 1999; 
Vousden, 2000). Indeed, some apoptosis regulatory genes are p53 targets, and these 
include Bax, Fas/CD92, IGF-I receptor and the binding of IGF-BP3, DR5 (a receptor 
for death figand TRAIL) and Bcl-2 (Rich et al, 2000). Also, p53 induces expression of 
MDM2, which escorts P53 from the nucleus and targets it for proteasomal degradation. 
As mentioned above, p53 is also implicated in the cell response to a variety of insults 
that do not involve obvious DNA damage, for example expression oncogenes such as c- 
Myc and EIA (Hermeking and Eick, 1994) and in the presence of chemotherapeutic 
agents (Lowe et al, 1993). 
A number of studies have suggested a fink between cell cycle events and apoptosis 
(Meikrantz and Schlegel, 1995). Various proteins that are involved in cell cycle con- 
trol, such as p53, pRB, Cdc25, Max, c-Myc, E2F-1, and EIA, also regulate the suscep- 
tibility of cells to apoptosis (Evan and Littlewood, 1998). Like mitotic cells, apoptotic 
cells also have condensed chromatin, rounded morphology, and dispersed nuclear mem- 
branes and apoptosis often occurs in proliferating tissues. The phase in the cell cycle 
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susceptible to apoptosis seems to be from late in G, or early S phase. Arrest in Go or 
early G, suppresses apoptosis in response to a range of factors, whereas arrest in G, or 
in S phase can accelerate or potentiate apoptosis (Meikrantz and Schlegel, 1995; King 
and CidlowskL 1995; Evan and Littlewood, 1998). Apoptosis appears to be linked in 
some cases to the aberrations in activity of CDKs (Meikrantz et al, 1994). The rapid 
up-regulation of cdc2 or CDK activity has been shown to be associated with onset of 
apoptosis, including induction of apoptosis following growth-factor withdrawal, TNF- 
cc, granzyme B, Fas, y-irradiation, heat shock and dexamethasone (Levkau et al, 1998; 
Shi et al, 1996; Zhou et al, 1998; Hakem et al, 1999; reviewed by Evan and Littlewood, 
1998). Increased expression of the CDK activator, cdc25A, was also shown to be re- 
quired for c-Myc-induced apoptosis (Galaktionov et al, 1996). In addition, the CKI p2l 
appears to play an important role in protecting cells from apoptosis (Wang and Walsh, 
1996; Lu et al, 1998) and cells or mice deficient in p27 and p57 show increased apopto- 
sis (Hiromura, et al, 1999; Yan et al, 1997). 
1.5.5 Apoptosis in Bone 
Apoptosis is important during embryonic devclopmCnt, skeletal maturation, adult bone 
turnover by modelling and remodelling processes, and during fracture healing and bone 
regeneration (reviewed by Hock el al, 2001). As explained above (section 1.3.3.2) the 
same growth factors and cytokines that stimulate osteoblast and osteoclast development 
can also influence their apoptosis. During bone formation (Jilka et al, 1998; Lynch et 
al, 1998) and fracture healing (Landry et al, 1997), osteoblasts and chondrocytes un- 
dergo a differentiation sequence that ultimately ends in apoptosis. Factors that promote 
osteoclastogenesis such as M-CSF and RANKL, also serve to inhibit the apoptosis of 
mature osteoclasts. Whereas anti-resorptive agents, such as calcitonin and bisphospho- 
nates, are pro-apoptotic for osteoclasts but inhibit osteoblast and osteocyte apoptosis 
(Plotkin et al, 1999; Manolagas, 2000). 
Little is known about the factors that control osteoblast apoptosis or the physio- 
logical importance of this process. Growth factors such as BNV-2, FGF-2 and the 
FGF-2 receptor may act as survival and apoptotic regulators, depending on the state of 
differentiation of the cells, in culture (Hay et al, 2001; Manusukhani et al, 2000). 
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Growth factors, such as IGF-I, IGF-II, FGF2, and PDGF are required for preventing 
osteoblast apoptosis in vitro, although their role in osteoblast apoptosis remains contro- 
versial (Hill et al, 1997; Jilka et al, 1998). TNF-cc and nitric acid induces osteoblast 
apoptosis in vitro (Kitajima et al, 1996; Damoulis and Hauschka, 1997; Jilka et al, 
1998). TNF-a may also have a role in bone cell apoptosis in vivo, since it regulates the 
bone turnover and loss associated with ovariectorny (Kimble et al, 1997), and gluco- 
corticoid and TNF-et-induced apoptosis in osteoblasts can be antagonised by IL-6-type 
cytokines (e. g., IL-6 and leukaemia inhibitory factor) and TGF-P (Jilka et al, 1998; Bel- 
lido et al, 1998). In primary calvaria, cell cultures, inhibitors of caspase-3 can block 
apoptosis (Weinstein et al, 1998) and the overexpression of Bcl-2 reduces glucocorti- 
coid-induced apoptosis (BeUido et al, 1998), supporting the theory that increased os- 
teoblast apoptosis may explain the pathogenesis of glucocorticoid-induced osteoporosis 
(Manolagas, 1999). Furthermore, the administration of PTH in vivo reduces the fre- 
quency of osteoblast apoptosis, possibly by stimulating the expression of FGF-2 and 
IGF-I in preosteoblasts and mature osteoblasts. These in turn induce the expression of 
Bcl-2 and BCI'XL, thereby lengthening the osteoblast's life span and so increasing bone 
formation. This could account for much of the anabolic response of the skeleton to 
exogenous PTH (Jilka et al, 1999; reviewed by Manolagas, 2000; Hock et al, 2001). 
Recent research has suggested that solubilisation of bone mineral during normal 
bone remodelling acts as a stimulus to osteoblast apoptosis. Human bone cells exposed 
to phosphate ions in the culture medium, show a dose-depcndent induction of apoptosis 
attributed to activation of the mitochondrial apoptosis pathway, which could be inhibited 
by inactivation of the plasma membrane sodium-inorganic phosphate transporter (Meliti 
et al, 2000). Furthermore, extracellular calcium sensitises ostcoblasts to the apoptotic 
action of phosphate (Adams et al, 2001) and the anti-apoptotic property of Calbindin- 
D28k has been attributed to inhibition of caspase-3 activity in osteoblast, in addition to its 
ability to chelate calcium (Bellido et al, 2000). Peptide fragments released from the 
extracellular matrix during remodelling may also play a role in apoptosis versus cell 
survival, for example osteonectin, fibronectin and RGD peptides may activate apoptosis 
in osteoblasts (reviewed by Hock et al, 2001). 
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Finally, in humans, increased osteocyte apoptosis, has been correlated with sites of 
rapid bone remodelling and in infant calvaria (Thomkinson et al, 1998; Noble et al, 
1997). Glucocorticoids and oestrogen withdrawal each promote apoptosis in osteo- 
blasts and in osteocytes (Thomkinson et al, 1997; Weinstein et al, 1998; reviewed by 
Manolagas, 2000; Hock et al, 2001). Also, at sites of bone resorption, osteocytes un- 
dergo apoptosis and are phagocytosed by osteoclasts (Bronckers; et al, 1996; Hughes et 
al, 1996). 
1.6 The c-Fos transcription factor and bone cell function 
The c-fos protooncogene has clearly been shown to be one of the most important regu- 
latory genes in normal bone development and in bone disease. The c-Fos protein is a 
component of the AP-1 transcription factor complex that either stimulates or represses 
transcription of target genes by binding to AP-1 sites, leading to the regulation of 
transformation, cell cycle progression, differentiation, and apoptosis, (reviewed in Angel 
and Karin, 1991; Morgan and Curran, 1991; Karin et al, 1997; Liebermann et al, 1998; 
Shaulian and Karin, 2001; Jochurn et al, 2001). The AP-1 complex represents a multi- 
gene family composed of the fos-related (c-fos, fosB, fra- I and fra-2) and jun-related 
(c-jun, jun B and jun D) genes (for review, see Angel and Karin, 199 1; Shaulian and 
Karin, 2001). The AP- I proteins are members of the basic region-leucine zipper (bZIP) 
family of transcription factors which can form homo- and hetero-dimers with each 
other, with activating transcription factors (ATF2, ATFYLRFl, B-ATF), and with Jun 
dimerisation partners (JDPI and JDP2) via their leucine zipper regions (reviewed by 
Angel and Karin, 1991; Chinenov and Kerppola, 2001). Fos proteins can only hetero- 
dimerise with Jun family members, whereas Jun proteins can form homo- or heterodi- 
mers, with Jun, ATF and CREB proteins (Angel and Karin, 1991; Shaulian and Karin, 
2001). More recently, Maf proteins (v-Maf, c-MaO and the neural retina specific gene 
product (Nrl) have also been shown to form heterodimers with c-Jun or c-Fos; whereas 
other Maf related proteins such as MafB, MafF, MafG and MafK only heterodimerise 
with c-Fos (Shaulian and Karin, 2001; Chinenov and Kerppola, 2001). Fos dimers are 
not stable but can bind DNA by forming Fos/Jun complexes which are more stable than 
Jun/Jun complexes (Angel and Karin, 199 1). 
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AP-1 complexes can act as both positive and negative regulators of transcription by 
binding to AM consensus sequences (5'-TGAG/CTCA-'3), which are also known as 
TREs (phorbol 12-0-tetradecanoate- 13 -acetate [TPA] response elements), in the regu- 
latory regions of target genes. However, Jun-ATF dirners or ATF homodimers prefer 
to bind to the cAMEP-responsive element (CRE; 5'-TGACGTCA-3'). Overall, the AP- I 
activity can be modulated at many levels, including differential expression of AP- I pro- 
teins, dirnerisation of partners and protein-protein interactions with other transcription 
factors, in addition to phosphorylation and stabilisation of individual members (reviewed 
by Angel and Karin, 1991; Karin el al, 1997; Shaulian and Karin, 2001; Jochurn et al, 
2001). 
The c-fos gene 
The proto-oncogene c-fos is the normal cellular homologue of the v-fos oncogene, the 
transfom-dng gene originally identified in the FBJ and FBR-murine sarcoma viruses 
(MSV). The FBJ- and FBR-MSVs were isolated from spontaneous and radiation in- 
duced-osteosarcomas, respectively (Finkel et al, 1966; Finkel and Biskis, 1968; for 
review, see Verma and Graham 1987). 
The c- gene is a member of the immediate early gene family, whose transcripts fos 
are rapidly and transiently induced, devoid of de novo protein synthesis, in many differ- 
ent types of cells in response to a wide range of stimuli such as serum, phorbol esters, 
and growth factors (reviewed by Karin, 1997). The c-fos mRNA has a short half-life 
due, in part, to the presence of a 67-basepair sequence in the 3' nontranslated region 
responsible for the rapid degradation of the c-fos mRNA (Meijflnk et al, 1985). Re- 
moval of these sequences has been shown to be important for ensuring high, stable ex- 
pression of c-fos rnRNA and protein in the generation of transgenic animals (Grigori- 
adis, 1993; see section 1.6.4). 
1.6.2 Function of c-Fos 
Despite the early identification of AP-I transcription factors and retroviral homologs of 
some of its components, the biological function of c-fos and other AP-1 family members 
are still being elucidated. The first in vivo indications linking Fos-related proteins to a 
specific biological function in bone came from the initial studies involving the isolation 
48 
1. Introduction 
of the v-fos gene from spontaneous bone turnours in mice and the finding that the v-fos- 
containing FBJ- and FBR-MSVs can induce osteosarcomas following injection into 
rodents (Finkel et al, 1966; Finkel and Biskis, 1968; Ward and Young, 1976). It was 
already known at that time that the over-expression of c-fos was sufficient to induce 
transformation of immortalised rat fibroblasts (NMer et al, 1984). Also the bZIP region 
of v-Fos (and hence that of c-Fos) was shown to be sufficient for immortalisation and 
transformation of chick embryo fibroblasts, and was thought to increase binding of c- 
Jun to the target genes whose activation results in transformation (Jenuwien and Muller, 
1987; Yoshida et al, 1989; reviewed by Shaulian and Karin, 2001). 
In addition, the striking induction of c-fos expression in response to growth factors 
also implicates c-Fos in cell proliferation. However, the studies in c-fos knockout mice 
and ectopic expression of c-fos in vitro and in vivo, demonstrated that c-Fos is not es- 
sential for the viability, proliferation and differentiation of most cell types, with the ex- 
ception of some cells that are involved in bone formation (Dony and Gruss, 1987; 
Ruther et al, 1987 and 1989; Field et al, 1992; Brusselbach et al, 1995; Brown et al, 
1998; reviewed in Kovary and Bravo, 1991; Shaulian and Karin, 2001; Jochurn et al, 
2001). Indeed, AP-1 has been implicated in the control of proliferation for many years 
since its activity is induced upon mitogenic stimulation and various Fos and Jun proteins 
have distinct expression patterns during cell cycle progression (Angel and Karin, 1991; 
Kovary and Bravo, 1991; Lallemand et al, 1997). However, c-Fos is dispensable for 
normal fimction in most cell types, for example fibroblasts and embryonic stem (ES) 
cells lacking c-Fos (from c-fos knockout mice) proliferate normally (Field et A 1992; 
Brusselbach et al, 1995; Shaulian and Karin, 2001; Jochum et al, 2001), indicating no 
growth abnormality. c-Fos is more likely to play a role in growth induction, since mi- 
cro-injection of neutralising antibodies to c-Fos in fibroblasts have shown that c-Fos 
(and Fos B in similar studies) is required for initiation of growth following mitogenic 
signalling, but not the maintenance of proliferation (Kovary and Bravo, 1991). Func- 
tional redundancy may mean that other Fos proteins compensate for the absence of c- 
Fos. Indeed, fibroblasts deficient in both c-Fos and Fos13 show reduced proliferation 
and c-Fost FosB-" mice are about 30 per cent smaller than wild-type litter mates or the 
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corresponding single mutants (Brown et al, 1998; reviewed by Shaulian and Kar4 
200 1; Jochum et al, 200 1). 
The most important evidence regarding the function of c-fos in bone was gained 
from loss-of-function studies, whereby c-fos deficient mice lack osteoclasts and develop 
an osteopetrotic phenotype (Johnson et al, 1992; Wang et al, 1992). Also, c-Fos was 
shown to be important for the oncogenic transformation of osteoblast and chondrocytes 
using gain-of-function studies (Grigoriadis et al, 1993; see 1.6.4 below). 
Evidence suggesting that c-Fos may have a specificity for bone tissue is ftirther 
suggested by studies which demonstrated that, during early embryonic mouse develop- 
ment, c-Fos expression was found in extra-embryonic tissues (Muller et al, 1983), while 
expression during late embryonic development was restricted to the growth regions 
during endochondral ossification of foetal bone (Dony and Gruss, 1987; De Togni et al, 
1988; Sandberg et al, 1988). In adults, c-Fos continued to be expressed in bone, as well 
as in the central nervous system and some haematopoietic cell types, such as macro- 
phages, granulocytes and mast cells (Smeync et al, 1992; for review, see Grigoriadis et 
al, 1993). Interestingly, c-Fos was found to regulate the expression of a number of 
genes which are thought to have distinct roles in bone metabolism and remodelling, for 
example osteocalcin, collagenase, COLIAl and stromelysin (Schule el al, 1990; 
Schonthal et al, 1988; Kerr et al, 1988), further implicating a role for c-Fos in the 
regulation of bone cell function. Furthermore, in certain bone cell culture models, c-fos 
expression is induced by ostcotropic hormones, such as PTH (e. g., Clohisy et al, 1992; 
Kano et al, 1994) and a correlation exists betweenfos- andjun-related gene expression 
and differentiation of primary fetal rat calvarial cells (McCabe et al, 1995; Stein and 
Lian et al, 1993). 
With respect to pathological bone, expression of c-Fos is high in lesions from pa- 
tients with Paget's disease and fibrous dysplasia (Hoyland and Sharpe, 1994; Candeliere 
et al, 1995), and c-fos expression is associated with a number of spontaneous and ra- 
diation-induced murine and human osteosarcomas (Schon et al, 1986; Wu et al, 1990). 
However, these studies do not demonstrate a causal role for c-Fos in these turnours and 
also raise the possibility that high levels of both, the c-Fos transcript and protein, may be 
only a consequence of turnour formation. The specificity of c-Fos-induced bone func- 
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tion and tumourigenesis was only demonstrated with in vivo studies involving transgenic 
and knockout mice (Ruther et al, 1987 and 1989; Johnson et al, 1992; Wang et al, 
1992; Grigoriadis, 1996). These studies have shown c-Fos and other AP-1 components 
(mainly members of the Fos family) have important functions in both osteoclast, osteo- 
blast, and chondrocyte biology (recently reviewed in Shaulian and Karin, 2001; Jochum 
et al, 2001). 
1.6.3 Knockout mice lacking c-fos and the role of c-Fos in osteoclast 
differentiation 
To help address the function of the c-fos gene during embryonic development and post- 
natal biology, loss of function experiments using gene targeting via homologous recom- 
bination in ES cells were used. Mice lacking c-Fos are viable and fertile. However, 
these mice lack osteoclasts resulting in an osteopetrotic phenotype characterised by a 
net increase in bone mass, as well as the absence of tooth eruption (Johnson et al, 1992; 
Wang et al, 1992; Grigoriadis et al, 1994). These results suggested that c-Fos, is dis- 
pensable for embryonic development and osteoblast differentiation, despite the fact that 
osteoblasts are susceptible to oncogenic transformation by c-Fos in vivo (see 1.6.4 be- 
low). c-Fos deficient mice also show abnormalities of the haeniatoPoietic system and 
lymphopenia. These abnormalities were both found to be secondary to the bone phe- 
notype, since subsequent experiments involving transplantation of haernatopoietic stem 
cells into lethally irradiated recipients showed that c-Fos was not necessary for the dif- 
ferentiation and activity of haematopoietic cells (Okada et al, 1994; Jain et al, 1994). 
Using osteoclast markers (TRAP and MMP-9) it was demonstrated that c-Fos- 
deficient mice show a complete lacked of functional, multinucleated osteoclasts and 
their immediate precursors (Grigoriadis et al, 1994). Furthermore, the osteopetrosis 
could be rescued by transplantation of wild-type haernatopoietic stem cells into lethally 
irradiated mutant mice, whereas mutant haernatopoietic progenitors could not form 
osteoclasts in the presence of wild-type osteoblasts. These experiments demonstrated 
that the block in differentiation in c-Fos-deficient mice was intrinsic to the osteoclast 
lineage, rather than the stromal/osteoblastic cells. Furthermore these loss of function 
studies supported the notion that osteoclast and macrophages may share a common 
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progenitor cell and identified a biological function for c-Fos in osteoclast differentiation 
and bone remodelling, and possibly also for osteoclast-macrophage lineage determina- 
tion (reviewed in Grigoriadis et al, 1996). 
Recent research using retroviral gene transfer into c-Fos mutant osteoclast precur- 
sors in vitro and expression of a Fra-1 transgene in vivo have shown that Fra-1 can 
most efficiently, out of all Fos proteins, complement for the absence of c-Fos in osteo- 
clast differentiation (Matsuo et al, 2000). In addition, knock-in mice generated by the 
insertion of thefra-1 gene into the c-fos locus resulted in a total restoration of osteo- 
clast differentiation (Fleischmann et al, 2000). Structure-function analysis also demon- 
strated that the major C-terminal transactivation domains of c-Fos and FosB are dispen- 
sable for the rescue of osteoclast function, although not for Fra-1, which lacks a trans- 
activation domain. In addition, ectopic Fra-1 expression stimulates osteoclast differen- 
tiation both in progenitor cell fines and primary osteoclast progenitors (Matsuo et al, 
2000; Owens et al, 1999); although Fra-1 transgenic mice do not show any osteoclast 
abnormalities (Jochurn et al, 2000). The role of Fra-1 in osteoclast differentiation re- 
mains unclear since osteoclast differentiation does not require the presence of Fra-1 
(Schreiber et al, 2000). However, the osteoclast differentiation factor RANKL induces 
Fra-l expression in a c-Fos dependent way, highlighting the link between RANK signal- 
ling and AM expression during osteoclast differentiation (Matsuo et al, 2000). 
1.6.4 c-Fos specific transformation of osteoblasts and chondroblasts 
To further study c-Fos functions in cell differentiation and development, c-Fos was 
ectopically expressed in transgenic: mice. These mice were shown to develop bone le- 
sions due to the in vivo induction of transformation by c-Fos. Two c-fos transgenic 
mice lines have been generated in which expression of the c-fos gene was under the 
control of either the human metallothionine promoter (hMT) or the promoter region of 
the heavy chain of the major histocompatabiHty complex (MHC) class I antigen, H-2Kb 
(112). In addition, the 3' mRNA destabilising sequences and polyadenylation (polyA) 
site of c-fos were replaced with a 3' LTR from the FBJ-MSV to provide a polyadenyla- 
tion signal for termination of the mRNA molecule and to ensure stability of the c-fos 
mRNA. These constructs were termed Mr-c-fosLTR and H. 2-c-fosLTR, respectively. 
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MT-c-fosLTR mice developed specific lesions in the long bones as early as 2-3 weeks 
after birth. However, only a low frequency of these mice developed osteosarcomas 
after a considerably long latency period of 9-10 months (Ruther et al, 1987; 1989). The 
H2-c-fosLTR transgenic mice induced osteosarcoma formation especially in the areas of 
the distal femur and proximal tibia after 4-6 weeks after birth and were more prevalent 
than osteosarcomas from MT-c-fosLTR (Grigoriadis et al, 1993). By 14 weeks, these 
lesions rapidly developed into large calcified turnours present in virtually all bones of the 
body. Histological analysis of these turnours revealed that they resembled chondroblas- 
tic osteosarcomas and they were highly mineralised, containing large areas of bone lined 
with numerous osteoblastic cells expressing high levels of alkaline phosphatase activity. 
Exogenous c-fos expression occurred between 2-3 weeks of age in calvaria, long bones 
and spine indicating that expression of the transgene in bone tissue occurs post-natally 
and before the initial appearance of bone lesions. Northern blot analysis on tumour 
tissue as well as on unaffected tissues of adult transgenic mice revealed that, as well as 
turnour tissue, the transgene was also expressed at high levels in the heart, lung, brain 
and salivary glands. Furthermore, established cell lines generated from these tumours 
were also shown to express high levels of exogenous c-Fos as well as bone cell marker 
genes. When injected into nude mice, these cell lines were tumourigenic with a latency 
period of 2-5 weeks, some of which gave rise to osteosarcomas, expressing exogenous 
c-fos mRNA and c-Fos protein in osteoblastic cells (Grigoriadis et al, 1993). 
The phenotype of the c-Fos transgenic mice was demonstrated to be specific to c- 
Fos, since transgenic mice overexpressing other AP-1 family members (e. g., Jun or 
FosB) do not develop any abnormalities despite transgene expression in the bone tissue. 
However, if a c-jun transgene was co-expressed in these mice, the c-Fos-induced osteo- 
sarcomas were shown to occur at a higher frequency than single c-Fos transgenic mice, 
although there was no difference in the time of onset of turnour formation (Wang et al, 
1995). These turnours; contained great quantities of neoplastic bone, were more remod- 
elled, and contained large numbers of multinucleated osteoclast-like cells in comparison 
to turnours isolated from age matched single c-Fos transgenic mice (Wang et al, 1995; 
reviewed in Grigoriadis et al, 1995). The results from c-Fos/c-Jun double transgenic 
mice demonstrate oncogene cooperativity. 
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All together, these results demonstrated a specific role for c-Fos in bone tumour 
formation and suggested that osteoblasts are target cefls for transformation by the c-fos 
transgene. 
Further research showed that high c-Fos levels do not affect the differentiation po- 
tential of ES cells, since ES cells overexpressing c-Fos efficiently contribute to the de- 
velopment of chimeric mice (Wang et al, 1991). However, ectopic c-Fos expression 
also affects the transformation of chondroblastic cells since chimeric mice generated 
from c-Fos overexpressing ES cells develop chondrosarcomas with high efficiency at an 
skeletal sites containing cartilage (Wang et al, 1991). More recently, Thomas et al 
(2000) in our laboratory also showed that differentiation of chondrocytes is inhibited 
when c-fos is overexpressed during chondrogenesis in vitro. 
Previous work from our laboratory has demonstrated that in c-Fos-induced osteo- 
sarcomas, cyclin DI expression is specifically elevated upon initial expression of the c- 
Jos transgene in the pre-malignant osteoblasts and chondrocytes and not in other trans- 
gene expressing tissues (Sunters et al, 1998), suggesting that modulation of cell cycle 
regulators may be a target of c-Fos in osteoblast and chondrocyte transformation. In- 
deed, cyclin DI is a known AP- I transcriptional target (reviewed by Shaulian and Karin, 
2001; Jochurn et al, 2001). Moreover, Dr. A. Sunters provided further in vitro evi- 
dence in MC3T3-El cells in that induction of exogenous c-Fos resulted in a reduction in 
cell cycle time and premature GI-S phase transition via deregulated cyclin E/A-CDK2 
dependent mechanisms (Sunters et al, 2000) (see also Chapters 4 and 5). 
1.6.5 c-Fos and apoptosis 
The c-Fos/AP-1 transcription factor has also been implicated in the control of cell death 
and survival, depending on the type of apoptotic insult and cell type investigated (re- 
viewed by Karin et al, 1997; Shaulian and Karin, 2001). Specifically, many studies sug- 
gest that c-Fos may be a mediator of apoptosis, a concept based in the evidence that c- 
fos expression increases in cells undergoing apoptosis. (Buttyan et al, 1988; Colotta et 
al, 1992; Smeyne et al, 1993; Hafezi et al, 1997; Pruschy et al, 1997; Inada et al, 1998; 
Wenzel et al, 2000; Grimm et al, 2001). The potential role of c-Fos in normal physio- 
logical apoptosis during development came from studies on the nervous system of c-fos- 
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1acZ transgenic mice (Smeyne et at, 1993). High expression of c-fos was shown to 
precede and correlate with neuronal cell death following treatment with kainic acid or 
surgical lesion, as well as in a neurodegenerative mutant. Additionally, non-neural tis- 
sues demonstrated high expression of fbs-lacZ, these included the secondary palate, 
nasal septum, developing tooth germ, and embryonic heart valve cushions, all areas 
where apoptosis normally occurs, along with hypertrophic chondrocytes undergoing 
programmed cell death during bone formation and epiphyseal bone growth (Smeyne et 
al, 1993). Increased expression of c-Fos, along with the Jun family members, could 
also be detected following castration and upon apoptotic regression of rat secretory 
epithelial cells lining the ducts of the rat ventral prostate and during involution of the 
mammary gland at weaning, a process associated with apoptosis of milk-producing 
epithelial cells (Buttyan et al, 1988; Marti et al, 1994). Moreover, while c-Fos is es- 
sential for fight-induced photo-receptor apoptosis; in the retina, it is defective in c-fos 
deficient mice and Fra-1 can substitute for c-Fos in these mice (Hafezi et al, 1997; 
Fleischmann et al, 2000), although it is unclear whether this is due to a requirement for 
c-Fos in mediating the cell death process or whether a deficiency in c-Fos throughout 
development alters the expression of genes required for apoptosis. 
The role of ectopic c-Fos expression on apoptosis fol. lowing senun withdrawal was 
investigated previously in greater detail in Syrian hamster embryo (SHE) cells and a 
human colorectal carcinoma (RKO"53+/+) cell line (Preston et al, 1996), where induction 
of c-Fos caused apoptosis in these cell lines. A positive role for c-Fos in modulating 
apoptosis was also demonstrated in serum-deprivrd rat fibroblasts transformed by c-Fos 
compared to normal fibroblasts (Smeyne et al, 1993). In addition, in fibroblasts from 
fos-lacZ mice, c-fos-lacZ expression was shown to precede apoptosis induced by Eto- 
poside (Smeyne et al, 1993). Evidence for a putative role for c-Fos in apoptosis during 
in vitro osteoblast differentiation was shown when there was up-regulation of various 
members of the AP-1 complex including c-Fos expression at the later stages of devel- 
opment when apoptosis is evident (McCabe et al, 1995). 
c-Fos has also been implicated in the apoptosis of dffferent cell types which are de- 
pendent on distinct factors for their growth and survival such as IL-6 and IL-2- 
dependent murine lymphoid cells (Colotta et al, 1992). Also, high levels of Fos and Jun 
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proteins correlated with Nerve Growth Factor (NGF) withdrawal from primary rat sym- 
pathetic neurones, which are dependent on the NGF for their survival (Estus et al, 
1994). 
Interestingly, however, in contrast to apoptosis induced by serum withdrawal, re- 
search has suggested that c-Fos does not promote apoptosis, during normal development 
and c-Fos may play a protective role. In c-Fos deficient embryos and adults, c-Jun defi- 
cient embryos, and c-Fos/c-Jun double knockout embryos, apoptotic cell death occurred 
normally in vivo in developing embryonic tissues and adult thymus and ovary, regardless 
of the absence of a functional c-fos gene (Roffler-Tarlov et al, 1996). The absence of c- 
Fos also had no effect on neuronal cell death in the spinal cord following sciatic nerve 
section, or in heterozygous weavers' cerebellae (Roffler-Tarlov et al, 1996). Moreover, 
primary cells isolated from c-Fos null mice can undergo normal apoptosis (Gajate el al, 
1996). 
Furthermore, c-Fos may protect cells against apoptosis under certain circumstances 
(e. g., Walker et al, 1993; Schreiber et al, 1995; Ivanov and Nikolic-Zugic, 1997; He et 
al, 1998). An example for a protective role for Fos against apoptosis is that induced by 
short-wavelength UV light. Using 3T3 fibroblasts from c-fos deficient mice and wild- 
type c-fos++ cells, it was demonstrated that clonogenic; survival and proliferation of cells 
lacking c-Fos following UV irradiation was drastically reduced and apoptotic cell death 
was significantly enhanced, in comparison to the wild-type c-fos"' fibroblasts (Schreiber 
et al, 1995). c-Fos is also vital in prolonging the life of immature CD'+"' double posi- 
tive (DP) thymocytes. This research found that there was an increase in spontaneous 
and signal-induced cell death of DP cells in c-Fos deficient mice in response to a variety 
of stimulL such as dexamethasone, ionomycin, and forskolin, but not from T-cell re- 
ceptor-mediated cell death, demonstrating a protective role for c-Fos in this system 
(Ivanov and Nikohc-Zugic, 1997). Furthermore, the reported induction of c-fos in cells 
undergoing apoptosis is reported to be a stress response that is counterbalanced by 
proteasome-mediated degradation of c-Fos protein, a process stabilised by Bcl-2 (He et 
al, 1998). 
Taken together, the causal role of c-Fos in apoptosis is more complex than first 
thought. The regulation of apoptosis by c-Fos is probably specific to the cell type and 
56 
1. Introduction 
the type of stimulus. Whilst in some cases c-Fos may stimulate cell proliferation, in 
others it may increase survival, and in extreme situations such as during environmental 
stress cell death may result. 
1.7 Homeobox genes and homeoproteins 
Horneoproteins are a group of helix-loop-helix transcription factors which regulate 
specific temporal and spatial patterns of gene expression involved in embryonic devel- 
opment. Each homeotic protein contains a highly conserved 60 amino acid segment 
known as the homeodomain. This is encoded by a 180 nucleotide DNA sequence called 
the homeobox. Gene expression is regulated by the binding of the homeodomain to 
specific DNA sequences (Krurnlauf, 1994). Hox genes, first discovered in Drosophila, 
were found to regulate the development of body plan, being expressed temporally in an 
order which reflected their linear arrangement on a chromosome (Graham et al, 1989). 
They have since been found to be highly conserved throughout a wide variety of spe- 
cies. In mammals, in addition to the Hox genes that are arranged into sets of four clus- 
ters, there are other homeobox-containing genes which form different small classes 
depending on the sequence or association with other conserved motifs. These include 
the Msx family of homeobox genes. 
1.7.1 The Msx family of homeobox genes 
The vertebrate homeobox-containing genes have been identified and shown to have a 
sequence diverged from the Hox sequence. Sequence comparisons of these genes, 
which show a more restricted pattern of expression have been predicted to have more 
specific functions of organogenesis and cellular differentiation. The Msx genes of ver- 
tebrates are a small family of homeobox-containing genes related to the Drosophila 
gene muscle-segment homeobox (msh). Msx] (initially known as Hox-7) was inde- 
pendently identified by two groups (Hill et al, 1989; Robert et al, 1989) and was found 
to have significant sequence identity to Drosophila msh gene; with 78% sequence simi- 
larity at the nucleotide level and 92% identity at the amino acid level. Monaghan et al 
(1991) later found a second closely related murine homeobox-containing gene, Msx2 
(formally termed Hox-8). This protein showed 97% sequence identity in the homeobox 
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region of Msxl and an overall. amino acid sequence comparison of 60%. The final 
member in this family is Msx3, but this protein shows greater identity to MSX] (98%) 
than Msx2 in both the horneodomain and conserved flanking sequence. This family is 
one of the most conserved homeobox-containing gene families, with the majority of 
conservation lying between the homeodomains and flanking region (Davidson, 1995). 
Both Msx] and Msx2 are considered to function as transcription factors. They are 
expressed in overlapping or related patterns from early stages of tissue differentiation, in 
a position-related, rather than cell-type specific manncr (Davidson, 1995; see Table I 
below). In situ hybridisation studies have shown that expression is evident in neural 
crest cells and their derivatives, such as branchial arches and mandibular arches, and 
craniofacial cartilage and membranous bone (Takahashi et al, 1991), developing cranial 
sutures in a region of bone deposition and resorption (Jabs et al, 1993; Kim el al, 1998; 
Liu et al, 1995), the developing mandible and tooth (MacKenzie et al, 1991; Jowett et 
al, 1993), and the apical ectodermal ridge (AER) and underlying mesenchyme of the 
limb bud (Davidson et al, 1991). The expression pattern of Msxl and Msx2 have been 
associated with epithelial-mesenchymal interactions in organogenesis (Davidson et al, 
1991; Takahashi et al, 1991; Robert et al, 1991; Jowett et al, 1993). In addition, MSX2 
has been implicated in the control of apoptosis in limb development and rhombence- 
phalic neural crest cells by regulating the expression of BMP4 (Ferrari et al, 1998; Gra- 
ham et al, 1994). 
Mice deficient in Msx], resulting from targeted gene disruption, die in the immedi- 
ate post-natal period. These mice exhibit dental and craniofacial development abnor- 
malities, which include incomplete cleft in the secondary palate, the failure of tooth and 
alveolar bone development in the mandible and maxifla, and defects in the skull, nasal 
bones, and inner ear (Satokata and Maas, 1994; Lidra et al, 1998). However, these null 
mutant mice exhibit no neural tube, limb, or eye defects, despite the fact that Msx] ex- 
pression occurs in these structures. Compensatory mechanisms may occur that enable 
embryos to overcome the disruption in some tissues that would normally require the 
expression of Msx]. Since Msxl and Msx2 show similar patterns of expression, func- 
tional redundancy may play a key role (Catron et al, 1996). In humans, mutations in the 
MSX1 gene have been involved in cleft palate (van den Boogaard et al, 2000) and tooth 
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agenesis (Vastardis et al, 1996; Hu et al, 1998). Moreover, Msx] may play a role in the 
temlinal differentiation of several cell types such as cartilage (MacKenzie et al, 1991; 
Mina et al, 1995) and muscle (Houzelstein et al, 1999), by enhancing cell proliferation 
and preventing differentiation. 
Table 2- Expression of msh-like genes during development (from Davidson, 
1995) 
Species Gene Principle reported sites of expression 
Mouse MSX1 Uterus, cervix, vagina, uterine wall, ectoplacental 
cone, amnion, allantois, umbilical vein, and Rathke's 
pouch. 
Msx I and Msx2 Primitive streak, somatopleural lateral mesoderm, 
dorsal ectoderm, neural plate, dorsal mesenchyme, 
dorsal region of the neural tube and of the brain 
(hindbrain, midbrain, and forebrain), choroid plexus, 
cranial neural crest cells, branchial arches, facial 
processes, tooth germs, eye, ear nose, vibrissae, 
heart, pericardium, limb bud, genital tubicle, tail and 
tail ridge. 
Msx3 Neural tube 
Xenopus Msxl and Msx2 Dorsal mesodermal mantle, lateral plate mesoderm, 
neural crest, dorsal neural tube, dorsal region of 
brain and heart 
Zebrafish msxA, A C, D Fin buds 
msxC, D Inner ear 
Drosophila I msh Segment muscles and ventral nervous system 
1.7.1.1 Msx genes and bone 
The strong expression pattern in cells at extreme ends of osteogenic: fronts of calvarial. 
sutures and in adjacent mesenchymal cells have led to the proposition that Msx2 has a 
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role to play in the differentiation of osteoprogenitor cells. Msx2 prevents differentiation 
and promotes proliferation of cells at the osteogenic fronts of calvariae, facilitating ex- 
pansion of the skull and closure of the suture (Liu et al, 1995; Liu et al, 1999). High 
levels of Msx2 transcripts have been demonstrated in early undifferentiated cultures of 
primary calvarial osteoblasts, with levels becoming undetectable as differentiation pro- 
gresses (Dodig et al, 1996; Dodig el al, 1999). Moreover, overexpression of Msx2 has 
been found to inhibit differentiation, down-regulate most markers of osteoblastic differ- 
entiation, and increase alkaline phosphatase expression in chick calvarial osteoblasts 
(Dodig et al, 1996; Satokata et al, 2000). The role of MSX2 in the differentiation of 
osteoprogenitor cells is supported by the evidence that a dominant mutation in the hu- 
man MSX2 gene (P148H; results in a substitution for a proline at position seven in the 
homeodomain) is associated with craniofacial abnormalities (Jabs et al, 1993; Ma et al, 
1996; Winograd et al, 1997). In particular, Boston-type craniosynostosis, or preco- 
cious fusion of the skull bones develops and in a few supported cases limb deformities 
result (Jabs et al, 1993). In contrast, the phenotype from Msx2 deficient mice, resem- 
bles that associated with the human MSX2 haplo insufficiency condition in parietal fo- 
ramina due to defective proliferation of osteoprogenitors at the osteogenic front of cal- 
varia, (Satokata et al, 2000). 
The role of Msx2 in human bone development is ffirther supported by the evidence 
that MSX2 has been identified in cDNA from adult human ostcoblasts cells and its ex- 
pression can be stimulated in vitro by 1,25-(011)2D3 which promotes osteoblastic differ- 
entiation (Hodgkinson et al, 1993). Msx2 expression has also been rcported in many 
established cell lines, such as osteoblastic cells (ROS 17/2.8, RCT 3, MB1.8) and pre- 
osteoblasts (RCT-1) in addition to neonatal rat calvarial. cells (Towler et al, 1994), but 
not in non-osteoblastic cells such as ROS 25/1 or undifferentiated MC3T3-El cells. 
Msx2 expression has been shown to inhibit the expression of osteocalcin and COLIA] 
(Towler et al, 1994; Dodig et al, 1996). 
Msx2 has been implicated in the formation of membranous bones rather than carti- 
lage. In experiments in which mesenchyme from the avian jaw (expresses Msx2 in vivo) 
was cultured with or without epithelium, cartilage formed in either case, but membrane 
bone formation and the maintenance of Msx2 expression required the presence of epi- 
60 
1. Introduction 
thelium (see review in Davidson, 1995). In addition, Msx2 may not be important in the 
regulation of differentiation of osteoblasts derived from long bone (Dodig et al, 1997). 
1.7.2 Factors controlling MSXgene expression 
As yet, very little is known about the molecular pathways in which the Msx genes func- 
tion. Evidence of regulatory processes upstream of Msx genes is emerging. BMIPs, in 
particular, BNT-2 and -4 have been implicated in the epithelial-mesenchymal tissue 
interactions with Msx genes. These genes are co-expressed with Msx] and Msx2 at 
many locations, including rhombomeres, limb buds and tooth germs (e. g., Vanio et A 
1993; Watanabe and Ide, 1993; Barlow and Francis-West, 1997; Kim et al, 1998). 
Several other members of the TGF-P family, for example TGF-, 8 and dorsalin, are also 
co-expressed with Msx genes (reviewed in Davidson, 1995); in addition other growth 
factors that have been implicated in controlling Msx gene expression, for example ex- 
ogenous FGF-2 and FGF-4, as well as BMP-4, can induce low levels of Msx] in disso- 
ciated limb mesenchymal cells in vitro. 
1.7.3 Downstream targets of Msx proteins 
Finally, increasing information is emerging about some of the downstream targets of 
Msxl and Msx2. The consensus horneodomain-binding sequence [c/g]TAATTG, has 
been found in the promoter of the genes encoding the signalling molecule Wntl and 
ostcocalcin, as well as in the promoter of Msx] itself (suggesting auto-regulation or 
cross-regulation with Msx2). Msx2, in combination with MINT, a Msx2 binding pro- 
tein, have been shown to transcriptionally repress osteocalcin gene expression (Hoffimn 
et al, 1994; Ducy et al, 1995; Banerjee et al, 1996; Ducy et al, 1997; Newberry et al, 
1997; GeoffTey et al, 1995; Towler et al, 1994; Newberry et al, 1999). Furthermore, 
during tooth development, reciprocal ternporo-spatial patterns of Msx2 and osteocalcin 
gene expression has been shown (Bidder et al, 1998). In addition, the homeodomain 
transcription factor, Dlx2, induces osteocalcin expression in osteoblasts by antagonising 




The regulation of genes by growth factors, hormones and transcription factors is im- 
portant in the development and remodelling of bone throughout life. In particular, the c- 
Fos proto-oncogene has been implicated in both osteoclast and osteoblast function and 
the Msx homeobox-containing genes have important roles in osteoblast differentiation 
during development. 
A) c-Fos has been shown to be important in regulating the activity and differentiation 
of osteoclasts and osteoblasts, and shown to be highly expressed in the osteoclasts 
of patients with Paget's disease, a bone remodelling disease. To understand the role 
of c-Fos in bone ceU function, the aims of this thesis are: 
1) To investigate the role of Fos in osteoclast function, and possibly provide a 
working model for Paget's disease, this thesis aims to use an in vivo gain-of- 
function approach to generate transgenic mice which overexpress c-Fos in os- 
teoclasts. 
2) To examine the consequence of inducible c-Fos over-expression in an osteoblas- 
tic cell line using a tetracycline-repressible gene construct such that the effects 
of ectopic c-Fos expression on osteoblast proliferation and differentiation may 
be assessed in vitro. 
3) To ascertain the role of ectopic c-Fos expression in osteoblast apoptosis in vitro. 
B) Previous studies have demonstrated a role for Msx genes in bone and tooth devel- 
opment, and the regulation of Msx2 by the osteotropic honnone, 1,25-(OH)2D3. 
To study further the expression of Msx genes in osteoblasts, the ainis of this thesis 
are also: 
1) To investigate the possible regulation of Msx2 by another osteotropic hormone, 
Parathyroid hormone (PTH), using reporter gene constructs, and analysis of 
endogenous MSX gene expression in osteoblast-like cell lines. 
2) To examine the in vivo expression of Msxl and MW in osteoblasts of post- 
natal mouse bone using in situ hybridisation analysis and P-galactosidase ex- 
pression from Msx]-lacZ knock-in transgenic: mice. 
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2.1 General Abbreviations 
cc-NEM cc-minimal essential medium + ribonucleosides and deoxyribonu- 
cleosides 
APS An-unonium, Persulphate 
ALP alkaline phosphatase 
ATP adenosine triphosphate 
BCA Bicinchoninic: acid 
BCIP 5-bromo-4-chloro-3-indolyl phosphate 
bp base pairs 
BMP Bone morphogenetic protein 
BSA Bovine serum albumin 
cDNA complementary DNA 
CTP cytidine triphosphate, 
dATP deoxyadenosine, triphosphate 
dCTP deoxycytidine triphosphate 
dGTP deoxyguanosine triphosphate 
ddATP dideoxyadenosine triphosphate 
ddCTP dideoxycytidine triphosphate 
ddGTT dideoxyguanosine triphosphate 
DEPC Diethyl pyrocarbonate 




DIVEM Dulbecco's Modified Eagles Medium 
EDTA Ethylene diamine tetra-acetic acid 
EtBr Ethidium bromide 
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GAPDH Glyceraldchyde Phosphate Dehydrogenase, 
GTG genetic technology grade 
GTP guanosine, triphosphate 
dH20 Deionised water 
HC1 Hydrochloric acid 
HEPES N-2-hydroxyethylpiperazine-N'-2-ethanesulphonic acid 
IMS Industrial methylated. spirits 
kb kilobases 
mA milli amperes 
min minute/s 
MOPS 3(N-Morphohno)propanesulphonic acid 
mRNA messenger RNA 
NaOAc Sodium acetate 
NEB New England Biolabs 
NTP nucleotide triphosphate 
PAGE Polyacrylamide Gel Electrophoresis 
PBS Phosphate buffered saline 
PCR Polymerase Chain Reaction 
rpm Revolutions per minute 
sec seconds 
SDS Sodium dodecyl sulphate, 
SSC standard saline citrate 
TAE tris acetate-EDTA buffer 
Tc Tetracycline 
TBS Tris-buffered saline 
TBST Tris-buffered saline with Tween 
TE tris-EDTA buffer 
TEMED NNN, N-tetramethylethylenediamine 
TESPA 3-aminopropyltriethoxysflane 
TRAP Tartrate Resistant Acid Phosphatase 
Tris Tris(hydroxymethyl)aminomethane 
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tRNA transfer ribonucleic acid 
TTP thymidine triphosphate 
Tween 20 Polyoxyethylene sorbitan monolaurate 





wt wild type 
X-gal 5-bromo-4-chloro-3-indolyl-p-galactosidase 
2.2 Standard Solutions and Media 
All chemicals were obtained from BDH (Poole, UK), biochemicals were obtained from 
Sigma (Poole, UK) and all enzymes were from Promega, (Southampton, UK) unless 
otherwise stated. All cell culture media and supplements were cell culture grade ob- 
tained form Gibco BRL (Paisley, UK) or Sigma. Batch tested fetal calf serum for tissue 
culture use was obtained from Meldrum (Hants, UK), Gibco BRL and Summit (Denver, 
CO, USA). 
2.3 Manipulation of DNA 
2.3.1 Ethanol precipitation of DNA 
DNA was routinely precipitated by the addition of 0.1 volumes of 3M NaOAC followed 
by 2.5 volumes of ethanol, and precipitating the mixture at -80*C for I hour. The pre- 
cipitate was isolated by centrifugation for 15 min at the maximum speed possible (usu- 
ally 14,000 rpm) for the tube used. The pellet was washed with 70% ethanol before 
suspending in TE (I OmM Tris-HCI, I mM EDTA) or dH20. 
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2.3.2 Plasmid transformation of E. coli 
2.3.2.1 Preparation of chemo-competent E. coli 
XL I -B or DH5a E. coli cells from a frozen stock were streaked out onto LB agar plates 
(1.5% Bacto agar [Oxoid] in LB medium) containing 15ýtg/nil of tetracycline. A single 
colony was used to inoculate 5ml of LB medium (1% w/v bactotryptone [Oxoid], 0.5% 
w/v yeast extract [Oxo id], 0.17M NaCl, pH7.5) supplemented with 15 Pg/ml of tetracy- 
cline. The culture was incubated overnight at 37"C with shaking at 250 rpm in a New 
Brunswick G25 orbital incubator. A volume of overnight culture (I ml) was transferred 
to a sterile conical flask containing 100ml of LB medium and grown until a 600nm ab- 
sorbance of 0.94-0.95 was achieved. The cells were then transferred to two SOn-A poly- 
propylene centrifuge tubes (Beckman) and chilled on ice for 15 min. The cells were 
pelleted by centrifugation at 2500 rpm at 4'C for 15 min in a Beckman JA-20 rotor. 
The supernatant was discarded and the pellet was resuspended in 10ml of Comp. Buffer 
I (80mM calcium chloride, 50mM magnesium chloride) and left on ice for 10 min. 
Pelleting; and resuspending was repeated twice, the second time the pellet being resus- 
pended in Comp. Buffer 2 (lOOmM calcium chloride) at 5xI09 cells/ml. An equal vol- 
ume of glycerol was slowly added and the mixture was aliquoted into 1.5n-d eppendorf 
tubes. This was frozen in liquid nitrogen and stored at -80"C. 
2.3.2.2 Transformation of chemo-competent E. coli 
Frozen allquots of competent cells were thawed on ice. DNA solution (approximately 
Ing) was added to cells (100pl) in pre-chilled 1.5ml eppendorf tubes. The tubes were 
incubated on ice for 30 min after which time the cells were heat shocked at 42'C for 90 
sec, and placed on ice for ftu-ther 2 min before adding 500ýd SOC medium (2% w/v 
bactotryptone, 0.5% w/v yeast extract, 5.5mM NaCl, 2.5mM KCI, pH7, I OmM M902). 
The transformed cells were then incubated for 30 n-dn shaking at 370C after which time 
cells (50pl, I 00ýtl, 200ýd allquots) were plated onto LB agar plates containing I 00ýtg/ml 
ampicillin and incubated overnight at 37"C. 
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2.3.3 Small scale preparation of plasmid DNA (mini-prep) 
Individual colonies were inoculated into 3ml of LB medium containing I OOpg/ml ampi- 
cillin and incubated overnight at 37T in loosely capped 15ml tubes shaking at 250rpm. 
Aliquots of 1.5ml were transferred to eppendorf tubes and pelleted at 2,000g for 10 
min. Meanwhile, the remaining culture was stored at 4T. Plasmid DNA was extracted 
from bacterial cells using a Qiagen plasmid extraction kit (Qiagen, Crawly, UK) ac- 
cording to manufacturer's instructions. 
2.3.4 Large-scale preparation of DNA (maxi-prep) 
The 100pl aliquot of cell suspension saved from the mini-preparation (see above) was 
added to 250ml of LB medium containing 100jigIn-A ampicillin in a sterile conical flask 
and incubated overnight at 37*C with shaking at 250 rpm. Plasmid DNA was isolated 
using a Qiagen Plasmid Amplification Kit (QlAfilter Plasn-ýd Midi/Maxi protocol) ac- 
cording to manufacturer's instructions. The concentration of DNA in solution was 
determined by optical density (OD) at 260nm and 280nm using a Pharmacia GeneQuant 
I spectrophotorneter. 
2.3.5 DNA cloning 
Specific DNA fragments were purified from a plasmid backbone or any unnecessary 
DNA by restriction digestion. For the restriction digestion of DNA, 2ýfl of DNA from 
the small-scale preparation of plasmid DNA was mixed with 2gl of the appropriate I Ox 
restriction enzyme digestion buffer (Promega or NEB), I unit of the appropriate enzyme 
(Promega or NEB), and dH20 was added to a final volume of 20PI. The mixture was 
incubated for I hour at 37"C in an eppendorf tube. When larger quantities of DNA 
were required such as in preparation of DNA for production of DNA probes, the final 
volume and constituents were suitably scaled up. 
DNA was resolved by gel electrophoresis on GTG agarose gels containing 
0.5pghnl EtBr in Ix TAE buffer (40mM Tris-HCI, 5mM NaOAc, ImM EDTA, pH7.7) 
on a strength of agarose (ICN) appropriate for the separation (usually between 0.6 - 
1.2%). The DNA samples were mixed with gel-loading buffer (6x concentrated solu- 
tion: 15% Ficoll [Type 400; Pharmacia], 0.1 % bromophenol blue, 0.1 % xylene cyanol 
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F'F, 0.1% Orange G) and loaded onto the gel alongside 5ýd of a molecular weight size 
nwker (Promega). When the correct sized band was sufficiently distinct (against a 
suitable size DNA marker) it was excised from the agarose gel slice under UV illumina- 
tion and purified with QlAquick gel extraction kit or Qiacx gel isolation resin (Qiagen) 
according to the manufacturer's instructions. 
2.3.5.1 Digestion of DNA for microinjection and preparation of probes 
TRAP-c-fosLTR construct 
The murine TRAP promoter (pBS-TRAP; obtained from Dr. G. D. Roodman, San An- 
tonio, see Boyce et al, 1995) was previously fused to full length genon-dc sequence of 
the murine c-fos gene in which the 3' destabilising sequences have been replaced by a 3' 
long terminal repeat (LTR) from the FBJ-murine sarcoma virus (TRAP-c-fosLTR). The 
construct (6.9kb) was removed from the plasmid pBluescriptSK using HindIII restric- 
tion sites for the microinjection into fertilised eggs. A 0.8kb BamIR v-fos fragment, 
isolated from the pXfos vector, was used as a DNA probe for the Southern blot analysis 
to detect 1.8kb exogenous c-fos DNA (see also Chapter 3, Figure 1). 
DNA probes 
Probes were prepared by restriction enzyme digestion of the fbHowing plasmids to de- 
tect specific transcripts in Northern blot analysis: 




V-fos 0.8 Baml-H pxfOs 
fra-I 0.23 EcoRl, Xbal pfra-1-8 4.2 
c-jun 0.45 EcoRl, Xbal pc-jun EXho2 0.45 
MMP-9 0.3 EcoRl, Smal pSP64 2.3 
Msx2 0.3 HindIll, Pstl pBsSK 1.3 
UAFMI 1.0 BamM pG3PCR4 1.4 
ALP 2.5 EcoRl pAT153 2.5 
*= v-fos probe: Detects 2.2kb endogenous and 2kb and 3. Okb 
exogenous c-fos transcripts in TRAP-c-fosLTR mice and 1.8kb 
exogenous transcript from pM2-c-fos construct. 
pBsSK = pBluescript SK 
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Riboprobes 
Plasmids was Unearised with the foHowing enzymes for specific anti-sense and sense 
riboprobes; the table also shows the polymerase enzymes and hydrolysis times used for 





Size (kb) Plasmid Hydrolysis 
time 
pB15 sense EcoRl T3 0.49 pBsSK II min 48 sec 
anti-sense Sall T7 0.49 pBsSK II min 48 sec 
MMP-9 sense EcoRl SP6 0.3 pSP64 
anti-sense BamHI SP6 0.3 pSP65 - 
MSxI sense EcoRl T7 0.7 pSP72 17 min 20 sec 
I anti-sense BgIII SP6 0.7 pSP72 17 min 20 sec 
Msx2 sense I BgIII I SP6 1 0.85 1 pSP72 1 24 min 27 sec I 
anti-sense ý HindIII T7 0.85 1 pSP72 1 24 min 27 sec 
pBsSK = pBluescript SK 
2.3.6 Preparation of a Random Prime DNA Probe 
The cDNA sequence to be used as a template for making [a-32p]-dCTP-labeHed probes 
was isolated from a plasmid by restriction endonuclease digestion followed by agarose 
gel isolation and purification (see section 2.3.5). The DNA template (25ng) was heat 
denatured at 95-100"C for 2 min before cooling on ice. The DNA was random prime 
labeHed using either a Prime-a-GeneTm System (Promega) or Ready-To-GoTm DNA 
labelling beads (Amersham-Phamiacia Biotech, Amersham, UK) according to manu- 
facturer's instructions, and [CC-32p]-dCTP (50ptCL 300OCi/mmol; NEN, Boston, MA) 
was used as a choice of isotope labeHed nucleotide. 
The probe was purified from unincorporated nucleotides using ProbeQuant' G-50 
Micro columns, (Amersham Pharmacia Biotech) according to the manufacturers in- 
structions. The probe was denatured by heating to 100'C for 2 min or by the addition 
of NaOH (OAN final concentration), before addition to Church's Buffer (0-5M 
Na2HP04 pH7.2,7% SDS, ImM EDTA, pH8.0) in the hybridisation bottlc (scction 
2.7.3 and 2.8.4). 
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2.4 Production of Transgenic Mice 
Mice were generated using standard transgenic techniques by the department's trans- 
genic facilities and a dedicated technician for these procedures. AH procedures were 
carried out under Home Office license. 
2.4.1 TRAP-c-fosLTR transgenic mice 
For the generation of TRAP-c-fosLTR transgenic mice, a HindIII fragment of TRAP-c- 
fosLTR construct (section 2.3.5.1) was microinjected into fertilised eggs according to 
standard procedures, followed by transfer into foster females. Founder animals were 
screened by Southern Blot analysis of tafl DNA for the presence of the transgene (see 
section 2.7). X-rays were taken of anaesthetised mice at different ages (Dr. P. Liepins, 
Dept. of Radiological Sciences, Guys Hospital, London). 
2.4.2 Msxl-lacZ transgenic mice 
Wild type (1) female mice (B6CBA strain) were mated with Msxl-lacZ heterozygous 
(') males (obtained from Benoit Robert, Institut Pasteur, France). These heterozygotes 
have the n1acZ reporter gene inserted into the Msx] homeobox domain resulting in a 
null mutation but show normal development (Houzelstein et al, 1997). Expression of 
Msx] gene can be monitored in heterozygous offspring by 0-galactosidase histochemis- 
try. Identification of heterozygotes was assessed by detecting P-galactosidase activity 
in hemi-sected heads (embryonic age days 16.5 and 18.5 and neo-natal; Day 0 being the 
sign of vaginal plug after mating) or ear tissue removed from offspring after post-natal 
age day 6 (section 2.5.6) 
2.5 Histochemistry 
2.5.1 Harvesting of Mouse Embryos and offspring 
For control tissue, mice of CD I strain (Charles River, Margate, UK), were mated over- 
night. Embryos at specific stages were dissected from euthanised mothers and extra- 
embryonic membranes. Limbs and calvaria were removed with as little surrounding 
muscle as possible, and fixed in 4% PFA (w/v in PBS). Post-natal CDI mice and 
TRAP-c-fosLTR mice were culled at the indicated stages of development and tissue 
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transferred immediately to 4% PFA. For embryos and early post-natal tissue the tissue 
was fixed overnight at room temperature and 48 hours for later staged mice. Bone 
tissue of mice older than 2 days were decalcified with 0.5M EDTA, until bone could be 
easily cut with a scalpel blade. The PFA was removed and the embryos were washed 
successively for 10 n-dn with depc-PBS before paraffin vacuum ffiffltration embedding 
whereby tissues were dehydrated through graded ethanol series and toluene and infil- 
trated with paraffin at 58"C overnight under vacuum (by the Department of Oral Pa- 
thology, Guy's Hospital, London). 
2.5.2 Sectioning of paraffin embedded tissue 
Paraffin embedded samples were sectioned on a Reichert-Jung I 140/Autocut microtome 
(Lamb) using disposable microtome blades (Lamb) to produce 5gm thick sections. 
Sections were floated onto water in a water bath containing depc-H20 pre-warmed to 
45*C. As the wax melted, sections were mounted onto organosiliconised (TESPA) 
slides, left to air-dry at 37*C for 2 hours, before incubating overnight at 5011C. Sections 
were stored at VC until ready for use. 
2.5.3 Histological staining 
Unless otherwise stated sections were stained with Haernatoxylin and Eosin or Eosin 
alone. Sections were dewaxed in Histoclear for 10 min at room temperature and then 
passed through a graded series of ethanols (100%, 90%, 80%, 70%, 50%, 30% (v/v) 
for 2 min, followed by dH20. Slides were stained in water-based Haernatoxylin for I 
min and rinsed in dH20 for 2 min. Sections were destained for I min in acid/dH20(ap- 
proximately 2 drops HCI in 400ml dH20), before rinsing in dH20for 2 min. Sections 
were dehydrated in 30%, 50% and then 70% ethanol before staining for 30 sec in Eosin 
(Eosin Yellowish in 80% ethanol; Sigma). Finally, sections were dehydrated further in 
90% (2 min), 95% (1 n-dn) and 100% ethanol (twice for 30 see). Sections were cleared 
in DPX mounting medium (BDM and covered with glass coverslips (Chance, Proper, 
England). 
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2.5.4 Immunohistochemistry 
The immunolocalisation of c-Fos and Bcl-2 proteins in sections from TRAP-c-fosLTR 
mice was assessed. All steps were performed at room temperature unless otherwise 
stated. Sections were dewaxed in Histoclear (twice for 20 min) and rehydrated as 
above with the exception of a final 5 min wash in Tris buffered saline (TBS; I OmM Tris- 
HCI pH8.0,150mM NaCl), instead of dH20. For samples to be assessed for Bcl-2 
protein, sections were warmed in 0.2M Tris pH7.8 at 37*C for 5 min, before antigen 
retrieval in 1% trypsin in 0.2M Tris pH7.8 (w/v) at 370C for 10-30 min. Trypsin was 
washed away by immersion in TBS for 5 min. The endogenous peroxidase activity for 
all samples was then blocked by rinsing in methanol containing 3% hydrogen peroxide 
solution (v/v) for 30 min at room temperature. Sections were rehydrated (2 min for 
each step) in 90%, 80%, 70% and 50%, 30%, 0% (v/v) IMS/dH20 then washed in 
dH20 (5 min). Pen-neabilisation was carried out in 1% SDS in TBS (w/v) for 5 min, 
followed by rinsing in TBS (twice for 5 n-dn). Any non-specific binding sites were 
blocked by incubation in 10% Goat serum (v/v) and 2% BSA (w/v) in TBS for 30 min, 
before primary c-Fos and Bcl-2 antibodies (both were batch-tested rabbit polyclonal 
IgGs, obtained from Santa Cruz laboratories, CA, USA) were applied at a dilution of 
1: 100 in 10% Goat serum v/v in TBS to each section and incubated for I hour at room 
temperature. Negative controls consisted of TBS alone. Sections were then washed 
three times in TBS before being incubated for I hour with a 1: 300 dilution of the secon- 
dary antibody (biotinylated Goat-(x-rabbit, Vector Laboratories, Burlingame, CA, USA) 
in TBST (0.05% Tween 20 in TBS, pH8.0). The antibody was washed away by three 
washes using TBST and the sections were stained for 30 min with Avidine Biotin Com- 
plex (Vector laboratories). Any excess stain was removed by washing in TBST. Sec- 
tions were permeabilised in 0.5% triton in TBS (v/v) for 5 min before staining with 
Sigma Fast DAB (Diaminobenzidine; Sigma) for approximately 10 min. The excess 
stain was removed with dH20 before the slides were counterstained for 4 sec with 
Haernatoxylin and destained briefly in dH20. Sections were mounted in Aquamount 
(BDH, Merck). 
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2.5.5 TRAP Histochernistry 
For the identification of TRAP positive osteoclasts, bone sections were dewaxed and 
rehydrated to dH20 as described above and then into PBS, before incubation at 37"C in 
TRAP staining solution. This was prepared by first dissolving Naphthol-AS-TR- 
phosphate (60mg) in 300ýd dirnethylformamide (DW). Acetate buffer containing 
20mM Glacial acetic acid and 80mM anhydrous sodium acetate, (pH5.2), was added to 
a final volume of 60ml. Sodium tartrate (1.38g) was added to a final concentration of 
IOOmM. Whilst this was mixed, 60mg Fast Red TR salt was added, and the final solu- 
tion filtered through a 0.2pm filter unit before the pH was confirmed to be pH5.2. Fol- 
lowing the appearance of TRAP positive cells (approximately 20 min), sections were 
washed with dH20, before being counterstained briefly with Haernatoxylin as described 
above, and mounted in Aquamount. 
2.5.6 Staining of foetal tissue and bone for 0-galactosidase activity 
For the identification of heterozygous embryos of Msx]-lacZ mice, embryos were dis- 
sected from euthanised mothers and extraembryonic membranes, and placed in glass 
dishes. Half of the hemi-sected head and limbs of each embryo were fixed overnight in 
2% formaldehyde, 0.2% glutaraldehyde, 0.02% Nonident P-40, and 0.01% Sodium 
deoxycholate in PBS. These were washed for I hour in PBS and then incubated in X- 
gal staining solution (IOmM potassium ferricyanide, 10mM potassium ferrocyanide, 
2mM MgC12, and 20mM X-gal in PBS) at 37'C until a blue colour developed (about 24 
hours). Similarly the ear tissue of post-natal mice were fixed for I hour and stained 
with X-gal. 
The remaining halves of limbs and heads from embryonic and post-natal mice were 
used for analysis of Msx]-lacZ expression. However a novel procedure was used to 
prepare bone samples which helped to eliminate the unnecessary background staining 
that can be observed with neonatal samples of bone or bone which has been mineralised 
(recommended by Diana Cummings, University of Maryland, USA). Freshly, dissected 
bone tissue was fixed in 4% PFA in PBS overnight. Foetal samples were divided such 
that half limbs or hemi-sected head of the animal were stained prior to demineralisation 
and the other half after dernineralisation and sectioning to confirm that dernineralisation 
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did not inhibit P-galactosidase activity. Tissue was dernineralised in 25% Formic 
acid/7.5% sodium citrate at 4"C for 6 hours and cryoprotected in 30% sucrose (w/v in 
PBS) overnight before freezing by quick immersion in a methanol/dry ice bath and 
storing at -80"C. Sections (5-7prn) were prepared using a cryostat at -40'C and ad- 
hered to polylysine coated slides (BDH). Sections were fixed in 4% PFA in PBS and 
stained for P-galactosidase activity, as above, and counterstained with Safranin (0.01% 
w/v in dH20). Adjacent sections were stained with Haematoxylin and Eosin as de- 
scribed above. Due to the problem of background staining of P-galactosidase, ear and 
bone tissue from wild-type mice was used as a negative control. Also, sections from 
late stage embryonic (stage E17) to early post-natal (day 3) tissue were included as a 
positive control for expression analysis (see Chapter 6.5). 
2.6 Tissue Culture 
2.6.1 Mammalian Cell lines and stock solutions 
The following cell lines were used in these studies: the human osteosarcoma, cell lines 
SaOS-2 and MG63 (both from American Type Culture Collection, Manassas, VA, 
USA), the rat osteosarcoma, cell fine ROS 17/2.8 (gift from Professor Gideon Rodan, 
Merck Research Laboratories, Merck & Company Inc, West Point, PA, USA), murine 
MC3T3-El osteoblastic cells and Monkey COS cells (both from European Collection of 
Cell Cultures, Salisbury, Wiltshire, UK). Also, primary rat osteoblastic cells, supplied 
by D. Harmey, were obtained by sequential enzymatic digestion of 21 -day fetal rat cal- 
varia using a modification of the methods of Bellows et al (1998). 
The following stock solutions were prepared in tissue culture grade dH20and 
stored at -20*C, unless otherwise stated: 
Tetracycline I mghnI stock in dH20, filtered (using 0.2 ptm filter unit) 
Ascorbic acid 5mg/ml stock in dH20, filtered (using 0.2pm filter unit) 
P-glycerophosphate 1M stock in dH20, filtered (using 0.2ýLrn filter unit) 
B&T-2/BW-4 10-200ttghnl in 0.2%BSA in PBS, stored at -80*C (Ge- 
netics Institute, Cambridge, MA) 
PTH Amino acid fragment 1-34; 1 OOmM stocks in PBS 
75 
2. Materials and Methods 
1,25-(OH)2D3 I OmM stock in ethanol (100%) from Calbiochern (Not- 
tingharn, U. K. ) 
Dexamethasone I OOn-A4 stock in ethanol (100%) 
2.6.2 Maintenance of osteoblast-like cell lines 
All cells were manipulated under sterile conditions in a Class 11 cabinet. Cells were 
maintained at 37T in an atmosphere of 5% (VIV) C02 in air (Forma Scientific). SaOS- 
2, ROS 17/2.8 and MG63 cells were maintained in DNEM (Sigma) supplemented with 
10% heat-inactivated FBS (E. C. approved from Gibco BRL), I% glutamine (200mM L- 
glutamine and 1% penicillin and streptomycin (5,000 units/ml penicillin, 5,000mg/ml 
streptornycin) (Gibco BRL). MC3T3-EI cells and primary rat osteoblasts were simi- 
larly maintained, but with the exception of cc-MIEM instead of DMEM. FBS from Mel- 
drum or Gibco BRL was used for medium for most experiments except for differentia- 
tion experiments when FBS from Summit was used. Cells were sub-cultured when 
monolayers were confluent in a 1: 5 ratio approximately twice weekly, by treatment with 
0.05% (w/v) trypsin-EDTA at VIC for 5 min to ensure release from the culture vessel 
and the trypsin was then neutralised with culture medium. 
2.6.3 Estimation of cell concentration 
To count the cells for experiments, cells in culture were trypsinised as above and sus- 
pended into a suitable volume of medium. A sample of cell suspension was diluted 1: 10 
with 0.4% (w/v) trypan. blue (Sigma) and counted in a haemocytometer (the trypan blue 
is excluded from viable cells). The cell suspension was the diluted into the required 
concentration. 
2.6.4 C ryop reservation of cells 
FoUowing treatment with trypsin, ceU peHets were resuspended in 40% FBS, 50% cul- 
ture medium and 10% DMSO at approximately 1XI06 ceUs/ml and frozen at -80'C 
overnight in cryotubes (Nunc, Gibco) in an insulated container and then transferred to a 
liquid nitrogen ceU storage bank. 
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2.6.5 Stable transfection of MC3T3-E1 with pJMF-2-c-fos and pJMF-2-luc 
vectors 
Exponentially growing MC3T3-EI cells were transfected using Effectene reagent 
(Qiagen) according to manufacturer's instructions. Cells were seeded at 10' cells per 
10cm dish and incubated overnight. Transfection with pRAF-2-c-fos, pJMF-2-luc vec- 
tors or rninus DNA control was carried out overnight in the presence of Tc (10ýtg/n-d), 
according to Qiagen's recommendations for 10cm. dish. 
FoHowing 48 hours in culture the transfected cefls were passaged from each dish 
into 4 dishes at varying densities. Cells were cultured with 300pg/ml G418 (Sigma) for 
two weeks to allow for colony selection. Medium was replaced every 2-3 days. Cell 
death was abundant and individual cells gave rise to well separated colonies. Control 
(no DNA) transfections resulted in complete cell. death within 4 days. Individual clones 
were picked by first washing the culture vessel with PBS, followed by isolating the area 
using steel cloning rings which had been carefully coated with silicone gel around the 
base. Colonies were treated by gentle trypsinisation to release the colonies and trans- 
ferred to the wells of a 48-well plate, for clonal propagation. Clones were propagated 
in culture for analysis of genotype including exogenous c-Fos expression (KTI. 1-22; 
section 2.8.4) and luciferase activity (KT2.1-7; section 2.6.6.4). 
2.6.6 Transient transfection of cells 
2.6.6.1 Transfection of p2l and Bcl-2 in KT1.5 cells using Effectene 
To assess the affects of the CDK2 inhibitor p2l and anti-apoptotic protein Bcl-2 on c- 
Fos-induced apoptosis, KTI. 5 cells were transfected with p2l or Bcl-2 expression 
plasmids. KT1.5 cells were cultured on glass coverslips in 6-well plates in the presence 
and absence of Tc: for 24 hours to induce c-Fos expression. Three wells were allocated 
per group. Cells were transfected overnight in the absence of Tc with pcDNA-3, p2l- 
HA (Dr. A. Yeudall, Craniofacial Development Dept., King's College London) and 
pBcI-2 vectors (Dr. S. Korsmeyer, Depts of Pathology and Medicine, Harvard Medical 
School, Boston, MA) or in the absence of DNA using Effectene reagent following 
manufacturer's instructions for 6-well plate. In addition, a secreted placental alkaline 
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phosphatase (SPAP) reporter vector (pCMV-SPAP; a gift from Glaxo, SmithKline, 
Stevenage, UK), was included as the internal control for transfection efficiency between 
groups. This reporter product codes for a heat resistant secreted placental alkaline 
phosphatase, which is secreted into the medium and can be easily detected without dis- 
turbing the cells. Following the removal of transfection medium, cells were cultured for 
a further 24 hours with standard medium ± Tc. Culture medium was assayed 24 hours 
later for SPAP activity (detailed in section 2.6.6.3), with three samples per transfection 
group. Cells were washed three times with PBS before apoptosis was induced by serum 
withdrawal (0% FCS, 0.1% BSA), ±Tc: for 24 hours. Cells were then fixed and stained 
with propidium iodine for assessment of apoptosis (section 2.6.11). 
2.6.6.2 Lipofection of cells with pMW-CAT, pSV40-CAT and pCAT-Basic 
vectors 
Factors known to be important in bone development, in particular PTH, were screened 
for their ability to induce the expression of two murine Msx2-CAT (Chloramphenicol 
acetyhransferase) reporter gene constructs containing the 1.2kb or 2kb Msx2 upstream 
regulatory sequence. The 1.2kb Msx2-CAT construct (Figure 8.1 -Appendix) was pre- 
pared by Jane Hodgkinson (PhD thesis, 2000) by inserting a murine 1.2kb MSX2 pro- 
moter fragment into pCAT-Basic (Promega) upstream of the CAT coding sequence in 
this plasrnid. The 2kb Msx2-CAT construct was a gift from Dr. R. Maxson, Los Ange- 
les, USA (Liu et al, 1994, Liu et al 1999). The 2kb Msx2 fragment used in this con- 
struct is located approximately 3kb upstream of the transcription start site (pers. comm). 
Furthermore, the control plasmids that were used included pCAT-basic (Promega), 
a negative control for transfection, and pSV40-CAT (Promega), which consists of 
pCAT-basic and SV40 promoter sequence, a strong constitutive promoter and hence 
positive control. In addition, pCMV-SPAP was included as the internal control for 
transfection. 
Since the efficiency of lipofection is dependent upon many factors, preliminary ex- 
periments were designed to establish suitable quantities of Lipofectamine TM (Gibco 
BRL) and DNA according to manufacturer's instructions. From this experiment the 
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highest lipofection efficiency was observed in samples when I gg DNA and 8 pl Lipo- 
fectamine were used in I ml of culture medium (data not shown). 
Cells were seeded into 6-well plates 24 hours before transfection so that the cells 
were approximately 60% confluent for the time of transfection. The Epofection of cells 
was carried out using 8pM Lipofectamine and I jig/ml of the following vector DNAs: 
1.2kb Msx2-CAT, 2kb Msx2-CAT, pCAT-basic, or pSV40-CAT according to manu- 
facturer's instructions for 6-well plates. pCMV-SPAP (0.2pg/ml) was also included in 
each of the aforementioned transfection reactions as an internal control for transfection 
cfficiency. Cells were transfected overnight in serum-free conditions, before medium 
was changed to 10% FCS by the addition of an equal volume (IMI) of 20% culture 
medium for a further 5 hours. By this the, cells had recovered, were passaged by tryp- 
sinisation into the wells of a 6-well plate, and cultured for a further 24 hours before a 
sample of medium was taken for assessment of SPAP activity (section 2.6.6.3). Cells 
were treated with osteotropic: factors or vehicle control in 2% foetal bovine serum for 
up to 24 hours. These factors included PTH, 1,25-(OH)2D3. BNT-2, BUT-4, FGF-4, 
FGF-8, Sonic hedgehog and dexamethasone concentrations as indicated. 
Following treatment, cell extracts were prepared in Promega's Ix Reporter Lysis 
Buffer (300ýfl) and CAT activity monitored by assessing the incorporation of 14 C- 
chloramphenicol (ICN Flow) using liquid scintillation counting according to the Pro- 
mega protocol. CAT activity was represented in counts per minute (CP". Samples 
were standardised for protein content (section 2.9.4) and SPAP activity to control for 
transfection cfficiency. Due to the fact that there was variability in the levels of CAT 
activity (or CPM) between experiments the data was standardised between experiments 
by expressing CPM for treatment as a ratio of the CPM for the control (T/O: the relative 
CAT activity). 
Co-transfecting cells with constructs, such as CMV-SPAP, can result in a lower 
transfection efficiency and reporter gene response. Therefore, a comparison was made 
between Msx2-CAT-transfected and CMV-SPAP/Msx2-CAT co-transfected SaOS-2 
cells in their response to PTH. SaOS-2 cells were transfected with pMsx2-CAT (1.2kb 
construct) alone or pMsx2-CAT plus pCMV-SPAP vector. Following transfection, 
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cells were treated for 24 hours with PTH (IOnM), before extracts were prepared for 
assessment of CAT activity as described above. 
2.6.6.3 Estimation of SPAP activity 
Alkaline phosphatase cleaves the phosphate group from the substrate p-nitrophenyl 
phosphate (pNPP) yielding a yellow-coloured product, p-nitrophenol (pNP), whose 
absorbance can be measured at 405nM. Samples of medium were taken at 24 hours to 
confirm transfection efficiency by measuring the amount of SPAP activity before any 
treatment was added (Tate et al, 1990). To do this, 50pl spent medium was heat- 
inactivated at 65'C for 30 min, to inactivate any endogenous alkaline phosphatase. 
PNPP reaction mixture (Iml) was added, mixed and transferred to a plastic cuvette, 
then the reaction was developed in the dark. This reaction mixture consisted of 5MM p- 
nitrophenylphosphate (PNPP) in DEA buffer (IM diethanolamine, 0.28M NaCl, 0.5m. M 
MgC12H20, pH9.85). The absorbance at 405mu was measured when a yellow colour 
started to develop. The concentration of SPAP in the original medium in units/ml were 
calculated as follows: 
[SPAP] units/ml = Abs4o5. /t x 18.5 x Vol 
where, AbS 405nm = Absorbance at 405nm, 
t= time of PNPP reaction (in min), 
Vol = volume of medium assayed (n-A). 
2.6.6.4 Estimation of Luciferase activity in KT luciferase clones 
KT luciferase clones (KT2.1-2.7) and AT7.8 (positive control) were plated in a 6-well 
plate and cultured for 4 days ± Tc (I OjtghnI). Cell lysates were prepared in Ix Reporter 
Lysis Buffer (Prornega; 145ýtl/well). Lucifcrase activity (20ýd cell extract) was assessed 
according to manufacturer's instructions, using a lurninometer (10 sec reading) and the 
amount of light intensity produced was standardised for the protein content of each 
sample (section 2.9.4). 
2.6.7 Osteoblast differentiation 
Wild type (wt) MC3T3-EI cells, c-Fos clones KTI. 5 cells and AT9.2 cells, and the 
Luciferase clone KT2.1 were cultured to induce differentiation for a minimum of 30 
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days. Cells were plated at a density of 2xIO4 cells/well of 24-well Plate, in standard 
medium: a-MEM supplemented with 10% FCS (Meldrum) and Tc (10ýtgftrd). The 
culture medium was replaced after 24 hours with differentiation medium: a-NEM sup- 
plemented with 10% FCS (Summit), 50gg/mI ascorbic acid, lOmM P-glycerophosphate, 
Tc (0, l[tg/ml) and BNT-2 (0, lOOng/n-d). The medium was replaced every 3 days. 
After 30 days, cultures were fixed in 4% formaldehyde in PBS and stained for alkaline 
phosphatase activity and mineral as described in section 2.6.8. In addition, similar cul- 
tures were set up for mRNA expression analysis by RT-PCR (sections 2.8-5) and quan- 
titative assessment of alkaline phosphatase activity as described in 2.6.9. 
2.6.8 Histological identification of alkaline phosphatase 
Cells were fixed as previously described and the cells were rinsed with dH20, and then 
incubated in dH20 for 15 min before the substrate for alkaline phosphatase was added. 
For 50ml substrate 5mg Naphthol AS MX-P04 was dissolved in 200ýfl DNF. This was 
mixed with 25 ml 0.2M Tris-HCI pH8.3,25 ml dH20 and 30mg Red Violet or Fast Red 
TR Salt. The mixture was filtered (0.2gm filter unit) immediately before it was added 
to the cell layer. Cells were incubated with substrate for approximately 20-30 min at 
37*C, before the stain was washed off with three changes of dH20 and finally stored in 
dH20. 
2.6.9 Quantitative assessment of alkaline phosphatase activity 
KT 1.5 and KT2.1 cells were cultured in differentiation medium including Tc (0,1 ýtg/ml) 
and BUIP-2 (0, lOOng/n-d) for 35 days as described in section 2.6.7. Cells were washed 
with PBS and scraped from the well into an eppendorf tube with 200ýd 50mM Tris-HCI, 
pH7.4. Cells were sonicated (20 sec on ice) and pelleted by centrifugation at 5000 rpm 
for 30 rnin at 4*C. The supernatant was tested for alkaline phosphatase (ALP) activity 
as described section 2.6.6.3 with the exception that extract was not heat-inactivated 
before assessment. Protein concentration per sample was determined using the BCA 
protein assay reagent (section 2.9.4) so that alkaline phosphatase activity could be ex- 
pressed in units ALP/[Lg protein/well. 
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2.6.10 Osteoblast proliferation assay 
For analysis of proliferation, MCM-El, KTI. 5 and KT2.1 cells were plated (in 24- 
and 48-well plates at between 102 and 104 cells/crrý) in standard medium (as above) for 
24 hours, then changed to differentiation medium containing Tc and BNP-2, or re- 
mained in standard medium, as indicated for each experiment. Cells from triplicate 
wells were individually trypsinised from the culture vessel and cell numbers counted 
(section 2.6.3) at the indicated times. 
2.6.11 Assessment of osteoblast apoptosis by Propidium Iodine and TUNEL 
Cells were stained with propidiurn iodine (PI) for the assessment of apoptosis in all 
experiments. Cells grown on glass coverslips (12mm diameter) were fixed for 5 min 
with 50% acetone in methanol (v/v) pre-chilled to -20*C. Coverslips were air-dried 
briefly (2-5 min), before cells were rehydrated with PBS. Coverslips were stored at 4*C 
until analysis. Excess PBS was removed before cells were stained with lOOpg/ml PI 
and 0.1 mg/mI RNase A in PBS. Coverslips were washed three times with PBS before 
mounting upside down onto clean glass slides with Vectashield mounting medium 
(Vector Laboratories) for analysis using fluorescence microscopy. Apoptotic nuclei 
were quantified by counting at least 100 cells per field in 5 fields of view per coverslip. 
DNA strand breaks during apoptosis were determined by TUNEL (TdT-mediated 
dUTP nick end labelling) assay using the In Situ Cell Death Detection, POD kit (Roche, 
Germany). In this histochemical test, the Terminal deoxyribonucleotidyl transferase 
(TdT) enzyme attaches fluorescein-labefled nucleotides (dUTP) to the Y-OH group of 
broken DNA. Incorporated fluorescein is detected by anti-fluorescein antibody Fab 
fragments from sheep. In one experiment, cells grown on glass coverslips were fixed 
with PFA for I hr at room temperature and rinsed in PBS. The cells were permeabilised 
(0.1% Triton X-100 in 0.1% sodium citrate) for 2 min on ice. Coverslips were rinsed 
twice in PBS and excess PBS absorbed away from the coverslip using 3MM paper. 
Cells were incubated with TUNEL reaction mixture (1: 10 dilution of terminal transfer- 
ase solution in label solution) in a humidified chamber for 60 min at 37*C. Coverslips 
were rinsed again with PBS (three times), before mounting onto glass slides with Vec- 
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tashield for analysis using fluorescence microscopy. Negative controls were made by 
omitting the terminal transferase from the reaction mixture. 
2.6.11.1 Assessment of apoptosis in KTI. 5 cells induced by serum withdrawal or 
TNF-cc 
For the induction of apoptosis, KTI. 5 and KT2.1 cells were plated on glass coverslips 
(4 per well) in a 6-well plate in cc-NEM supplemented with 10% FCS and Tc 
(10pg/ml). After 24 hours the cells were washed three times in PBS and the medium 
was replaced with medium ± Tc for a further 48 hours. Following three washes with 
PBS, apoptosis was induced for 48 hours by serum-withdrawal ((x-IýEM supplemented 
with 0.1 % BSA) ± TNF-a (3 Ong/xnl; R&D Systems) or 10% FCS ± TNF-a before cells 
were fixed for apoptosis assessment (section 2.6.11). 
Caspase inhibitors Z-VAD-frnk and DEVD-CHO (Calbiochern) were used to in- 
hibit the apoptosis induced by serum withdrawal in the presence of c-Fos expression. 
Preceding induction of apoptosis, cultures were set up as above and then various re- 
gimes were used to study these inhibitors: 
1) Cells (+ Tc only) were treated complete growth medium (10%) or serum with- 
drawal (0% FCS, 0.1% BSA), and a range of Z-VAD-fink concentrations (0,3, 
10,1 WgND. After 24 hours treatment cells were fixed and assessed. 
2) Cells (± Tc) were pretreated for 24 hours ± Z-VAD-fmk (10ýtý, before me- 
dium was replaced with complete growth medium (10%) or serum withdrawal 
(0% FCS, 0.1% BSA) ± TNF-cc (30ng/n-A), and ± Z-VAD-fink. Cells were 
treated for further 48 hours before cells were fixed and assessed. 
3) Again, cells (± Tc) were pretreated but for I or 6 hours ± Z-VAD-fink (I Ogm), 
before apoptosis was induced by serum withdrawal (0% FCS, 0.1% BSA) ± Z- 
VAD. After 48 hours treatment cells were fixed and assessed. 
4) Cells (± Tc) were pretreated for I hour ± DEVD-CHO (3,3011M), before me- 
dium was replaced with complete growth medium (10%) or serum withdrawal 
(0% FCS, 0.1% BSA) ± DEVD-CHO. After 48 hours treatment cells were 
fixed and assessed. 
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5) Once more, ceUs (± Tc) were pretreated for I hour ± DEVD-CHO (30[iM), 
before apoptosis was induced by serum withdrawal (0% FCS, 0.1% BSA) plus 
TNF-a (30ng/ml), ± DEVD-CHO. CeRs were treated for further 48 hours be- 
fore cefls were fixed and assessed. 
The CDK2 inhibitor, Roscovitine (Calbiochem), was also used to inhibit the apop- 
tosis induced by serum withdrawal in the presence of c-Fos expression. Preceding 
apoptosis induction, cultures were set up as above, then ceus (± Tc) were pretreated for 
I hour Roscovitine (0,3,10,30liM), before apoptosis was induced for 48 hours by 
serum withdrawal (± Roscovitine) and assessed as before. 
The effects of Roscovitine and Z-VAD-fmk were also assessed on Etoposide- 
induced apoptosis. CeUs were set up as above and were pretreated for I hour with 
Roscovitine (30ýM) or Z-VAD-fmk (10,30gW before induction of apoptosis by Eto- 
poside (I OOpg/rnl; Sigma) for 48 hours. 
Finally, cells were quiesced before induction of apoptosis. Cells were cultured ± 
Tc for 24 hours before quiescence was induced in 0.5% serum for 24 hours, then a fur- 
ther 24 hours ± Roscovitine (30ýM in 0.5% serum). Apoptosis was induced for 48 
hours by serum withdrawal (0% FCS, 0.1% BSA), or ceUs remained to be treated with 
0.5% serum, ± Roscovitine. 
2.6.12 Assessment of cAMP production 
The amount of cAW produced following treatment was assessed in order to confirm 
the activity of PTH used in the experiments in 2.6.6.2 above. Cells (SaOS-2, MC3T3- 
E 1, ROS 17/2.8) were plated at 1.25 x 10' cells per well of 24-well plate and incubated 
overnight. Cells were first pre-treated with serum-free medium containing 500ýiM 
isobutyltnethlyxanthine (IBMX; 400ptl) or DMSO (1% v/v) for 15 min. IBMX was 
removed and replaced with scrum-free medium containing IBMX (500ýtM) and PTH (0, 
10,1 OOmn), forskolin (I OpM) or DMSO. Following incubation at 37"C for 15 min, the 
treatment was terminated with the addition of 800ýil absolute ethanol at -200C. The 
ethanol extract containing the cAMP was removed and transferred to microcentrifuge 
tubes. The wells of the 24-well plate were washed with 400til ethanol (66% v/v) and 
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the extract transferred to the same appropriate tube. Samples were centrifuged in a 
microcentrifuge and supernatant containing cANT transferred to a new tube. The etha- 
nol was evaporated using a rotary, pulsed vacuum evaporator for approximately 350 
min, at 50*C. 
The Biotrak cAND enzymeimmunoassay (EIA) system (RPN225; Amersharn, 
Pharmacia Biotech) was used to determine the concentration of cAMP, by following the 
manufacturer's instructions for non-acetylation assay (standards of cANIP in the range 
of 12.5-3200fmol/well). The reaction was stopped by the addition of sulphuric acid, 
and the absorbance of reaction measured at 450nm in a microplate reader. Samples and 
standards were assayed in duplicate. Protein concentration was determined using the 
Bio-Rad DC Protein Assay (as detailed in section 2.9.4) to standardise the samples for 
cANIP concentration per pg protein (finol/ pg protein). 
2.7 Southern Hybridisation Analysis 
2.7.1 Preparation of genornic DNA 
For the genotyping of TRAP-c-fosLTR mice, DNA was isolated from tail ends by over- 
night incubation at 55*C in 700ýfl volumes of 50mM Tris-HCI pH7.5, lOOMM NaCl, 
l0m. M EDTA, 1% SDS, O. 5Vg/mI proteinase K (10mg/ml stock in depc-dH20). The 
resultant mixture was cleaned by the addition of 5001A of 6M NaCl (a saturated solu- 
tion) and 5 min continual shaking. The samples were centrifuged at 10,000g for 7 min 
and 7501il of supernatant removed to a new tube. The DNA was precipitated by the 
addition of 500gl of isopropanol and mixing for 2 min. The precipitate was then pel- 
leted by 5 min centrifugation at I 0,000g and the supernatant removed. The pellet was 
washed in 80OVI of 70% EtOH and the pellet isolated by 5 min centrifugation at full 
speed and all of the supernatant removed. The pellet was dissolved in 50-200gl TE, left 
to dissolve overnight at 4'IC or incubated at 37*C with gentle shaking for 2 hours. 
2.7.2 Southern blotting 
For genotyping of TRAP-c-fosLTR mice and identification of transgene integration, 
each DNA sample (IOpg) was digested with XbaI restriction enzyme overnight and 
electrophoresed on 0.8% agarose gel in Ix TAE, and the gel was photographed beside a 
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ruler. The gel was first depurinated in 0.25N HCI for 20 min with gentle shaking, and 
then denatured with 0.5M NaOIVl. 5M NaCl for 30 min. A sheet of charged nylon 
membrane (GeneScreen Hybridisation transfer membrane, NEN) and 3MM Whatmann 
paper were cut to the exact size of the gel and pre-wet in dH20for 10 min followed by 
IN SSC (dilution of standard 20x stock: 3M NaCl, 300MM sodium citrate, pH7.0). 
The following Southern transfer was then set up: First, a clean glass plate was laid on 
top of a sheet of 3MM paper. The gel was inverted and gently placed on top of this, 
followed by membrane, then 4 sheets of pre-wetted 3MM paper. Air bubbles were 
eliminated by the rolling of a pipette across the surface after each sequential positioning 
of the gel, the membrane, and the paper. Saran wrapTM was arranged around the gel so 
as to prevent a short-circuit of liquid. A 10cm high stack of highly absorbent paper 
towels, the same dimension of the gel, was placed on top of the transfer blot followed 
by a weight (approximately 250g). The transfer was allowed to continue overnight. To 
confirm completion of transfer, the gel was viewed under UV illumination for visualisa- 
tion of any remaining DNA. The position of the wells was marked in pencil on the 
membrane, before the membrane was rinsed whilst stationary in 50mM sodium phos- 
phate buffer (pH7.2) for 10 min followed by 10 min shaking. DNA was fixed to the 
membrane by UV-crosslinking whilst wet at 120V for 100 sec before baking at 80*C for 
I hour. Membrane was then stored between filter paper until hybridisation. 
2.7.3 Southern Blot Hybridisation 
The membrane was pre-hybridised for 30 min at 65'C with Church's Buffer (0-5M 
Na2BPO4 pH7.2,7% SDS, ImM EDTA, pH8.0) in a rolling bottle Techne Hybridisa- 
tion Oven at all stages. The probe (a 0.8kb Bam1II v-fos fragment labelled with a-32p 
as described in section 2.3.6) was denatured for 10 min with NaOH (0. IN final concen- 
tration). Fresh Church's Buffer was added to membrane and followed by the denatured 
v-fos probe. 
After hybridising overnight, non-specific hybridisation was removed by a series of 
15 min washes in Church's wash buffer (1% SDS in 40mM NaPi [89g Na2HP042H20, 
34ml H3P04. pH7.2]) at 65"C, until removal of background signal was observed. In 
between each wash, the membrane was temporarily removed from the bottle and moni- 
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tored using a Geiger counter and the washing stopped once the areas of the membrane, 
which were not expected to bind probe, were emitting low background readings. The 
membrane was then wrapped in Saran Wrap and autoradiography performed in an X-ray 
cassette at -80'C beside a piece of X-ray film (Kodak Scientific Imaging Film, X- 
OMAT'rm AR) and an intensification screen (GRI). If the resultant film revealed high 
background radioactivity the washing process was repeated. 
2.8 RNA extraction, Northern hybridisation analysis and RT-PCR 
All stock solutions (e. g., dH20, PBS, NaOAc) were treated with 0.01% DEPC over- 
night and autoclaved at 115T for 15 min prior to use or where this was not possible 
(e. g., agarose, SDS, diluted ethanol, NaCl) the constituents were carefully weighed out 
using RNase-free conditions and suspended in depc-H20. All washes and incubations 
were performed at room temperature with gentle agitation, unless otherwise stated. 
Following RNA extraction RNA was stores at -80T. 
2.8.1 Extmction of poly (A)' RNA 
Poly (A)' RNA was extracted by either of the two oligo d(T) column methods: extrac- 
tion using oligo d(T) cellulose from Roche or by the PolyATtract(9) Series 960OTM iSo- 
lation kit (Promega). 
Cells were cultured as described in section 2.8.4 and pelleted from the culture ves- 
sel by trypsinisation and centrifugation at 1200rpm for 5 min. The pellet was washed 
once with PBS and centrifuged again, before freezing at -801C until extraction was 
performed. The cell pellet was thawed on ice and resuspended in 5ml STE (0. IM NaCl, 
20mM Tris pH7.4, lOmM EDTA pH8.0), 200ýd proteinase K (10mg/ml) and 250ýd 
SDS (10% w/v stock). Cells were homogenised using a Polytron at setting 8 for 30 sec 
and incubated at 37"C for 30 min. NaCl (450pl; 5M) and 2ml of 50mg/ml oligo, (d)T 
(Roche) suspended in loading buffer (OAM NaCl, 20mM Tris pH7.4, IOMM EDTA 
pH8.0,0.2% SDS) were then added, and incubated overnight on a slowly moving 
shaker. Samples were centrifuged at 2,000rpm for 5 min, washed twice with Loading 
buffer (10ml), and finally resuspended in lOn-A Loading buffer to be poured to a Poly- 
PrepID Chromatography Column (Biorad). This was washed with In-A Loading buffer, 
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followed by I Oml Washing buffer (0.1 M NaCl, I OmM Tris pH7.4, I mM EDTA pH8.0, 
0.2% SDS). Finally, poly (A)' RNA was eluted into siliconised 30ml glass Corex tubes 
with 5ml pre-warmed (37*C) elution buffer (ImM Tris pH7.4, ImM EDTA pH8.0, 
0.2% SDS) and a sample taken for estimation of RNA integrity before being precipi- 
tated at -20"C overnight with 30gg transfer RNA (20mg/mI tRNA stock), 0.88ml 2M 
NaOAc and 12ml absolute ethanol. RNA pellet was produced by centrifugation at 
10,000rpm for 45 min at VC in Beckman JA-14 rotor, washed and centrifuged again 
with 70% ethanol, and briefly air-dried before being resuspended at 0.5mg/mI in depc- 
dH20. 
Tissue removed from TRAP-c-fosLTR mice at autopsy was frozen immediately in 
liquid N2 and stored at -80"C until RNA extraction was performed. To extract RNA, 
tissue fragments were transferred to a 50ml Falcon tube containing 8ml solution D (4M 
guanidium. isothiocyanate, 25mM sodium citrate, IOOmM P-mercaptoethanol, 0.5% 
laurlysarcosine, 0.1% Antifoam) and homogenised using a Polytron at full speed as 
above (45 sec or longer for bone and calcified tumour samples). NaOAc (800pl; 
pH4.0), 8ml Tris-saturated phenoL and 1.6ml chloroform were sequentially added with 
vigorous mixing in between each addition and incubated on ice for 15 min. Samples 
were transferred to 30ml Corex tubes for phase separation at 10,000rpm for 15 min in 
Beckman JA-14 rotor. The upper phase was removed and an equal volume isopropanol 
added for precipitation of RNA (-20"C, overnight). Samples were centrifuged again at 
I 0,000rpm for 15 min to produce an RNA pellet. The pellet was dissolved in 5ml ice- 
cold STE. Following on from this step, RNA was processed as above for extraction of 
poly (A)' RNA from cells. 
For the extraction of poly (A)' RNA by oligo d(T) columns using Promega, 
PolyATtractID Series 960OTm isolation kit, cells were grown in tissue culture and pel- 
leted from the tissue culture vessel by trypsinisation as before, but the cell pellet was 
washed with PBS before quick freezing in a methanol/dry-ice bath, until the extraction 
of poly (A)+ RNA according to Prornega's instructions. 
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2.8.2 Extraction of Total RNA 
Cells were pelleted from the wells of 24-well plate by trypsinisation as before. The cells 
in the pellet were lysed by the addition of 300ýd Solution D, followed by the sequential 
addition of 30ýd 2M NaOAc (pH4.0), 300ýd phenol (Tris-saturated) and 76ýLl chloro- 
form, with vigorous mixing in between each addition. The mixture was vortexed for 10 
sec and incubated on ice for 15 min. Phase separation was achieved by centrifugation at 
10,000rpm for 20 n-dn at 4"C. The aqueous phase was removed and RNA precipitated 
by the addition of 300pl isopropanol at -20'C overnight. The RNA was recovered by 
centrifugation at I 0,000rpm for 20 min at 4"C, and the pellet was resuspended in I 00AI 
Solution D and 200ýd ethanol for a further precipitation overnight at -200C. Samples 
were centrifuged at I 0,000rpm for 10 min at 4"C, the supernatant was removed and the 
pellet was washed in I OOgI 75% ethanol and centrifuged again. Following removal of 
the supernatant the pellet was briefly air-dried. The pellet was resuspended in 30ý11 
depe-H20. 
2.8.3 Northern blotting 
All equipment such as gel tank and combs were washed with 0.1 M NaOH followed by 
rinsing in depc-H20 in order to minimise RNase contamination. The denaturing gel was 
prepared by dissolving 3.15g high grade agarose (ICN) in 285ml dH20 and 7ml 50x 
MOPS (IM MOPS, 0.25M NaOAc, 0.05M EDTA) by boiling. After cooling, 59ml 
RNase-free formaldehyde was added to the gel mixture. 
RNA (I Ogg) samples were diluted to a volume of 201A with depc-dH20 before ad- 
dition of 20ýtl formamide, 7ýd formaldehyde (40%), 1 gl 50x MOPS and 2gl bromophe- 
nol blue. Samples were denatured at 700C for 5 min and immediately chilled on ice for 
5 min. Samples were run on the gel in running buffer composed of Ix MOPS in dH20: 
the gel was run at 100V for 30 min followed for 4 hours at 120V. A peristaltic pump 
was used after 30 min of electrophoresis to allow for the re-circulation of buffer. The 
gel was washed for 20 min in lOx SSC, with gentle shaking, before RNA was trans- 
ferred by Northern blot: First, 3MM paper, cut to a larger size than the gel, was placed 
on a glass sheet placed across a large tray containing I Ox SSC, so that the paper acted 
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as wick for the absorption of SSC. The top of the paper was also thoroughly wetted 
and air bubbles released using a plastic pipette. The gel and then a piece of pre-soaked 
nitrocellulose membrane filter (GeneScreen Hybridisation transfer membrane, NEN), 
cut to the same size as the gel, were placed on top of the paper and the support, ensur- 
ing there were no air bubbles. Approximately 8 sheets of pre-soaked 3MM paper and of 
dry 3MM paper, cut exactly the same size as the nitrocellulose filter, were placed on top 
of the gel, followed by paper towels to a height of 10cm. Following this, the proce- 
dures were the same as those for Southern blotting (section 2.7.2) 
2.8.4 Northern Blot Hybridisation 
The procedure for hybridisation of DNA probe was as described for Southern hybridi- 
sation (see section 2.7.3). Following hybridisation and analysis, the blot was washed 
for 30 min at 800C in stripping buffer (2mM EDTA, 1% SDS) in order to remove the 
bound probe, prior to rehybridisation with subsequent probes. 
For the assessment of transgene expression in different tissues from TRAP-c- 
fosLTR mice, poly (A)ý RNA extraction (using oligo d(T) column) and Northern blot 
analyses using 10jig mRNA per lane were carried out as described above. The v-fos 
was used as a probe for c-fos expression. This probe also hybridises to fox mRNA, a 
constitutively expressed mRNA in mouse tissues that can be used to normalise for 
loading. In addition, the blots were probed for c-jun, fra-1 and matrix metallopro- 
teinase 9 (MNT-9) transcripts (section 2.3.5.1 for fragment preparation). 
c-fos transgcne expression was also assessed in KTI. 5 clones. Cells were cultured 
in the presence and absence of Tc (0,10pg/ml) for 3-4 days in 15mm dishes until almost 
confluent. Poly (A)' RNA extraction (using oligo d(T) column), Northern blot analyses 
and a v-fos DNA probe were used as previously described. RNA extracted from 
pM2-c-fos transfected ATDC5 cells (DT12.4) was kindly donated by Dr. D. Thomas 
and used as a positive control for transgene expression. 
To evaluate the endogenous expression of MSX2 in SaOS-2 cells, cells were plated 
in l5rnm dishes and cultured until almost confluent before treatment with PTH (frag- 
ment 1-34; 0,10,1 OOnM) for 2,4 and 24 hours. Poly (A)' RNA extraction (using the 
Promega ofigo d(T) column polyATtract isolation kit) and Northern blot analyses using 
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10ýtg mRNA per lane were carried out as described above using DNA probes contain- 
ing Msx2 coding sequence, glyceraldehyde-3 -phosphate dehydrogenase (GAPDH) to 
control for mRNA loading, and alkaline phosphatase was used as a control for PTH 
activity (section 2.3.5.1 for DNA fragment preparation). 
2.8.5 RT-PCR 
Total RNA was extracted from MC3T3-EI and KTI. 5 cells differentiated for assess- 
ment by RT-PCFL Wild type (wt) MC3T3-EI cells and KTI. 5 cells (c-Fos clone) were 
cultured overnight at 2xI 04 cells/well of 24-well plates in a-MEM containing 10% FCS 
(Meldrum, Hants, UK), and in the presence of Tc; (Iýtg/ml) for KTI. 5 cells, to allow 
cells to settle and attach. Cells were washed with PBS and culture medium was 
changed to differentiation medium containing 10% batch-tested serum (Summit, Den- 
ver, CO, USA), ascorbic acid (O. Img/mI) and P-glycerophosphate (IOmM) in the pres- 
ence and absence of Tc (KTI. 5 cells) and BNW-2 (100ngln-A). Differentiation medium 
was changed every 3-4 days. Total RNA was extracted from cells in culture at day 1, 
15,30 (MCM-El cells) and 5,16,30 (KTI. 5 cells) as described in section 2.8.2. 
Primers for RT-PCR were obtained from Gibco BRL and the sequences of the 
primers were as foHows: 
GAPDH 
Anti-sense 5'-GAT GCA GGG ATG ATG TTC-39 
Sense 5'-CCA CGA GAA ATA TGA CAA-3' 
Product size 250kb 
Alkahne phosphatase 
Anti-sense 5'-TTC TGC TCA ATG GAC GCC GTG AAGC -3' 
Sense 5'-GCA GGA TTG ACC ACG GAC ACT TATG -3' 
Product size 409bp 
RT-PCR (reverse transcription-polymerase, chain reaction) was performed on the 
samples using a Gene ANT@ Thermostable Mh Reverse Transcription RNA PCR Kit 
(Perkin-Elmer) according to the manufacturers instructions. Briefly, the reverse tran- 
scription (RT) of 250ng total RNA into cDNA was performed by adding 5 units of rTth 
DNA polymerase to the reverse transcription master mix which included 250ng total 
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RNA, Ix reverse transcriptase buffer, ImM MnC12,200AM dNTPs, 1.5piM anti-sense 
primers and dH2O so that the total volume was 20ýd. To control evaporation or reflux- 
ing, the mix was overlaid with 50pl of mineral off (Sigma). Samples were incubated at 
70"C for 15 min in a Stratagene(V RoboCyclerO Gradient PCR machine using thermo- 
sensitive PCR tubes. 
The samples were maintained at 60C while the PCR master mix was added which 
included Ix chelating buffer, 1.5mM MgC12, and 0.3pM sense primers, made up to a 
final volume of I 00pl with dH20. PCR was performed as follows: After 3 min of pre- 
incubation at 95*C, amplification was performed for 30 cycles (MCM-El cells) or 24, 
28,30, and 32 cycles (KTI. 5 cells) consisting of I min denaturing at 95*C, I min of 
annealing at 70"C and I minute of extension at 60"C. The final cycle had a higher ex- 
tension time of 10 min at 60"C. Negative controls were included alongside all reactions 
to check for contamination, which contained all of the components of the reaction ex- 
cept RNA. 
2.9 Protein extraction and Western hybridisation analysis 
2.9.1 Protein extraction and SDS-PAGE 
Total cellular protein was extracted from cells for use in Western blotting. Briefly, cells 
were washed in ice-cold PBS, 800pl Tween lysis buffer (TLB: 50mM HEPES, 2.5mm 
EGTA, ImM EDTA, 150mM NaCl, 0.1% Tween-20, ImM NaF, IMM NaV04.30mM 
P-glycerophosphate, ImM DT-F, lOOpghnl PMSF, Igg/ml leupeptin, pepstatin and 
aprotinin, pH8) was added to the culture dish (I 5mm dish) and cells were scraped from 
the dish into a pre-chilled eppendorf tube. Cells were lysed by one freeze (dry ice)/thaw 
(on ice) cycle and with sonication (2x 15 sec). Following centrifugation (10,000 rpm at 
VC for 10 min), the protein concentration of the soluble fraction was determined with 
the BCA protein assay (see section 2.9.4) and the cell lysate was stored at -80'C. 
Protein sample (30-SOpg) was size fractionated using SDS-PAGE (Flowgen, Pro- 
seive) and electroblotted onto nitroceHulose membranes (GeneScreen Hybridisation 
transfer membrane, NEN). To make 20ml of a 8% resolving SDS-PAGE gel 2.85ml 
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dH20,0.8ml Acrylamide/bis, 1.25ml Tris-HCI (1.5M, pH8.8), 50PI 10% SDS, 50PLI 
10% APS, and 2.25ýtl TENED (Sigma) were mixed together. This was immediately 
poured between clean, pre-assembled SDS-PAGE plates and overlaid with H20- 
saturated butanol and allowed to polymerise for 20 min. The 1120-saturated butanol 
was removed and the gel surface washed well with dH20. The stacking gel, which con- 
sisted of 3.1 ml dH20,500ýd Acrylamidelbis, 1.25ml 0.5M Tris-HCI (pH6.8), 50ýd 10% 
SDS, 100gl 10% APS, 5pl TEMIED, was poured over the top and a clean comb in- 
serted before the gel had polymerised. 
Protein samples were mixed with R loading buffer (I 85mM Tris-HCI pH6.8, 
0.45M mercaptoethanol, 6% SDS, 0.1% Bromophenol Blue, 30% Glycerol) at a ratio 
of 2: 1. Samples, along with a protein molecular weight marker (NEB), were then 
heated to I 00*C for 5 min, quenched on ice for 2 min, pulsed I 0,000rpm, vortexed and 
then re-pulsed before loading on the gel. The gel was rim at 8mA in electrophoresis 
buffer (25mM Tris-base, 250mM glycine pH8.3,0.1% SDS) until the blue dye front 
entered the running gel, then at a constant 130V until the blue dye had migrated to the 
bottom of the gel. 
2.9.2 Western blotting 
Six pieces of 3MM Whatmann paper, cut to a size just larger than the resolving gel, 
were soaked in transfer buffer (I 29mM glycine, 25mM Tris-base, 10% methanol). One 
piece of nitrocellulose transfer membrane, cut to the size of the resolving gel, was first 
soaked in 100% methanol for 15 sec, then in dH20 for 5 min, and finally equilibrated for 
at least 5 min in transfer buffer. 
The membrane was placed on top of three pieces of pre-soaked filter paper. The 
gel was placed on top of the membrane and the three remaining pieces of pre-soaked 
filter paper were placed on top of this. Any air bubbles were smoothed out following 
each layering. This was placed onto a transfer cassette holder, which was closed and 
placed in a transfer tank so that the side of the cassette holder with the gel was facing 
the cathode. Transfer was allowed to proceed in transfer buffer for I hour at maximum 
voltage and 200mA. 
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To visualise the protein after transfer was completed, the membrane was soaked in 
methanol for 15 sec; and then left to dry for 30 min on a piece of filter paper. The dry 
blot was immersed in 20% methanol in d1120 for 2 min, then placed on a light box for 
transillumination of bands and photography. Following this, the blot was first placed in 
100% methanol for 20 sec, then in dH20 for 5 min, followed by TBS for 5 min. 
2.9.3 Protein detection 
Blots were blocked overnight at 4'C in 5% milk powder (Sainsbury's dried milk) in 
TBS. The blot was washed in TBST (TBS containing 0.1% Tween-20) for 5 mirL 
Primary antibody incubations (c-Fos, Bcl-2, Bax, P-actin; see below) were performed in 
1% milk powder in TBST for I hour at room temperature (or overnight at VC for c- 
Fos). The blot was rinsed briefly in TBST, then washed for 15 min and twice for 5 min 
in TBST. 
The membrane was incubated with the appropriate horseradish peroxidase (HRP) 
conjugated rabbit secondary antibody (DAKO, Denmark) diluted at 1: 2000 in 1% 
milk/TBST for I hour at room temperature on a rocking platforrn. The membrane was 
then briefly rinsed twice in TBST followed by one wash for 15 min and 2 washes for 5 
min again in TBST. Protein bands were visualised with the ECL Western blotting de- 
tection system (Arnersham Pharmacia, Biotech) following manufacturer's instructions. 
Bands were visualised by placing a sheet of film (Kodak) on top of the membrane and 
exposing it at different time points (usually 10 sec, 40 sec, 2 min, 5 min). 
For this thesis, the fbHowing primary antibodies (obtained from Santa Cruz Bio- 
technology, CA, USA) were used: c-Fos rabbit polyclonal IgG (diluted 1: 1000), Bcl-2 
rabbit polycloml IgG (1: 1000), Bax rabbit polyclonal IgG (1: 5000), and P-Actin goat 
polyclonal IgG (1: 2000). 
For the assessment of c-Fos protein in KTI. 5 clones, cells (KTI. 5,1.14,1.201, 
1.22) were cultured in 0,1, or 10ýtghnl Tc for 4 days before protein extracts were pre- 
pared and 30gg of protein was separated on SDS-PAGE (8%) gels as described above. 
A chondrogenic ATDC5 c-Fos over-expressing clone, DT8.6, was used as a positive 
control for c-Fos protein. Western blots were probed with a c-Fos specific antibody 
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(specific band - 62 kDa in size). In addition, blots were probed with P-actin antibody 
(-42 kDa) to control for loading. 
To assess for Bcl-2 and Bax protein Mowing induction of apoptosis in the pres- 
ence of exogenous c-Fos in KTI. 5, KT2.1, and AT9.2 cells, cells were cultured ± Tc 
for 48 hours to induce c-Fos expression, followed by either 10% serum or 0% serum 
(0.1% BSA) in a-MEM to induce apoptosis for 3 days. Protein extracts were prepared 
and 50gg of protein was separated on SDS-PAGE gels. An 8% gel was made to assess 
for c-Fos and P-Actin protein and a 12% gel for Bax (23 kDa), Bcl-2 (29 kDa) and P- 
Actin. Protein from the PI. 7 osteoblast-like cell line, derived from the bone turnours of 
H2-c-fosLTR mice (Grigoriadis et al, 1993), was included as a positive control. 
2.9.4 Estimation of protein concentration 
For the determination of protein concentration in lysates prepared in lysis buffbrs for 
Western analysis, Luciferase assays and alkaline phosphatase assays (sections 2.9.1, 
2.6.6.4,2.6.9, respectively), the BCA (Bicinchoninic; acid) protein assay reagent (Pierce, 
Rockford, Illanois, USA) was used according to manufacturer's instructions. For ex- 
tracts prepared for the assessment of cAMP following PTH treatment (section 2.6.12) 
protein concentrations were also estimated using the Bio-Rad DC Protein Assay fol- 
lowing the manufacturer's instructions. 
2.10 In Situ Hybridisation 
All stock solutions (e. g. dH20, PBS) were treated with 0.01% DEPC as described in 
section 2.8. Washes and incubations were performed at room temperature with gentle 
agitation, unless otherwise stated. 
2.10.1 Riboprobe synthesis 
Preparation of plasmid DNA for the production of the sense and anti-sense RNA probes 
was as described in section 2.3.5 and 2.3.5.1. FoHowing purification of DNA, Digoxi- 
genin (DIG) or C5 Sj-dUTP incorporated riboprobes were prepared by in vitro tran- 
scription as described below. 
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2.10.1.1 Digoxigenin (DIG) RNA labelling 
The DNA template (1-2[tg) was incubated at 37"C for 2 hrs with 2gl of lOx Transcrip- 
tion buffer (Promega), 2pl of 10x DIG RNA Nucleotide mix (10nim GTP, ATP, and 
CTP, 6.5mM UTP, 3.5mM digoxigenin UTP; Roche), 2 ýd 0.1 M DTT, I gl (26 units) of 
RNase inhibitor (Promega), 241 (40 units) of either T3, T7, or SP6 RNA polymerase 
(Promega) and dH20 added to a final volume of 20pl. The DNA template was removed 
by the addition of 2ýd RNase-free DNase I (10units/ýtl) and incubated for a finiher 15 
min at 37"C. The RNA transcripts were precipitated by the addition of 2.5pl 4M lith- 
ium chloride and 75pl of ethanol at -20'C overnight. The RNA was peheted by cen- 
trifugation at VC for 20 min, washed in 70% (v/v) ethanol in depc-dH20, air dried and 
resuspended in 20-100pl depc-dH2.0 and I til RNase inhibitor (Promega). Riboprobes 
were briefly vortex and dissolved for 20 min at 371C. A sample of the riboprobe (I- 
10pl) was then analysed on a gel as above to determine the quantity of riboprobe syn- 
thesised. 
2.10.1.2 [35S]-dUTP riboprobe syntbesis 
Riboprobes were produced according to the following Promega protocol. Linearised 
DNA template (2-3ýtg) was mixed with 51il 5x Transcription Buffer (Promega), 0.5pl 
IM DTT (BDII), 1.2ýd lOmM GTP, 1.2gl lOm. M ATP, 1.241 lOmM CTP, and 50ýLM 
UTP and 71il I OMCi/Mj [35S]-UTP (ICN Flow). Depc-dH20, RNA Polymerase (T3, T7 
or SP6; Promega) and I ýd RNase inhibitor (Promega) were added to make a total vol- 
ume of 25pl and incubated at 37*C for I hour and 40 min. To this reaction, 0.5pl 
DNase (Promega) was added together with 0.5gl tRNA (10mg/ml), 0.5ýd IM DTT and 
0.5gl RNase inhibitor (Promega). This was incubated for a further 10 min at 37*C. 
The riboprobe was precipitated at -801C for I hour or overnight by adding 300ý11 100% 
ethanol, 101d 3M NaOAc pH5.2, IM DTT and 95pl depc-H20 to the reaction mixture. 
Following centrifugation at 13,000rpm the riboprobe pellet was washed with IOMM 
DTT in 70% (v/v) ethanol twice, air dried for 10 min and re-suspended in 50ýd 50mM 
DTT in depc-HO. 
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2.10.1.3 Hydrolysis of riboprobes 
Labelled riboprobes (50ýtl) that were greater than 300bp in length were hydrolysed by 
addition of 50ýd hydrolysis buffer (40mM NaHC03,60mM Na2C03 pHI0.2, O. IM 
DTT) at 60'C for t min where: 
t= (L,, -Lf) /KxL,, x Lf 
L. = plasmid insert length (kb), Lf = length of riboprobe required (optimum 
riboprobe length for tissue penetration is 0.3kb), and K= hydrolysis constant 
for the hydrolysis buffer used = 0.11. 
Hydrolysis was stopped by the addition of 6ýtl 3M ammonium acetate pH5.2,3pl 
glacial acetic acid and 137ýd ethanol. The hydrolysed probe was precipitated at -80'C 
for at least 1 hour or overnight before centrifugation at 13,000 rpm for 15 min to pro- 
duce a pellet. The pellet was washed twice in I OmM DTT in 70% (v/v) ethanol, air 
dried for 10 min and resuspended in 501il 50m. M DTT in depc-H20. 
2.10.2 DIG in situ hybridisation 
Briefly, slides were pre-warmed to 501C before they were dewaxed using Histoclear. 
Sections were rehydrated through a decreasing series of ethanol in depc-dH20(100,95, 
80,60,30% v/v) and finally depc-dH20, post-fixed for 20 min in 4% PFA in PBS and 
washed thrice inPBS to ensure removal of PFA. Sections were treated with OAM HCL 
followed by three PBS and one depc-dH20 waslL Sections were pre-equilibrated in 
digestion buffer (20mM Tris-HCI, 2mM CaCl2pH7.4) followed by digestion for 15 min 
(30 min for sections from decalcified turnours of TRAP-c-fosLTR mice) at 37'C with 
protcinase K (I Opg/ml in digestion buffer). Proteinase K was washed away with three 
PBS washes before sections were fixed again in 4% PFA in PBS and washed three times 
in PBS. Sections were acetylated with freshly prepared 0.25% v/v acetic anhydride in 
OAM triethanolamine, pH8 for 20 min with continuous stirring and finally washed 
(thrice) with PBS. The area of slide not covered with section was carefully dried with 
clean tissues so that paraffin wax borders (using a DAKO paraffin pen) could be made 
around the sections. Pre-hybridisation buffer (100[d) containing 50% formamide 
(Sigma), 1mg/ml BSA, 0.02% (w/v) Ficoll, 0.02% polyvinylpyrrolidine, 5x SSC, 
250gg/ml yeast tRNA, was carefully applied to each section. Slides were put on glass 
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rods in a hybridisation box lined with tissues saturated with 5x SSC and 50% v/v form- 
amide and sections were pre-hybridised for 24 hours at room temperature. 
DIG-labelled riboprobes were added to hybridisation solution (at approximately 20- 
200ng/ml). This was denatured at 85*C for 5 min and incubated on ice, before 50-70pl 
was added to each section and covered with parafilm cut approximately to the size of 
the sections. Following 5 min incubation at 80*C and cooling to hybridisation tem- 
perature, hybridisation was carried overnight at 50-701C. After hybridisation, the tissue 
sections were washed with a series of washes; once for 5 min in 5x SSC at hybridisation 
temperature; I hour in 0.2x SSC at hybridisation temperature, followed by 10 min 
cooling to room temperature in 0.2x SSC. 
The DIG hybridisation signal was detected using the Nitroblue tetrazolium (NBT), 
5-bromo-4-chloro-3-indoyl-phosphate (BCIP) substrate solution according to manu- 
facturer's (Roche) instructions. Briefly, slides were washed in Bl-DIG (100nim Tris, 
150mM NaCl, pH7.5); followed by incubating for I hour in 132-DIG consisting of 1% 
Blocking reagent (Roche) in Bl-DIG; then incubated for I hour with anti-DIG Fab- 
fragment alkaline phosphatase conjugate (0.2% v/v in B2-DIG). Unbound antibody was 
washed off by gentle shaking for 15 min (twice) in BI -DIG. Sections were equilibrated 
in B3-DIG (I OOmM Tris, I OOmM NaCl, 50mM MgC126H20, pH9.0), before B3-colour 
(0.338mg/n-d NBT, 168mg/n-A X-phosphate/BCIP, 0.25mg/ml Levamisole, in B3-DIG) 
was added and allowed to develop (10 min to 72 hours) in the dark. The reaction was 
stopped by washing sections in B4-DIG (10mM Tris, ImM EDTA, pH8.0). If the hy- 
bridisation signal was low, sections were lightly counter-stained with Haematoxylin and 
mounted in Aquamount with glass coverslips (Chance). 
2.10.3 [3SI-dUTP in situ hybridisation 
The prehybridisation treatments were similar to DIG in situ hybridisation. Briefly, slides 
were dewaxed in Histoclear and rehydrated through the ethanol series as described 
above. Slides were rinsed twice in depc-dH20, followed by immersion in 0.2M HCl (20 
min) and 2x SSC (5 min). Sections were treated for 15-30 rnin at 37'C with 10pg/ml 
proteinase K in lOOmM Tris-HCI, 50mM EDTA, pH8.0; washed with 0.25% w/v gly- 
cine in PBS (2 n-dn); and post-fixed in 4% PFA in PBS for 15 min. PFA was removed 
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by two washes in PBS and sections were acetylated for 10 min as described for DIG in 
situ hybridisation. Sections were washed in PBS before dehydration through ethanol 
series and left to air dry wrapped in tissue paper for at least I hour. 
Probes were diluted in hydridisation buffer: 50% forrnarnide, 10% (w/v) dextran 
sulphate, 5OmM DTT, lmghnI BSA, 0.02% (w/v) Ficoll, 0.02% polyvinylpyrrohdine, 
50pghnl poly A RNA, 5OOpg/mI yeast total RNA, 0.3M NaCl, I OmM Tris (pH7.4), and 
0.5 M EDTA. This was denatured at 70"C and cooled on ice, before 70PLI was added to 
each pre-treated section and covered with parafilm. Hybridisation was carried out at SO- 
65*C overnight in a sealed hybridisation box containing 50% fonnamide, 5x SSC 
soaked tissues. 
After hybridisation slides were quickly transferred to a rack for the following 15 
min washes (2x SSC, 50% formamide, and lOmM DTT): one at 551C with agitation, 
during which time the coverslips were flushed off; another at 55*C; and then one at 
65*C. Slides were equilibrated at 37*C for 15 min (twice) in RNase buffer (500MM 
NaCl, lOmM Tris-HCI, pH8.0, ImM EDTA), before treatment with 20ýtg/ml RNase A 
in RNase buffer for 30 min at 37T. Slides were washed in RNase buffer to remove 
RNase A (15 min, 37"C), before being washed twice in 2x SSC, 50% formamide, 
I OmM DTT at 65*C for 20 min; once in 0.1 x SSC, I OmM DTT at 650C for 20 min; and 
5 min at room temperature in O. Ix SSC. Slides were dehydrated in 70% ethanol (v/v) 
with 0.3M ammonium acetate, 95% ethanol (v/v), and finally 100% (v/v) ethanol for 2 
min each and air-dried. 
Slides were exposed to X-ray film (Kodak) overnight to examine both the quality 
of hybridisation and to estimate time of exposure for autoradiography. Subsequently 
slides were dipped in Ilford nuclear K5 emulsion gel, melted at 40"C and diluted 1: 1 
with dH20 containing 2% v/v glycerol. Slides were left to air dry for 2 hours in a light- 
tight box. The slides were exposed at 4C (in the dark in a light-tight and air-tight box 
containing silica gel crystals) for approximately 10-14 days depending on radioactive 
signal. Before being developed, slides were prewartned to room temperature, then 
immersed in Kodak D 19 developer for 5 min at 18"C, rinsed in dH20 (2 min), and fixed 
for 5 min in ammonium thiosulphate. Slides were washed for 15 min in the dark, under 
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running tap water foRowed by two washes in dH20. Sections were counterstained with 
Haernatoxylin and Eosin, dehydrated and cleared in Histoclear before being mounted 
using DPX mounting medium with glass coverslips. 
2.11 Statistical analysis 
All experiments were repeated in triplicate unless otherwise stated. All data are pre- 
sented as means S. D. In all cases, differences between groups were analysed by Stu- 
dents t-test: *(or P<0.05; **(or "') p<0.01; ***(or "") p<0.001. 
2.12 Photography 
Slides were analysed using an Olympus BH-2 photornicroscope with phase contrast and 
dark field optics. Photography was done under both dark and light field, using an 
Olympus system 2 camera and Fujichrome or Kodak 64T film. at an ISO setting of 64. 
Fluorescence microscopy was carried out using photornicroscope, at an ISO setting of 
3200, using Fuji 1200 asa film speed. Slides were converted to colour prints using 
Printscan on Adobe photoshop. 
Northern. and Southern blots were scanned directly into Adobe photoshop using an 
Epson Flat bed scanner. 
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3. A putative role for c-Fos in the pathophysiology 
of Paget's Disease 
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3.1 Introduction 
Paget's disease of bone is a chronic skeletal disorder characterised by areas of rapid 
bone turnover, deformity and degeneration. Patients with the disease have an in- 
creased risk of malignant transformation, and are more likely to develop osteosar- 
comas (Freemont, 1996). The primary lesion in Paget's disease is thought to involve 
bonc-resorbing osteoclasts, which are increased up to 50 to I 00-fold both in number 
and multinuclearity, resulting in an increase in bone turnover. The specific causes of 
the apparent increase in osteoclast activity, in addition to the molecular mechanisms 
underlying cellular transformation and oncogenesis are poorly understood. 
Several candidate factors have been associated with Paget's disease (reviewed 
by Gehron-Robey and Bianco, 1999): For example, the cytokine IL-6 is apparently 
up-regulated specifically in Pagetic osteoclasts, which constitutively express IL-6 
receptors and the transcription factor NF-IL-6, suggesting a possible autocrine role 
for IL-6 (Hoyland et al, 1994; Reddy et al, 1999; for review, see also Mee and 
Sharpe, 1993). Paget's disease has a strong familial tendency, suggesting there is a 
genetic component to the disease (reviewed by Hul, 1999). Indeed, it has an inexpli- 
cable geographical distribution, with the disorder being found to be most common in 
Europe, North America, Australia, and New Zealand (Barker et al, 1984). The 
overall prevalence rates from radiology studies in hospitalised patients over 55 years 
found the highest frequency (4.6%) in England, particularly in the region of the in- 
dustrial north (6.3% to 8.3%), and France (2.4%), and lower rates were observed in 
other Western European countries (e. g., 0.7-1.7% in Ireland, 1.3% in Spain and 
West Germany, and 0.5% in Italy and Greece). Similarly high rates were found in 
the older population in Australia and in New Zealand (34%) and North America (2- 
3%). Moreover, Paget's disease is a disorder of older people (aged 55 years or 
older), but which affects women and men equally. 
A genetic aetiology of Paget's disease is supported by a study showing that 15% 
to 30% of patients have a positive family history of the disorder (Siris et al, 1991). 
Both Paget's disease and the Paget's-related disease Familial Expansile Osteolysis 
(FEO) have been mapped to a susceptibility locus on chromosome l8q in some 
families (Cody et al, 1997; Haslarn et al, 1997; Hocking et al, 2000). Interestingly, 
this locus (termed PDB2 in Paget's disease) is in a candidate interval containing the 
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gene for RAN& the receptor found on osteoclasts and important for osteoclast 
differentiation. Recent work, however by Wuyts el al (2001) have discounted mu- 
tations in RANK or OPG as the possible cause of Paget's disease and recently, mu- 
tations affecting RANK have been demonstrated in patients with FEO (Hughes et al, 
2000). Furthermore, there were several polymorphisms in the second intron of 
OPG, which need to be further investigated. An additional locus (PBD I) has been 
mapped on chromosome 6, with a possible association between Paget's disease and 
the HLA complex, and at least one other exists elsewhere in the genome (Fortino el 
al, 1977; Haslam et al, 1998). The anti-apoptotic gene Bcl-2 has also been mapped 
to 18q and recent preliminary data indicate that Bcl-2 expression is up-regulated in 
Paget's disease (Haslam et al, 1997; Cody et al, 1997; Mee, 1999). Pagetic; osteo- 
clasts also respond differently to osteotropic factors such as 1,25-(OH)2D3 and cal- 
citonin. The increased sensitivity to 1,25-(OH)2D3 may be a result of increased ex- 
pression of vitamin D receptor (VDR) mRNA or increased affinity for the VDR 
(Mee et al, 1996; Menaa et al, 2000). In addition, the presence of IL-6 may en- 
hance the responsiveness of Pagetic osteoclasts to RANKL (Menaa et al, 2000), 
which is also unregulated in Pagetic osteoblastic; stromal cells (Menaa et al, 2000; 
Neale et al, 2000). A viral actiology has also been postulated, with a number of 
studies implicating pararnyxoviruses including: measles, respiratory syncytial virus, 
simian virus 5, parainfluenza virus Type 3, and canine distemper virus (reviewed by 
Singer, 1999). 
Previous expression studies in Pagetic osteoclasts has demonstrated that there is 
an increase in c-Fos expression (Hoyland and Sharpe, 1994); an observation that 
provides a possible explanation for the molecular basis of Paget's disease, including 
the potential for cellular transformation and oncogenesis. As stated in Chapter I 
(section 1.6.3 and 1.6.4), gain-of-fimction and loss-of-function studies have impli- 
cated c-Fos in the regulation of bone development and bone disease. c-Fos is asso- 
ciatcd with a variety of biological processes, ranging from transfonnation, to cell 
cycle progression and differentiation (Angel and Karin, 1991). Transgenic mice 
overexpressing c-fos using constitutive promoters (e. g., H2-c-fosLTR mice) develop 
remodelling osteosarcomas due to specific c-Fos-dependent oncogenic transforma- 
tion of osteoblasts (Grigoriadis et al, 1993). Moreover, histopatho logical analysis 
revealed many features which resemble Paget's disease (Grigoriadis et al, 1993; 
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Ruthcr et al, 1989; Wang et al, 1992). In contrast, c-Fos knockout mice lack os- 
teoclasts and develop the bone remodelling disease osteopetrosis (Wang et al, 1992; 
Grigoriadis et al, 1994), clearly demonstrating that c-Fos is an essential gene for 
osteoclast differentiation and bone remodelling in general (see also Grigoriadis et al, 
1995 for review). Thus, the gain- and loss-of-function analyses have clearly impli- 
cated the c-Fos proto-oncogene and AP-1 transcription factor in osteoclast differen- 
tiation, bone cell transformation and turnour formation, all of which are features of 
Paget's disease. 
To ftirther examine the role of c-Fos in Paget's disease, and consistent with the 
observations that osteoclasts in Pagetic bone express high levels of c-Fos (Hoyland 
and Sharpe, 1994), the airn of this chapter was to generate transgenic mice in which 
c-fos is overexpressed specifically in osteoclasts using the promoter for tartrate- 
resistant acid phosphatase (iRAP). Some of the results from this work were pub- 
lished recently (Beedles et al, 1999). 
3.2 Generation of TRAP-c-fosLTR transgenic mice 
The murine TRAP-c-fosLTR construct was prepared by Dr. A. E. Grigoriadis and 
consists of a murine TRAP promoter (pBS-TRAP; obtained from Dr. G. D. Rood- 
man, San Antonio; see Boyce et al, 1995) fused to a full length genomic sequence 
for the murine c-fos gene (Figure 3.1). This promoter was chosen because it is ex- 
pressed at high levels in osteoclast precursors and differentiated osteoclasts, and it 
has been shown previously to function reliably for targeting transgenes to osteo- 
clasts in mice (Boyce et al, 1995; Schwartzberg et al, 1997; Hentunen et al, 1997). 
The 3' mRNA destabilising sequences and polyadenylation (polyA) site of c-fos 
were replaced by a 3' long terminal repeat (LTR) from the FBJ-murine sarcoma 
virus. This modification is essential for ensuring stability of the exogenous c-fos 
mRNA (Ruther et al, 1987; Grigoriadis et al, 1993). This vector gives rise to two 
exogenous c-fos transcripts, a 3. Okb transcript, which terminates at the polyA site in 
the LTR and which encodes for the functional c-Fos protein, and a shorter 2. Okb 
transcript, which terminates at a cryptic polyA site present in the FBJ-derived se- 
quence (Figure 3.1). The construct was microinjected (without plasmid sequences) 
into fertilised eggs by Dr. N. Faruque, followed by transfer into foster females. 
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Figure 3.1 - The DNA construct (TRAP-c-fosLTR) used for the generation 
of TRAP-c-fosLTR transgenic mice. The murine TRAP promoter (pBS-TRAP; 
Boyce et al, 1995) was fused to a full length genomic; sequence for the murine c-fos 
gene in which the 3' mRNA destablising sequences have been replaced by a 3' long 
terminal repeat (LTR) from the FBJ-murine sarcoma virus (Ruther et al, 1987). 
Two exogenous c-fos transcripts are synthesised as indicated. H- HindIII; X- 
XbaI. The location of the transgene specific probe (pB15) used for in situ hybridi- 
sation analysis has been depicted. 
A total of nine founder animals were obtained which contained between -5 and 
50 copies of the transgene as determined by Southern blot analysis of tail DNA (see 
section 2.7). Of these, five developed noticeable swellings in the long bones be- 
tween 3-6 weeks of age, and some mice were severely growth retarded. Radio- 
graphic analysis of phenotypic founder animals indicated the presence of marked 
skeletal abnormalities in virtually all bones, in contrast to the normal skeletal devel- 
opment in transgene-negative littermates (Figure 3.2). Two related phenotypes 
were observed in these five transgenic animals. Three founders displayed a severe 
sclerotic phenotype over the entire skeleton with long bones, vertebrae, pelvis and 
skull being severely affected (Figure 3.2 A). In the remaining two founder animals, 
skeletal lesions were detected which developed very rapidly into very large calcified 
turnours (Figure 3.2 B). Again, these lesions were present in most bones of the 
skeleton. All phenotypic mice developed these skeletal abnormalities shortly after 
birth (3-6 weeks post-natally), prior to reaching sexual maturity, and together with 
the size and severity of the lesions, attempts to breed them and obtain transgenic 
offspring were not successful. Nevertheless, the generation of five independent 
founders which developed similar phenotypes (see also below) clearly indicated that 
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the defects were independent of the transgene integration site, and suggested that 
exogenous c-Fos expression was causal in generating the skeletal abnormalities. 
Figure 3.2. - Skeletal abnormalities in TRAP-e-fosILTR transgenic mice. 
Radiographic analysis of wild-type (left) and transgene positive (right) littermatcs. 
showing the severity oflesions in transgenic bone. (A) X-rays ol'a 5 week-old nor- 
mal mouse (no. 228-2) and its age-matched transgenic littermate (no. 228-1) 
showing specific radio-dense lesions in all bones (arrows), including long bones, 
vertebrae, pelvis and skull. (B) X-rays of a5 week-old normal mouse (no. 250-8) 
and its age-matched transgenic littermate (no. 250-9) showing large calcified tu- 
mours (arrow). Radiographs were prepared by Dr A. E. Grigoriadis. 
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From this work only single founder animals could be produced, such that differ- 
ent animals were used for different experimental procedures, as summarised in Table 
3.1, and in the respective figure legends. 
Table 3.1 - Phenotype of individual TRAP-c-fosLTR mice 
Mouse number Phenotype Figure 
228-1 Sclerotic 3.2 A 
250-9 Calcified tumour 3.2 B 
1766 Sclerotic 3.3 A 
250-9 Calcified tumour 3.3 B 
228-1 Sclerotic 3.4 and 3.5 
3.3 Northern blot analysis of tissues from TRAP-c-fosLTR 
transgenic mice 
To investigate whether there was a relationship between the development of the 
skeletal phenotypes in the founder transgenic mice and expression of the c-fos trans- 
gene, Northern blot analysis was performed on poly(A)+ RNA isolated from tissue 
samples of normal and tumour tissues (see section 2.8). In one particular transgenic 
founder, exogenous c-fos was expressed in tumour-bearing bones and at lower lev- 
els in the heart, but not in any other tissues (Figure 3.3 A). Endogenous c-fos RNA 
was also expressed in the intestine and muscle, and at lower levels in brain and liver 
tissues. In a second independent founder, transgene expression was detected at high 
levels in lesional. bone tissue, but also at lower levels in liver which did not develop 
any macroscopic abnormalities (data not shown). Significantly, Northern blot analy- 
sis of tissues from the four founder animals which did not develop any bone abnor- 
malities failed to demonstrate expression of the c-fos transgene in tissues analysed 
(data not shown). These data therefore suggest that the expression of exogenous c- 
fos was likely to be responsible for the development of the observed skeletal lesions. 
Further Northern blot analysis was carried out for another transgenic founder. 
As observed above, exogenous c-fos expression was confirmed in tumour-bearing 
bones, calvaria and the tumour itself (Figure 3.3 B), with no other tissues demon- 
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strating expression of the transgene. This Northern blot was also probed for other 
AM family members. Northern blot analysis for c-jun, showed no change in ex- 
pression (Figure 3.3 B). c-jun was ubiquitously expressed, with low levels discerni- 
ble in long bone and tumour. In contrast, the Fos-related gene (fra-1) was ex- 
pressed in long bone and turnour tissues of TRAP-c-fos-LTR mice (Figure 3.3 B) 
but is not reported to be expressed at high levels in adult wild type bone. These 
results are consistent with the fact thatfra-I is a Fos-responsive gene (Braselmann 
et al, 1992; Schreiber et al, 1997; Matsuo, et al, 2000; Fleischmann et al, 2000; 
Jochum et al, 2001; see discussion below). Finally, expression analysis for NVAP-9 
(Gelatinase B), a marker for osteoclasts, showed that levels were specifically high in 
bone tissue and tumours from TRAP-c-fosLTR mice (Figure 3.3 B). This would 
suggest that there are many osteoclasts present in the tissue. This was later con- 
firmed by TRAP histochemistry and in situ expression analysis for MAV-9 (see 
below). 
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Figure 3.3 - Northern blot analysis of c-fos transgene expression in differ- 
ent tissues of a TRAP-c-fosLTR transgenic mice. (A) The Northern blot niý: Pi- 
brane from mRNA ot'one transgcnic 1bunder (no. 1766) was hybridised with a P- 
labelled v-/Os probe which detects both exogenous (3. Okb) and endogenous (2.2kb) 
c-fi)s transcripts (as described in section 2.8.4). The endogenous. /OX gene (0.6kb) 
was used as a control lor RNA loading. The exogenous c-los transcript was evident 
in turriour-bearing bones (+T) like tibia and calvaria, compared with no signal in 
bones lacking turnours (-T). (11) A second founder animal (250-9) was hybridised 
with the v-fi)s probe to confirm transgene was expressed especially in bones con- 
taining tumour. In addition, a probe fior c-jun was used (3.2 and 2.7kb transcripts). 
which appeared to be ubiquitously expressed, but was low in bone and lumour. 
Furthermore transcripts lbr. /ria-1 (4.2kb) and AIMP-9 (2.3kb) were fiound to be 
highly expressed (B). 
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3.4 Histopathological analysis of skeletal lesions from TRAP-c- 
fosLTR transgenic mice 
Histopathological analysis was performed on sections from representative long 
bones of TRAP-c-fosLTR transgenic mice. Although no quantitative assessment 
was made, the Haernatoxylin and Eosin staining of sections (section 2.5) revealed an 
apparent increase in the number of osteoclasts, with high munbers of nuclei. Also 
there was increased bone trabeculae and numbers of osteoblasts and a marked bone 
marrow fibrosis when compared to bones from non-transgenic littermates (Figure 
3.4 A, B). Long bones in general also exhibited a poorly developed cortical bone 
(data not shown). 
Histochernical staining for the osteoclast marker TRAP demonstrated a marked 
increase in the number of osteoclasts (Figure 3.4 Q compared to wild-type bones 
where only a few osteoclasts were observed primarily fining the distal endochondral 
growth plate (data not shown). Further examination, showed that the osteoclasts in 
the transgenic bones appeared to be larger than normal, containing a larger number 
of nuclei per osteoclast (Figure 3.4 D, E). The lesions appeared to undergo exten- 
sive bone remodelling as evidenced by the numerous reversal lines present in all 
trabeculae (Figure 3.4 D, E), which would indicate increased osteoclast activity. In 
addition to osteoclasts and osteoblasts, occasional pockets of chondrocytes were 
observed suggesting that chondrogenic cells or specific precursors were also af- 
fected (data not shown). 
To confirm further the increase in number and activity of osteoclasts within 
these remodelling lesions, non-radioactive in situ hybridisation analysis was per- 
formed on adjacent sections of transgenic bones for matrix metalloproteinase-9 
(MNIP-9), as detailed in section 2.10, which is another specific marker for osteo- 
clasts in situ (Reponen et al, 1994; Grigoriadis et al, 1994). The results suggested 
that all TRAP-positive cells were also expressing high levels of NBIP-9 (Figure 3.4 
F), which were large and contained numerous nuclei (Figure 3.4 G, H), confirming 
that these were bonafide osteoclasts. 
To investigate the cell-specificity of c-fos transgene expression, non-radioactive 
and radio-active in situ hybridisation analysis was carried out with a transgene spe- 
cific probe, pBIS (Figure 3.1). In situ hybridisation analysis indicated that the 
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transgene was expressed in the osteoclasts within the lesions (Figure 3.5 A-D). 
However, clearly not all osteoclasts appeared to express the transgene (Figure 3.5, 
A and Q. In addition there was expression in non-osteoclastic cells presumably 
osteoblasts or osteoblast precursors (Figure 3.5 A and Q. Furthermore, transgene 
expression was clearly evident in the osteoblasts of bone which had not yet pro- 
gressed to turnour (Figure 3.5 D). 
3.5 Immunohistochemistry of lesions from TRAP-c-fosLTR 
transgenic mice 
To investigate the ccU-specific expression of the c-Fos protein within these lesions, 
irrimunocytochemical analysis was performed on adjacent sections using a murine c- 
Fos polyclonal. antibody (see section 2.5.4). The results indicated that high levels of 
c-Fos protein were detected in almost all osteoclasts lining the bone surfaces (Figure 
3.5 E, F). In addition, c-Fos protein was expressed in some, but not all osteoblasts 
and chondrocytes (Figure 3.5 E, F) and in many fibroblastic connective tissue cells 
within these lesions (data not shown). It should be emphasised that the antibody 
used in these experiments detects both endogenous as well as exogenous c-Fos 
proteins, therefore it is perhaps not surprising that many cell types might be ex- 
pressing c-Fos. Indeed, this is suggested by the Northern blot analyses where en- 
dogenous; c-fos RNA was also detected within the bone lesions (Figure 3.3). Taken 
together, the features of the phenotype which develops in c-fos-overexpressing 
transgenic mice are an increase in the number and multinuclearity of osteoclast-like 
cells and the generation of lesions characterised by high rates of abnormal bone 
turnover. 
Hoyland and Sharpe (1994) previously observed that high levels of c-Fos are 
also present in bone cells of patients with Paget's disease. To assess cell specificity, 
the expression of c-fos was investigated by radioactive in situ hybridisation tech- 
niques. They found high levels of c-fos expression in multinucleated osteoclasts in 
Pagetic bone, whereas c-fos expression in osteoclasts present in control osteophyte 
tissue was not detectable (see Hoyland and Sharpe, 1994; Beedles et al, 1999). In 
addition, the expression of c-fos mRNA was confirmed by immunohistochemical 
staining for c-Fos protein on ad acent sections (Hoyland and Sharpe, 1994). These 
data further implicate a role for c-Fos in the altered osteoclastic activity which is a 
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characteristic of Paget's disease. More importantly, the striking similarities between 
the morphology and activity of the osteoclasts present in Paget's disease compared 
with those which develop in TRAP-c-fosLTR transgenic mice, suggest that these 
mice might be useful for further delineating the molecular basis for the altered osteo- 
clastic behaviour, and perhaps, the subsequent events that lead to osteosarcoma 
formation. 
Previous work has suggested a role for Bcl-2 in normal and Pagetic osteoclasts 
(Selander et al, 1997; Lagasse and Weissman, 1997; Cody et al, 1997; Mee, 1999), 
with Bcl-2 message levels being upregulated in Pagetic ostcoclasts compared to 
normal osteoclasts. Since apoptosis is the ultimate fate of the osteoclast, it is possi- 
ble that the observed increase in size of the osteoclasts in TRAP-c-fosLTR mice may 
be a result of increased Bc1-2 expression and hence survival. To investigate the the 
expression of genes involved in apoptosis of the osteoclasts in TRAP-c-fosLTR 
mice, the expression of the anti-apoptotic protein Bcl-2 was studied by immunohis- 
tochemistry (section 2.5.4). Interestingly, there were high levels of Bcl-2 protein in 
the osteoclasts of these mice (Figure 3.5), compared to wild type osteoclasts (data 
not shown). Bcl-2 protein was clearly visualised around the ruffled border of these 
osteoclasts. Clearly, high levels of Bcl-2 protein were not observed in the osteo- 
blasts of these lesions. Thus, Bcl-2 may be affording an anti-apoptotic function 
specifically in these osteoclasts, resulting in a prolongation of their existence and 
hence functionality (Lagasse and Weissman, 1997; Okahashi et al, 1998). It is not 
unlikely that the increased longevity of these osteoclasts is contributing to fusion 
potential and subsequent multinucleated phenotype and functionality observed in 
TRAP-c-fosLTR mice. 
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Figure 3.4 - Histological analysis of TRAP-c-fosLTR transgenic mice. 
Haematoxylin and Eosin stained sections of a typical wild-type tibia (A) and a 
TRAP-c-fosLTR transgenic tibia (B), demonstrating the presence of increased bone 
trabeculae in transgenic mice compared to non-transgenic littermates. The bone 
marrow space is largely fibrotic with little haernatopoietic cell activity (*). TRAP 
histochernistry detected increased numbers of osteoclasts (C-E) compared to wild- 
type bone (data not shown). (C) Detection of TRAP-positive osteoclasts in adjacent 
sections to B, and (E) a high power view of multinucleated, TRAP-positive osteo- 
clasts (counterstained with Haematoxylin). Arrows in D and E show reversal lines. 
Digoxigenin-labelled anti-sense riboprobes for MNIP-9 detected high levels of ex- 
pression of MMP-9 in TRAP-positive, multinucleated osteoclasts of TRAP-c- 
fosLTR transgenic: mice (F, G, H). Control sense riboprobe hybridisations revealed 
no specific signal (1). All sections are 5Rm paraffin sections prepared and stained as 
described in section 2.5. Arrowheads in all panels indicate osteoclasts. gp - growth 
plate, b- trabecular bone. A, B, Ix 100; C, F x2OO; D, E, G, H x400. 
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Figure 3.5 -In situ analysis of c-Fos transgene, c-Fos and Bcl-2 protein in 
the lesions which develop in TRAP-c-fosLTR transgenic mice. Digoxigenin 
(DIG)-labeUed anti-sense (A) and 32 P-labelled (C) riboprobes for the B15 transgene 
sequence detected high levels of expression of transgene transcripts in 
multinucleated osteoclasts within the lesions of TRAP-c-fosLTR transgenic mice 
(arrowheads in A and Q. However, occasionally osteoclasts were observed which 
appeared to be void of transgene expression (arrows in A and Q. Transgene ex- 
pression was also apparent in non-osteoclastic ceUs (* in A and Q which may be 
ostcoblasts. DIG control sense riboprobe hybridisation revealed no specific signal 
(B) and sense control data is not shown for 32P. Iabelled probes. Immunolocalisation 
of c-Fos protein using a murine polyclonal antibody confirms the expression of c-Fos 
in osteoclasts (E, F). Ostcoblasts also express c-Fos in some areas, although clearly 
negative osteoblasts are also observed (arrow in E). Similarly, some chondrocytes 
express c-Fos (arrow in F). Immunolocalisation of Bcl-2 protein using a murine 
polyclonal antibody confirms high levels of Bcl-2 protein localised to the ruffled 
border of osteoclasts (arrow in E) of bone lesions, compared to control sections 
probed with goat serum/TBS alone (F). All sections are 5ýtm paraffin sections pre- 
pared and stained as described in section 2.5. DIG-labelled sections and immunolo- 
calisation sections were briefly counterstained with Haernatoxylin and 32 P-labelled 
sections were counterstained with Haematoxylin and Eosin before mounting and 
photography. C, H x2OO; A, B, D, E, F, G A00. 
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3.6 Discussion 
In this chapter the consequences of ectopic c-Fos expression in mature osteoclasts 
have been investigated in an attempt to mimic the high levels of c-Fos which are 
observed in Pagetic osteoclasts (Hoyland and Sharpe, 1994). While earlier c-Fos 
knockout experiments have demonstrated unequivocally that c-Fos must be ex- 
pressed in osteoclast progenitors for normal differentiation (Grigoriadis et al, 1994), 
it was not possible in that study to discern whether c-Fos is also required for the 
fusion and activity of fully differentiated, multinucleated osteoclasts. This study has 
shown that targeting c-fos expression to osteoclasts under the control of the osteo- 
clast-specific TRAP promoter (TRAP-c-fosLTR mice) results in the rapid develop- 
ment of highly remodelling lesions and formation of bonc tumours. Five independ- 
ent transgenic founder mice were identified which expressed exogenous c-Fos but 
which unfortunately could not be bred to generate individual families of transgenic 
mice due to the severity and early onset of the phenotype. Thus, while the absolute 
causal role of c-Fos in the development of these phenotypes is difficult to prove by 
analysing only founder animals, it is clear that the observed skeletal defects were 
very specific to c-Fos overexpression and independent of the transgene integration 
site. 
The phenotype amongst affected animals, such as the time of onset, the his- 
tological characteristics, the cellular composition, ctc., were remarkably similar in all 
boncs analysed from all founder mice, suggesting that the defects were likely to be 
caused by cctopic c-Fos expression. Notably, all lesions contained numerous ostco- 
clasts, most of which contained a very large number of nuclei when compared to 
osteoclasts in wild-typc littcrmatcs, and in this regard these lesions exhibit some 
similarities to Paget's disease. The osteoclasts expressed high levels of TRAP ac- 
tivity in addition to NUAP-9, which is a reliable marker for osteoclasts in situ. Fur- 
thermore, preliminary analysis using in situ hybridisation has also found similar lev- 
cls of cathepsin K in the osteoclasts of these lesions (data not shown), further sup- 
porting the ostcoclasts' functionality. 
From these findings, it is tempting to speculate that the consequences of this in- 
creased osteoclast number and activity in TRAP-c-fosLTR mice are the consequen- 
tial stimulation of a cascade in which there is an increase in the recruitment and dif- 
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ferentiation of osteoblasts, which leads to a highly remodelling lesion in which os- 
teoclastic bone resorption and ostcoblastic bone formation are accelerated, causing 
bone deformation. Despite the fact that the initial appearance of some of the skeletal 
defects (e. g., as in Figures 3.2 A, 3.4 B) might suggest an osteopetrotic phenotype, 
implying that osteoclasts are inactive, the presence of abundant reversal lines and 
continued growth of these lesions suggests that this is not the case. This neverthe- 
less remains to be confirmed by examining in greater detail the morphology of the 
transgenic osteoclasts and by measuring their resorptive activity in vitro (see also 
below). Moreover, the fact that some of the transgenic mice developed very large 
bone turnours also suggests that additional events are occurring following expres- 
sion of the transgene, such as activation of genes which are important in the growth 
control of specific bone cell populations (Sunters et al, 1998; Sunters et al, 2000). 
While this is a possible scenario, we cannot exclude the possibility that the early 
lesions would have eventually expanded extracortically to resemble more the tumour 
lesions (e. g., Figure 3.2 B), and which would not have been observed because the 
mice were sacrificed at a relatively early age. 
Expression analysis of other AP-1 family members in this study demonstrated 
thatfra-1, a c-Fos responsive gene thought to be important for osteoclast differen- 
tiation and function, is up-regulated in the long bone and turnours of TRAP-c- 
fosLTR mice. Fra-1 has been shown to be the most potent osteoclastogenic Fos- 
family member protein in vitro, but unlike other cell types, transcriptional activation 
in osteoclasts requires c-Fos protein (Owens et al, 1999; Matsuo et al, 2000). To- 
gether c-Fos and Fra-1 mediate the osteoclastogenic stimulatory effect of 
RANKURANK signalling in osteoclasts (Matsuo et al, 2000). Furthermore, Fra-l 
together with NFAT3 have been shown to stimulate the TRAP promoter in vitro 
(Matsuo et al, 2000). In TRAP-c-fosLTR mice Fra-1 may be further augmenting 
any effects of c-Fos, by additionally stimulating the exogenous TRAP promoter and 
hence increasing ectopic; c-fos transgene expression. Thus, the c-Fos induction of 
fra-1 expression in TRAP-c-fosLTR mice could be increasing the differentiation 
potential of osteoclasts. 
Assessing the possible causes of turnour formation in TRAP-c-fosLTR mice is 
very important, as the turnours resemble, to a certain extent, the remodelling osteo- 
sarcomas which develop in other c-Fos transgenic: mice (H2-c-fosLTR; Grigoriadis 
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et al, 1993). In H2-c-fosLTR mice, chondroblastic osteosarcomas develop due to 
specific transformation of ostcoblastic cells, and osteoblasts express high levels of 
the transgene. The fact that there are large numbers of osteoblasts (and in some 
cases chondrocytes) in TRAP-c-fosLTR lesions, a large proportion of which ex- 
pressed c-Fos protein by immunocytochemical. analysis (Figure 3.4) and c-Fos/pB15 
transgcne (Figure 3.5), raises several possible interpretations: First, since the c-Fos 
antibody used cannot distinguish between endogenous and exogenous c-Fos, it is 
possible that c-Fos expression in osteoblasts reflects endogenous c-Fos protein; 
efficient expression of the endogenous gene is confirmed by the Northern blot analy- 
ses. This may be possible since expression of endogenous c-Fos in osteoclasts is 
normally very low (Sunters et al, 1998) and the activation osteoblasts by osteoclasts 
during bone formation may indeed turn on endogenous c-Fos expression (Grigori- 
adis et al, 1993). Second, it is possible that high c-Fos levels in osteoblasts could be 
interpreted as inappropriate expression of the transgene from the TRAP promoter, 
as evidenced by non-specific transgene expression in osteoblasts, such that, there 
was 'leaky' expression of the TRAP promoter in osteoblasts leading to the observed 
tumour phenotype. Possible explanations for this scenario might be attributed to the 
3' FBJ-LTR which was used in the construct. Although it has been demonstrated 
unequivocally that this fragment is necessary for cfficient expression of c-Fos in 
bone tissue, it cannot be excluded that there exist sequences within this fragment 
which can override or alter the specificity of the selected promoter. The evidence 
that this could indeed occur in transgenic mice has previously been discussed (Grig- 
oriadis et al, 1993; Wang et al, 199 1). 
Taken together, the skeletal abnormalities which develop in TRAP-c-fosLTR 
transgenic founder mice share some properties with Paget's disease, namely, an in- 
crease in the number of large, active osteoclasts which express high levels of c-Fos, 
increased remodelling activity, and cellular transformation and tumour formation. 
Other characteristics are also shared, for example, high Bcl-2 levels in osteoclasts 
(Haslarn et al, 1997; Cody et al, 1997; Mee, 1999), were observed in TRAP-c- 
fosLTR mice. Furthermore, preliminary evidence suggests that in the remodelling 
osteosarcomas in H2-c-fosLTR mice (Grigoriadis et al, 1993), high levels of Bcl-2 
expression have also been observed in osteoclasts (E. El-Emir and A. E. Grigoriadis, 
unpublished observations). The increased expression of Bcl-2 may account for the 
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increased potential for cellular transforrnation and tumourigenesis observed in these 
mice. 
The results from this study are based solely on founder animals, as it has been 
difficult to obtain further families of transgenic mice. It is very clear that independ- 
ent families of transgenic mice must be generated to determine unequivocally pa- 
rameters such as the time of onset of transgene expression, the time of onset of mi- 
croscopic phenotypic changes, the target cells for transformation in these mice, etc. 
Furthermore, establishing fines of TRAP-c-fosLTR transgenic mice will also provide 
a useful tool for investigating osteoclast activity in vitro, for example by investigat- 
ing the osteoclastogenic; capacity or altered gene expression of haematopoietic 
spleen precursors, or by culturing cells derived from tumours in the presence of 
RANKL (Lacy et al, 1998; Kong et al, 1999; Yasuda et al, 1998), which is essential 
for osteoclast differentiation. It is also likely that immortalised osteoclastic cell fines 
can be established from these lesions, as has been shown for other oncogenes tar- 
geted to osteoclasts (Hentunen et al, 1997). Finally, although TRAP-c-fosLTR 
transgenic mice cannot be considered as definitive models for Paget's disease, their 
usefulness will become evident by investigating whether the increased osteoclast 
activity and remodelling defects can be inhibited using anti-resorptive compounds 
such as bisphosphonates, either in a preventative way, or to treat already formed 
skeletal lesions. It is becoming very clear that the causes of Paget's disease will be 
multifactorial. The generation of TRAP-c-fosLTR mice will address only one com- 
ponent of the observed abnormalities in Paget's disease, namely, the up-regulation of 
c-Fos, and will provide a well-defined, readily manipulatable system to test the con- 
sequences of altered c-Fos expression in osteoclasts. 
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4. Effects of ectopic c-Fos expression on osteoblast 
proliferation and differentiation in vitro 
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4.1 Introduction 
c-Fos and AP-1 have been shown to be important in regulating the activity and dif- 
ferentiation of different bone cell types (as detailed in Chapter I and demonstrated in 
Chapter 3). In addition to the effects of c-Fos on osteoclasts, gain-of-function 
studies have shown that c-Fos specifically transforms osteoblasts (Grigoriadis et al, 
1995; Jochum, et al, 2001). However, the role of c-Fos in the differentiation, activ- 
ity and effect on c-Fos target genes in osteoblasts have not been fully investigated. 
Previous work in our laboratory has shown that cyclin DI expression is specifically 
elevated in the pre-nialignant osteoblasts and chondrocytes of H2-c-fosLTR mice 
and not in other transgene expressing tissues (Sunters et al, 1998), suggesting that 
cell cycle regulation may be one target of c-Fos in osteoblast and chondrocyte 
transformation. 
Furthermore, using a tetracycline-inducible c-Fos expression vector, pJMF2-c- 
fos, Sunters et al (2000) generated stable clones of the osteoblastic cell line, 
MC3T3-E1 (AT9.2 cells). In this system, exogenous c-Fos resulted in a reduction 
in cell cycle time and premature GI-S phase transition via deregulated cyclin E/A- 
CDK2 dependent mechanism, suggesting that deregulated c-Fos expression can alter 
osteoblast growth, which may contribute to malignant transformation. However, the 
effects of c-Fos overexpression on the osteoblast phenotype have not been fully 
investigated. AP-1 sites are found in the promoters of many bone specific genes, 
such as alkaline phosphatase, osteocalcin, collagen I and MNT-13 (Schule et al, 
1990; Schonthal et al, 1988; Matsuura et al, 1990; Owen et al, 1990), suggesting a 
potential role for c-Fos in osteoblast differentiation. 
In this chapter, investigations into the effects of ectopic c-Fos expression on the 
osteoblast phenotype have been described. Additional clones of MC3T3-E1 cells 
stably transfected with the pRAF2-c-fos vector were generated and the effects of 
exogenous c-Fos on ostcoblast proliferation and differentiation were investigated. 
4.2 Generation of stable cell lines of MC3T3-E1 cells which 
overexpress c-Fos 
The osteoblast-like cell fine MC3T3-EI was transfected with pJNff2-c-fos (Thomas 
et al, 2000), a tetracycline (Tc)-rcgulatable construct that results in expression of 
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exogenous c-fos in the absence of Tc (Figure 4.1). After transfection, cells were 
selected in medium supplemented with 3 00ýtg/ml Geneticin (G418) and I Optg/n-fl Tc, 
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Figure 4.1 - The DNA construct pJMF2-c-fos. Regulation of c-fos expres- 
sion is provided by constitutive expression of the Tc-repressed transactivator from a 
CMV promoter (Pcmv tTA). In the absence of Tc, the tTA protein binds to the Tc 
operator sequence ligated to a minimal human CMV promoter (tetO), directing the 
expression of c-fos. Transcription terminates at the SV40 poly A site (SV40 pA) of 
the expression vector pREP9 (Thomas et al 2000). The pJNfF2-1uc construct is 
identical to pJMF2-c-fos with the c-fos cDNA being replaced with a Firefly lucifer- 
ase gene (luc). 
Of the 24 G418-resistant clones isolated, 15 were examined for exogenous, c- 
fos expression by Northern blot analysis using poly (A)" RNA isolated from cells 
grown in the absence and presence of Tc (Figure 4.2). At least 6 strongly express- 
ing, positive clones (KTI. 5,1.20,1.14,1.22,1.2,1.3) and two weakly positive 
clones (KTI. 7,1.9) were identified. Four of these (KTI. 5,1.20,1.14,1.22) were 
selected for further screening of the c-Fos protein by Western blot analysis (Figure 
4.3). Clones KTI. 5 and KTI. 20 were shown to have the strongest levels of mRNA 
transcripts for exogenous c-Fos and c-Fos protein when cells were grown in the 
absence of Tc. Protein levels were reduced dramatically in the presence of I ýLg/ml 
Tc and completely absent at 10ýtg/ml Tc (Figure 4.3). Clone KTI. 5 was selected for 
further studies because it showed the best dose-dependent regulation in response to 
Tc. Clones KTI. 14 and KTI. 22 showed very little c-Fos protein when grown in the 
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absence of Tc, and were not studied further. KT1.5 and KT1.20 were initially in- 
duced to undergo differentiation in the presence of BMII-2 and K'Fl. 5 was chosen 
from this experiment for subsequent differentiation experiments since it showed a 
greater response to BMI-1-2-induced alkaline phosphatase activity (see below). 
In addition, stable clones of MC313-El cells were generated following trans- 
fection with pJMF2-1uc (e. g., KT2.1) which encodes the lucilerase (lue) gene in- 
stead of c- f6s. Seven stable G418-resistant clones were grown in the presence or 
absence of Tc and the extracts were assessed tbr luciterase activity (see Table 4.1 ). 
Clone KT2.1 was used for fijrther studies as a control fior transfiection and selection. 
as well as any effiects that the withdrawal ofTc may have on the cells. 
1.5 1.20 1.14 1.15 1.16 1.19 1.22 DT 
TC +--+-+-+++ 
1.8 kb j-- w IQ 
0.6 kb jw we 10440000 
1.1 1.2 1.3 1.6 1.7 1.8 1.9 1.13 DT 
Tc ++-+-+-++-+-+- 12.4 
1.8 kb w, 
0.6 kb - oft memo 
Figure 4.2 - Analysis of exogenous c-fos expression in KT clones. Northern 
blot analysis of poly (A)+ RNA from KT clones cultured in the presence and ab- 
sence of Tc (10[tg/ml) fior 3-4 days. The membrane was hybridised with it ' P- 
labelled v- The . 
16s probe which detects the exogenous (1.8 kb) c7fin transcript. 
endogenousfi)x gene (0.6 kb) was used as a control fbr RNA loading. RNA ex- 
tracted from pJMF2-c-ji)s transfected ATDC5 cells (D'1'12.4; Thomas el al, 2000) 
was used as a positive control. 
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KTI. 5 KTI. 14 
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KTI. 20 KT1.22 
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Figure 4.3 - Western blot analysis of four KT clones. Cells (K'1'1.5,1.14, 
1.20, and 1.22 cells) were cultured for 4 days bcIbre Western blot analysis (as de- 
scribed in section 2.9). A chondrogenic ATDC5 c-Fos expressing clone, DT9.6. was 
used as a positive control for c-Fos protein. */arrow -- non-specitic band. 
Table 4.1 - Analysis of KT luciferase clones. 
Luciferase activity 
(Light intensity / jig protein) 
Clone +Tc -Tc Fold-indLICtion 
KT2.1 0.00 0.27 
KT2.2 0.06 0.14 2.3 
KT2.3 0.06 0.05 0.8 
KT2.4 0.1 34.88 348.8 
KT2.5 1.99 0.14 0.1 
KT2.6 0.07 0.12 1.7 
KT2.7 0.08 0.01 0.1 
AT7.8 503.50 4882.00 9.7 
Luciterase activity of cell lysate from KT lue clones grown ± Tc (I Oýtg/ml). 
Luciterase activity oflysates was measured using Promega Firefly IAMIýrasc Assay 
System protocol (see section 2.6.6.4). Lysate from pJMF2-lue transtýcted MC3'1'3- 
EI cells (AT7.8) was used as a positive control. 
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4.3 Effects of exogenous c-Fos on osteoblast proliferation in 
differentiating cultures 
Previous studies in our laboratory have demonstrated that under normal serum con- 
ditions, exogenous c-Fos expression alone shows no effect on osteoblast prolifera- 
tion (Sunters et al, 2000). Parental wild type MCM-El cells can be induced to 
undergo osteoblast differentiation in the presence of P-glycerophosphate and ascor- 
bic acid, and also BNIP-2 (as described in method section 2.6.7). When KTI. 5 cells 
were induced to undergo differentiation in these conditions and in the presence of 
Tc, a greater number of cells appeared to be present in DNIP-2 treated cultures when 
viewed by phase contrast fight microscopy. This stimulation of proliferation was 
apparently further augmented by exogenous c-Fos expression (data not shown). To 
investigate in detail the role of c-Fos in osteoblast proliferation, KTI. 5 cells were 
assessed by growth curve analysis. Under standard culture conditions in 10% se- 
rum, the withdrawal of Tc induced no changes in proliferation either in the presence 
or absence of BNIP-2 (Figure 4.4 A). However, under differentiation conditions and 
in the absence of Tc there was evidence of increased proliferation of KTI. 5 cells at 
early time points (days 10 to 15), corresponding to the log phase of growth and the 
onset of multilayering (Figure 4.4 B). By day 16, of which time there is abundant 
multilayering and extracellular matrix deposition, cell proliferation in the presence 
and absence of Tc was eventually the same (Figure 4.4 B). 
To confirm that the stimulation of proliferation was due to the effects of exoge- 
nous c-Fos and not due to the withdrawal of Tc from the culture medium, growth 
curve analysis was performed for the parental cells MC3 T3 -E I and KT2.1 (luc) cells 
under differentiation conditions. MC3T3-El cells were initially cultured for 3-4 
passages in the presence of Tc (10pg/ml) and then cultured under differentiation 
conditions for up to 8 days in Tc (0,1,1 Opg/ml). Cell numbers were counted at 
varying time points during the log phase of growth. MC3T3-EI cells appeared to 
exhibit no change in proliferation in the presence or absence of Tc (Figure 4.5 A). 
However, an inhibition of KT2.1 cell proliferation was observed in the presence of 
10ýLg/ml Tc (Figure 4.5 B). This indicates that in the transfected clones, Tc: has a 
slight inhibitory effect on cell proliferation, and that the apparent increase in KTI. 5 
cell number following Tc withdrawal may not be due solely to increased exogenous 
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c-fos expression. Consistent with this possibility, Sunters; et al (2000) found that in 
10% serum, AT9.2 cells showed no changes in proliferation either in the presence 
and absence of Tc. Not withstanding the possible effect of Tc on KTI. 5 cell prolif- 
eration, BNV-2 was found to significantly increase cell number in the presence, but 
not absence, of exogenous c-fos expression, during the late exponential growth of 
the cultures. Based on these findings, further experiments to determine the effects of 
exogenous c-Fos expression on the differentiation of KTI. 5 cells, were conducted in 
the presence of Tc at I ltg/ml. 
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Figure 4.4 - The effects of exogenous c-Fos on proliferation of KTI. 5 cells (figure on 
previous page). Growth curve analysis of cells grown in (A) standard medium and (B) 
differentiation medium as described in section 2.6.10. Cells were cultured overnight in 
standard medium with Tc for 24 hours to allow cells to settle before treatment in standard 
medium (A) or differentiation medium (B i and ii) ±Tc 0 On/ml) and ±BM P-2 (I OOng/ml) 
for the indicated time points. Line graphs in B (iii) contain the same data from (ii) but data 
has been divided into +Tc and -Tc for simplicity. Cells were trypsinised and cell numbers 
counted at the times indicated for up to 26 days. Mean data represents cell counts from 3 
separate wells from individual experiments. Statistical analysis (Student's t-test): B (i) Bar 
graph, day 8, ** p<0.01 for +BMP-2 versus -BMP-2 (-Tc) and *** p< 0.001 for -Tc ver- 
sus +Tc (+BMP-2); day 16 *** p=0.001 for +BMP-2 versus -BMP-2 (-Tc) and -Tc versus 
+Tc (+BMP-2). B (ii) Line graph, ** p<0.01 and * p<0.05 for +Tc versus -Tc (+BMP-2). 
B (iii) * p<0.05 and *** p< 0.00 1 +BMP-2 versus -BM P-2. 
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Figure 4.5 - The effects of Tc withdrawal on proliferation of MC3T3-E1 
and KT2.1 cells. Growth curve analysis of MC3T3-El cells (A) and KT2.1 cells 
(B) grown in differentiation medium as described in section 2.6.10. Cells were cul- 
tured in standard medium for 24 hours before treatment in differentiation medium ± 
Tc (0,1, lOgg/ml) as indicated. Cell numbers were counted at the times indicated 
for up to 8 days. Mean data represents cell counts from 3 separate wells from indi- 
vidual experiments. *** p<0.001 lOpg/ml Tc versus 0 and Ipg/ml Tc (day 3); *** 
p<0.001 10ýtg/ml Tc versus Ipg/ml Tc and ** p<0.01 lOpg/ml Tc versus 0 P91H 
Tc (day 5); ** p<O. 011 Oýtg/n-A Tc versus 0 and I ýtg/H Tc (day 8). 
** 
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4.4 Effects of BMP-2 on differentiation of MC3T3-El and KT1.5 
cells 
The effects of exogenous c-Fos on the responsiveness of osteoblastic cells to factors 
known to be important for osteoblast differentiation was investigated next. Parental 
MC3T3-EI cells were cultured in the presence and absence of BMP-2 to assess the 
differentiation potential of this particular cell line (as detailed in methods section 
2.6.7). In untreated cultures there was limited expression of alkaline phosphatase as 
measured by histochernistry (Figure 4.6). Structures resembling bone nodules were 
not seen. Treatment with BMP-2 increased the number of alkaline phosphatase 
positive foci and their staining intensity (Figure 4.6). In addition, MC3T3-E1 cells 
were differentiated in the presence of either Dexamethasone (IOOnM) or 1,25- 
(OH)2D3 (IOnM). Treatment with 1,25-(OH)2D3 increased alkaline phosphatase 
activity when compared with untreated cultures. Very little stimulation of alkaline 






Figure 4.6 - Differentiation of MC3T3-E1 cells following treatment with 
BMP-2. Cells were cultured for 35 days ± BMP-2 (100ng/n-d) under differentiation 
conditions (section 2.6-7) before cultures were fixed and stained for alkaline phos- 
phatase activity (section 2.6.8). 
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In MC3T3-E I cells, the expression of alkaline phosphatase increased with time 
during the phase of differentiation. Using semi-quantitative RT-PCR of total RNA 
extracted at days 1,15 and 30 of differentiation, cells demonstrated a time- 
dependent increase in alkaline phosphatase mRNA expression over the time course 
of differentiation, which was stimulated further by BW-2 treatment (Figure 4.7). 




Figure 4.7 - RT-PCR analysis of basal and BMP-2 stimulated alkaline 
phosphatase (ALP) expression in MCM-El cells. Cells were cultured for 30 
days ± BMP-2 (100ng/ml) under differentiation conditions as described in section 
2.6.7. Total RNA was extracted at the indicated time points throughout the culture 
period, and RT-PCR was performed as described in section 2.8.5 for 30 cycles using 
primers specific for ALP (409 bp) and GAPDH (250bp). RT-PCR was also per- 
formed on samples containing water instead of RNA, where there was no generation 
of PCR products found (data not shown). 
KTI. 5 cells were also differentiated in culture to study the effects of exogenous 
c-Fos on the osteoblast phenotype and the responsiveness of these cells to growth 
factors following exogenous c-fos expression. The clonal selection of MC3T3-EI 
cells following transfection with pJMF2-c-fos or pJMF2-luc resulted in a change in 
phenotype of the cells. Although KTI. 5 cells grown in the presence of Tc remained 
capable of differentiating, they did so only in the presence of BN4P-2. Cells that had 
been differentiated for 35 days in the presence of Tc and BNW-2 showed a small 
number of alkaline phosphatase positive cell foci (Figure 4.8). In the absence of Tc, 
that is, in the presence of exogenous c-Fos the number and intensity of staining of 
these foci was increased. AT9.2 cells, an additional c-Fos overexpressing MC3T3- 
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EI clone generated by Dr. A. Sunters (Sunters et al, 2000), also showed increased 
numbers of alkaline phosphatase positive foci in the absence of Tc (Figure 4.8). 









Figure 4.8 - Histochemical staining for alkaline phosphatase (ALP) activ- 
ity following differentiation of KTI. 5 and AT9.2 cells. KTI. 5 cells were cultured 
for 35 days ± Tc (Iýtg/rnl) and ± BNW-2 (100ng/rnl) under differentiation conditions 
before cultures were fixed and stained for ALP (as detailed in section 2.6.8). 
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The effect of exogenous c-Fos on BMP-2-induced alkaline phosphatase activity 
in KTI. 5 cells was ffirther investigated using a quantitative measure of alkaline 
phosphatase activity and semi-quantitative RT-PCR. Cells were grown for 30 days 
in differentiation medium, in the presence and absence of exogenous c-Fos induc- 
tion, and with or without BNW-2 treatment. Extracts were assessed for alkaline 
phosphatase activity, which was standardised for protein content. Surprisingly, at 
day 30 exogenous c-Fos appeared to inhibit the BNV-2-induced increase in alkaline 
phosphatase activity (Figure 4.9). To confirm that the inhibition of alkaline phos- 
phatase activity was not due to the withdrawal of Tc from the culture conditions, 
KT2.1 (luc) cells were also treated under the same differentiation conditions. There 
were no changes in BMP-2-induced alkaline phosphatase activity when KT2.1 was 
cultured in the absence or presence of Tc (Figure 4.9). 
Serni-quantitative RT-PCR was used to gain ftirther insight into the c-Fos in- 
duced changes in BNW-2-induced alkaline phosphatase activity. Total RNA was 
prepared from cultures induced to differentiate over 30 days as described above and 
in section 2.8.5. The increase in alkaline phosphatase mRNA following BMIP-2 
stimulation was clearly inhibited following induction of exogenous c-Fos, although 
the effects of c-Fos were not apparent when the number of cycles was increased 
(Figure 4.10 A, B). Alkaline phosphatase expression was further determined in 
cultures from earlier stages of differentiation. Alkaline phosphatase mRNA was not 
detectable in undifferentiated cultures of KTI. 5 cells or MC3T3-El cells, as deter- 
mined by Northern Blot analysis (data not shown), but was detectable in differenti- 
ated cultures using RT-PCR. Throughout all stages of culture, alkaline phosphatase 
mRNA was detectable in the presence of BW-2 (Figure 4.10 B). At days 5 and 16 
alkaline phosphatase mRNA was detectable in BNV-2-treated cultures independant 
of exogenous c-Fos expression. At day 30, however, there was a marked reduction 
in the ability of BMP-2 to induce alkaline phosphatase mRNA in cultures maintained 
in the absence of Tc (Figure 4.10 Q. 
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Figure 4.9 - Assessment of alkaline phosphatase activity in differentiated 
cultures of KT1.5 and KT2-1 clones. Cells were cultured for 30 days ± Tc and ± 
BMP-2 (100ng /ml) under differentiation conditions (see section 2.6.7) and alkaline 
phosphatase, activity was determined as detailed in section 2.6.9. Alkaline phospha- 
tase activity was standardised for protein content (units ALP/ýIg protein/well). The 
means ± S. D. of quadruple samples are shown. These results are a representative 
example of at least two independent experiments. Ectopic c-Fos expression in the 
presence of BMP-2 showed a significant (** p<0.01) reduction in ALP activity 
compared to no c-Fos expression. 
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Figure 4.10 - RT-PCR analysis of basal and BMP-2 stimulated ALP ex- 
pression in KTI. 5 cells. Cells were cultured ft)r 30 days ± Tc and ± BMP-2 
(100ng/") under diffi2rentiation conditions as described in scction 2.6.7. Total 
RNA was extracted at the indicated time points and RT-PCR was carried out using 
primers specific for ALP and GAPD11 (see section 2.8.5). (A) Conditions were 
standardised for the final differentiation time point (day 30) by pcrtornling 24,28,32 
PCR cycles and then repeated for 28 and 30 cycles (B). (C) PCR was perlbrmed Ibr 
all indicated differentiation time points using 30 PCR cycles. PCR products arc 
indicated - ALP (409 bp) and GAPD11 (250bp). RT-PCR was also pcrl'orilled on 
samples containing water instead of RNA, where there was no generation of' PCR 
products found (data not depicted). 
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From these results obtained by quantitative alkaline phosphatase assays and RT- 
PCR, it appears that following diffierentiation, ectopic c-Fos expression inhibits the 
expression of BNT-2-induced alkaline phosphatase at later stages of differentiation. 
The increased alkaline phosphatase staining that was reported in the cultures induced 
to express exogenous c-Fos (Figure 4.8) may have been a result of a greater number 
of cells present giving the appearance of larger numbers of alkaline phosphatase, 
positive colonies. 
4.5 Discussion 
The AM transcription factor, c-Fos, has been implicated in a large variety of bio- 
logical processes including transformation, proliferation, apoptosis, and oncogenic 
transformation (Angel and Karin, 1991; Kovary and Bravo, 1991; Karin, 1997; Lei- 
bermann, 1998; Shaulian and Karin, 2001; Jochurn et al, 2001). The generation of 
transgenic mice, either by gain-of-function or loss-of-function, have provided im- 
portant insights into the biological functions of c-Fos component of the AM tran- 
scription factor complex. In particular, c-Fos transgenic mice develop osteosarco- 
mas, implying a role for c-Fos in bone cell differentiation, apoptosis and transforma- 
tion. To gain a better understanding of the role of c-Fos in bone cell phenotype at 
the in vitro cellular level, the ectopic; expression of c-Fos in MC3T3-E1 cells was 
studied. These cells represent a spontaneously immortalised (non-transformed) 
osteoblast cell line (Sudo et al, 1983), which behaves as an immature, committed 
osteoblast cell population that can undergo differentiation in response to intraceffular 
and extracellular signs (see below). 
MC3T3-El ceRs were transfected with a tetracycfine (Tc)-regulatable c-Fos 
expression construct (pM2-c-fos), to generate stable clones, one of which (KT 1 -5) 
was selected for investigations into the effect of ectopic c-Fos expression on the 
osteoblast phenotype. Wild type MC3T3-EI cells do not show any endogenous c- 
Fos expression either in the presence and absence of Tc under normal conditions. 
However, KTL5 cells showed tight regulation by Tc of exogenous c-Fos expres- 
sion. Furthermore, previous work by Suntcrs et al (2000) has shown that using this 
system, similar clones (e. g., AT9.2) were generated and the exogenous c-Fos pro- 
tein that was produced was functional in terms of specific DNA binding and trans- 
activation of reporter gene activity for AP- I sequences. 
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4.5.1 Inducible overexpression of c-Fos leads to the inhibition of the 
osteoblast phenotype and an increase in proliferation 
Ectopic c-Fos expression in a clonal cell line of MC3T3-El cells (KTI. 5) was 
shown to down regulate the BNV-2 induced expression of alkaline phosphatase 
during the later stages of osteoblast differentiation, with no effect observed during 
the earlier stages. 
Following clonal selection MC3T3-El cells, transfected with pJW2-c-fos, 
showed a partial loss in their ability to differentiate. This was perhaps not surprising 
since it is well established that MCM-El cells lose their differentiation potential 
with increased passage number (Wang et al, 1999). Indeed, deriving stable sub- 
clones from a parental clonal population, involves many population doubhgs before 
a sufficient number of cells are obtained to perform reproducible molecular and bio- 
chemical experiments. Nevertheless, the cells were still considered osteoblastic 
since they retained their ability to differentiate in response to BNQ-2, at least as 
represented by expression of alkaline phosphatase. This was confirmed by histo- 
chemical staining, in addition to using RT-PCR and biochemical techniques. 
In the parental MC3T3-El cells, the expression of alkaline phosphatase in- 
creased with time in culture, and BM[P-2 further stimulated its activity, whereas 
KTI. 5 cells grown in the presence of Tc: were essentially dependent upon BMP-2 
for expression of alkaline phosphatase. Interestingly, induction of exogenous c-Fos 
following Tc withdrawal in long-term KTI. 5 cultures caused a'marked reduction in 
BNV-2-dependent alkaline phosphatase mRNA expression and activity, compared to 
cells grown without c-Fos induction. These data suggest that one of the possible 
functions of c-Fos is to inhibit BUT-2-induced osteoblast differentiation. This is 
consistent with preliminary data from our laboratory, where transient transfection of 
primary mouse calvarial. osteoblasts with a c-fos expression vector, caused an inhibi- 
tion in the number of bone nodules formed and a concomitant decrease in alkaline 
phosphatase staining (Dr A. Sunters, personal communication). However, the re- 
sults using KTI. 5 cells were in apparent contradiction with the histochernical stain- 
ing for alkaline phosphatase where exogenous c-Fos appeared to increase BNIP-2 
induced alkaline phosphatase activity after 30 days in culture. This potential dis- 
crepancy is now believed to be due to the presence of a higher cell number in the 
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BMP-2/c-Fos cultures resulting in an overall increased staining pattern for alkaline 
phosphatase. 
Qualitative observations of the cells through phase contrast microscopy consis- 
tently showed an apparently greater number of cells in BMP-2 treated cultures fol- 
lowing ectopic c-Fos expression compared to control cells. Preliminary growth 
curve analysis during the earlier differentiation phase of KT1.5 cells confirmed a 
small but significantly higher number of cells cultured in the presence of BMP-2 and 
this was Ru-ther augmented by exogenous c-fos expression. However, it was diffi- 
cult to document accurately the increases in cell number at later stages, due to the 
difficulties in obtaining efficient single-ceU suspensions in ascorbic acid-containing 
cultures where there is abundant extracellular matrix. Thus, flirther experiments 
using alternative indicators of proliferation, such as Bromo-uridine incorporation, 
tritiated thymidine incorporation or DNA content will verify the effects of Tc with- 
drawal and BW-2 on proliferation of KT1.5 cells. That c-Fos and AP-1 are im- 
portant for cell proliferation has been shown previously. As described in sections 
1.6.2 and 1.6.4, cyclin DI is an AP-1 target gene, and inhibition of c-Fos using neu- 
tralising antibodies attenuates cellular responsiveness to mitogens in quiescent cells 
(Kovary and Bravo, 1991). However, c-Fos is clearly not essential for cell prolif- 
eration since c-Fos knockout cells proliferate normally (Field et al, 1992; Brussel- 
bach et al, 1995; Shaulian and Karin, 2001; Jochurn et al, 2001). This suggests 
functional redundancy amongst other c-Fos family members, and likely candidates 
include FosB, since c-Fos/FosB double knockout mice are -30% smaller than wild- 
type littermates, and double knockout fibroblasts exhibit impaired activation of cy- 
clin DI following serum stimulation (Brown et al, 1998). That exogenous c-Fos 
may give the cells a proliferative advantage in response, for example, to addition of 
growth factors including BMP-2, is consistent with recent observations in our labo- 
ratory in which an additional independent MC3T3-E1 sub-clone, AT9.2, that also 
harbours a Tc-regulatable c-fos gene, exhibits accelerated S-phase entry in response 
to serum mitogens (Sunters et al, 2000; see also Introduction, section 1.6.4. ). 
The effects of c-Fos overexpression on differentiation and development vary 
depending on the cellular background. Previous in vitro studies have shown that c- 
Fos and other members of the AP-1 complex are differentially regulated during os- 
teoblast differentiation (McCabe et al, 1995; Banedee et al, 1996). During the pro- 
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liferative stage of the rat calvarial osteoblast fife cycle, the levels of all Fos and Jun 
proteins are high, but gradually decline during the period of extracellular matrix 
production and mineralisation. In fully differentiated osteoblasts Fra-2 and JunD are 
the major proteins in the AP-I complex (McCabe et al, 1995; Owen et al, 1990). 
This implies that c-Fos plays a critical role in osteoprogenitor proliferation and it has 
been hypothesised that enforced expression of Fo§/Jun family members during pro- 
liferation and subsequent developmental stages maintains cells in a proliferative state 
and inhibits further maturation which is necessary for matrix mineralisation (Lian et 
al, 1991; Owen et at, 1990). To a certain extent, the results of in vivo gain-of- 
function studies are consistent with this "phenotype suppression hypothesis": High 
c-Fos expression does not affect the differentiation potential of embryonic stem (ES) 
cells, since ES cells overexpressing c-Fos efficiently contribute to the development 
of chimeric mice (Wang et al, 1991). In contrast, ectopic c-Fos expression inhibits 
differentiation of chondrocytes (Thomas et al, 2000) and chimeric mice obtained 
from c-Fos overexpressing ES cells develop chondrosarcomas (Wang et al, 1991). 
Moreover, c-Fos overexpression in H2-c-fosLTR mice results in transformation of 
osteoblasts leading to osteosarcomas, and it has been postulated that c-Fos immor- 
talises a sub-population of osteoprogcnitor cells which renders them susceptible to 
ftirther transformation (Grigoriadis et al, 1993). In contrast, while high levels of c- 
Fos can perturb osteoblast differentiation and cause transformation, osteoblasts can 
differentiate normally in the absence of c-Fos, as shown in the c-Fos knockout mice 
(Wang et al, 1992; Johnson et al, 1992; Grigoriadis et al, 1994), possibly as a result 
of the compensatory actions of related family members. 
That c-Fos may be involved in osteoblast differentiation and function is also im. - 
plied by the fact that known regulators of osteoblast differentiation and proliferation 
such as, TGF-P, PTH, and 1,25-(011)2D3. induce the expression of c-fos (Machwate 
et al, 1995; Palcy et al. 2000; Pearman et al, 1996; Kano et al, 1994; Clohisy et al, 
1992; Candeliere et al, 1991). Interestingly, recent preliminary data from the 23rd 
annual ASBMR meeting (2001) have shown altered osteoblastic responsiveness to 
PTH treatment in osteoblasts derived from c-Fos knockout mice (Demiralp et al, 
2001). Again, suggesting that c-Fos may function as an important mediator of 
growth factor signalling in osteoblasts. In this regard, the results in this chapter that 
exogenous c-Fos affects the BMT-2 signalling pathway is significant. The effects of 
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BNT-2 on osteoblast differentiation have been studied intensively over the past 
decade. Treatment of osteoblasts with BMEP-2 is known to stimulate alkaline phos- 
phatase activity and collagen synthesis, an effect which is enhanced in the presence 
of oestrogen, dexamethasone, or 1,25-(OH)2D3 (Takuwa et al, 1991). The actions 
of BM[Ps on osteoblast proliferation depend on the cell type (see review in Wozney, 
1993). Generally, treatment of osteoprogenitor cells with BM[Ps leads to increased 
cell proliferation. In MC3T3-El cells, transient treatment with BW-2 alone has 
been shown to stimulate alkaline phosphatase levels but not to affect proliferation 
(Takuwa et al, 1991). It is also well-established that BNT-2 treatment of non- 
osteogenic precursor cells (e. g., IOTI/2) can induce them to differentiate into an 
osteoblast phenotype. It is not yet known how the BMP-2 pathway and c-Fos/AP- I 
interact in KT1.5 cells, although in IOTI/2 cells, the BMT-2 effects have been pos- 
tulated to be mediated by the ERK/MAPK signalling pathway (Lou et al, 2000). 
The ERK/MAPK cascade is the most important mediator of increased expresion of 
c-fos and c-jun family members in response to growth factor treatment (Angel et al, 
1988). JunB, together with c-Fos, is thought to play a major role in BNT-2 signal- 
ling in osteoblasts (Palcy et al, 2000). Thus it would be tempting to speculate that 
in KTI. 5 cells, BMEP-2 is not exerting a maJor, direct effect on osteoblast prolifera- 
tion and differentiation. Rather it is having an indirect secondary action to increased 
expression of JunB and c-Jun proteins, which will form heterodimers with freely 
available ectopic c-Fos proteins to modulate the cffccts of ectopic c-Fos. 
The mechanisms by which exogenous c-Fos may inhibit BMP-2-induced alka- 
line phosphatase activity is not clear. The alkaline phosphatase promoter contains 
AP-I sites (Owen et al, 1990) and it is possible that when occupied they exert an 
inhibitory effect on the transcription of the alkaline phosphatase gene. Alternatively, 
c-Fos may modulate BUIP-2 effects by affecting the expression of BMP receptors, 
or the inhibitory SMADs (e. g., SMAD-6, SMAD-7). Interactions with other tran- 
scription factors, most notably Cbfal/runx2, may also contribute to the observed 
effects. BNV-2 can induce Cbfal expression in various osteoblast cell lines to co- 
ordinate osteoblast differentiation (Gori et al, 1999; Lee et al, 2000; reviewed in 
Yamaguchi et al, 2000), and c-Foslc-Jun heterodimers and Cbfal can physically 
interact and regulate osteoblast gene expression (Winchester et al, 2000; Hess et al, 
2001; Chinenov and Kerppola, 2001). 
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Clearly, further experiments need to be performed to address the potential 
mechanisms by which c-Fos may alter BMIP-2 signalling in KTI. 5 cells. 
4.6 Conclusions 
Inducible overexpression of c-Fos in MC3T3-El osteoblastic cells may result in an 
inhibition of the osteoblast phenotype in vitro. This was evidence by a decrease in 
BNT-2-induced alkaline phosphatase expression following ectopic c-Fos expression. 
Although these results are based on preliminary data, the mechanisms of this may 
potentially be mediated through a small increase in proliferation and inhibition of 
differentiation of cells. 
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5. A role for c-Fos on osteoblast apoptosis 
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5.1 Introduction 
Previous gain-of-function studies using H2-c-fosLTR transgenic mice found that 
apoptosis in c-Fos expressing transformed osteoblasts was increased relative to 
wild-type osteoblasts, but was maintained at relatively low levels throughout later 
stages of turnour formation, when high Bcl-2 levels were evident (Grigoriadis et al, 
1993; El-Emir PhD thesis). In addition, osteoblast like cell lines derived from late 
stage bone tumours of H2-c-fosLTR mice did not readily undergo apoptosis fol- 
lowing serum withdrawal or treatment with TNF-oc. From this work it was postu- 
lated that during the earlier stages of turnour formation, ectopic c-Fos expression in 
transgenic; mice leads to increased apoptosis in osteoblasts, but that there was an 
overaU disruption of the balance between proliferation and apoptosis in the osteo- 
blasts leading to malignant transformation. 
To gain fialher insights into the role of ectopic c-Fos expression in osteoblast 
apoptosis; prior to osteoblast transformation, KTI. 5 cells (described in Chapter 4) 
were used. These cefls were used to study the effects of c-Fos overexpression on 
apoptosis in osteoblastic cells because they are a non-transformed cell line and con- 
sidered to represent osteoblastic cells at an early stage of osteoblast differentiation. 
5.2 Effects of exogenous c-Fos expression on osteoblast apoptosis 
Cells were grown under standard conditions in the presence or absence of Tc to 
induce expression of exogenous c-Fos. Apoptosis was induced by serum withdrawal 
or serum withdrawal in the presence of TNF-a, and compared to control growth 
medium containing 10% serun-L The response of KTI. 5 cells to different concentra- 
tions of TNF-(x under reduced serum conditions was initially determined for 24 or 
48 hours treatment to induce apoptosis. From these results, 48 hours treatment at 
30ng/ml produced 50% apoptosis and was considered a suitable concentration for 
further experiments (data not shown). 
Cell morphology following treatment was first monitored by light microscopy. 
Cells grown in the absence of serum began to show a change in morphology after 48 
hours compared with those observed grown in medium containing 10% serum. 
Typically the cells retracted from the substrate, rounded up and eventually detached 
from the culture dish (Figure 5.1 A). The numbers of floating cells appeared to be 
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greater in the absence of Tc, i. e. when c-Fos was expressed, than that in the pres- 
ence of Tc. This appeared to be further potentiated in cells treated with TNF-a. 
To characterise further this apoptotic effect, cells were fixed and stained with 
propidium. iodide (PI) to quantify apoptotic nuclei under fluorescence microscopy. 
Morphological changes which are a hallmark of apoptosis such as cell shrinking, 
nuclear condensation, and nuclear fragmentation can be immediately scored using 
fluorescence microscopy and the percentage of apoptotic cells calculated. Figure 5.1 
shows the pro-apoptotic: effects of ectopic; c-Fos protein in KTI. 5 cells following 
serum deprivation and TNF-cc treatment. Very few, if any, apoptotic nuclei were 
present in cells cultured in 10% serum and there were no significant differences in 
apoptotic nuclei between Tc: treatments (Figure 5.1 B). Serum withdrawal clearly 
induced apoptosis, and could be observed when cells were grown in the absence as 
well as in the presence of Tc. However, when ectopic c-Fos was expressed (i. e. in 
the absence of Tc), there was a significant increase (-1.5-fold) in the number of 
apoptotic cells when compared with cells grown in the presence of Tc (data repre- 
sented in Figure 5.1 B). 
When cells were induced to undergo apoptosis in the presence of TNF-a and 
absence of serum, there was a marked increase in apoptosis in both the presence and 
absence of Tc, that was of similar magnitude in both treatment groups (Figure 5.1 
B). Moreover, when KTI. 5 cells were cultured under normal serum conditions and 
treated with TNF-a, the cells were less sensitive to TNF-cc than under reduced se- 
rum conditions (Figure 5.1 B). 
As controls, KT2.1 ceRs (a luciferase expressing clone; see Chapter 4) were 
also induced to undergo apoptosis by serum withdrawal and TNF-a treatment. Lev- 
els of apoptosis in the presence and absence of Tc were similar in both the presence 
and absence of TNF-a, indicating that the withdrawal of Tc: alone had no effect on 
apoptosis (Figure 5.2). 
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Figure - 5.1 - Ectopic c-Fos expression sensitises cells to apoptosis induced 
by serum withdrawal and TNF-a. (A) Morphological changes and propidium, 
iodide staining of KTI. 5 cells grown in the absence of serum and in the presence of 
TNF-a. KTI. 5 cells were cultured in the presence and absence of Tc for 48 hours 
to induce c-Fos expression. Medium was then replaced with complete growth me- 
dium (10%), medium lacking serum (0% FCS) or serum-free medium plus TNF-a 
(30ng/md). After 48 hours, cells were fixed and stained with propidium iodide (PI) 
and viewed using fluorescence microscopy. Arrows indicate -mitotic cefls and ar- 
rowheads denote apoptotic nuclei. Total magnification: x2OO. (B) Propidiurn iodide 
assessment of apoptosis of KTIJ ceRs grown in the absence of serum and in the 
presence of TNF-cc. Cells were treated as described in (A); in addition the data for 
ceUs treated with TNF-a (30ng/n-fl) in 10% serum have been shown. Apoptotic 
nuclei were quantified by counting at least 100 PI-stained cells per field in 5 random 
fields per coverslip. The mean % apoptosis (± S. D. ) of triplicate samples are shown. 
These results are a representative example of at least three separate experiments. 
(* *, p<0.01, compared to corresponding +Tc). 
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Figure 5.2 - Stimulation of apoptosis, under reduced serum conditions and 
TNF-cc in KT2.1 cells. Propidiurn iodide assessment of apoptosis of KT2.1 cells 
grown in the absence of serum and in the presence of TNF-a. KT2.1 cells were 
treated as described in Figure 5.1. The means (± S. D. ) of triplicate samples are 
shown. Cells treated with complete growth medium (10%) showed 0% apoptosis 
and have not been shown here. These results are a representative example of two 
independent experiments. 
In order to ffirther confirm that the cell death observed was apoptotic in nature, 
DNA strand breaks were determined by terminal deoxynucleotidyl transferase end 
labelling (TUNEL). This method detects DNA fragmentation and is indicative of a 
late stage of apoptosis. Cells were grown on glass coverslips under standard condi- 
tions in the presence and absence of Tc to induce expression of exogenous c-Fos 
before serum was withdrawn as above. Expression of exogenous c-Fos clearly in- 
creased the numbers of TUNEL positive cells following serum withdrawal as frag- 
mented and condensed nuclei were clearly distinguishable using this method (Figure 
5.3). To confirm the specificity of the assay the TUNEL reaction was carried out in 
the absence of TdT-transferase. Under these conditions, cells exhibiting fluores- 
cence could not observed. 
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Figure 5.3 - Assessment of c-Fos-induced apoptosis of KTI. 5 cells via 
TUNEL staining. KTI. 5 cells were cultured on glass coverslips as in Fig. 5.1 in 
the presence (A, C) and absence (B, D) of Te for 48 hours to induce ectopic c-fos 
expression, before serum was withdrawn. Cells were fixed and stained using the 
TUNEL technique as described in section 2.6.11. Only cells grown in 0% serum 
have been depicted due to absence of apoptotic nuclei in normal growth medium. 
Total magnification: x2OO (A, B) and x600 (C, D). 
Taken together, these results show that serum deprivation induces apoptosis in 
KTI. 5 ceHs which is potentiated by expression of exogenous c-Fos. TNF-cc can 
enhance this apoptosis but it is not potentiated ftu-ther by ectopic c-Fos expression. 
5.2.1 Effect of Caspase inhibitors on c-Fos-induced apoptosis 
To investigate the mechanism of c-Fos induced apoptosis, inhibitors of steps in the 
apoptosis pathway were used. Caspases play a well established role in the execution 
phase of apoptosis (see section 1.5.1), although caspase-independent apoptotic 
pathways also exist (e. g., Gross et al, 1999). The irreversible, broad-spectrum 
caspase-l-like inhibitor, Z-VAD-fink (benzyloxycarbonyl-Val-Ala-Asp-0-methyl- 
fluoromethyl ketone), was used to try to inhibit c-Fos induced apoptosis. This 
chemical has been shown to be an effective inhibitor of chemical and receptor- 
mediated apoptosis via inhibition of caspases 1,3,4, and 7 in a wide range of cell 
types (e. g., Cohen, 1997; Robertson et al, 2000; Johnson et al, 1999), including 
osteoblasts (Pucci et al, 1999). 
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The effect of Z-VAD-fmk was characterised first by a series of experiments aimed at 
establishing the effective doses and the optimal time of addition (Figure 5.4). To 
this end, KTI. 5 cells were initially cultured in the presence of Tc in standard condi- 
tions, before cells were cultured both in the presence or absence of serum, and in a 
range of Z-VAD-fink concentrations (0,10,30,100ýM). After 24 hours, cultures 
were assessed for signs of apoptosis as described above. 
Z-VAD-fink did not inhibit apoptosis induced by serum withdrawal (Figure 5.4 
B). The reason for this may have been that even though Z-VAD-fink is a highly cell 
permeable compound, cells need to be pretreated with Z-VAD-fink before apoptosis 
is induced. Thus, subsequent experiments were set up which incorporated various 
regimes of pretreatment, as described in Figure 5.4 A. 
To determine whether the pro-apoptotic: effect of c-Fos was mediated through 
caspase activation, cells were pretreated with Z-VAD-fink prior to stimulation of 
apoptosis. To confirm that Z-VAD-fink was active in inhibiting apoptosis, the inhi- 
bition of TNF-a induced apoptosis was used a positive control. Z-VAD-fink has 
been shown to alleviate TNF-a induced apoptosis in human prostate cancer cells 
(e. g., Kimura and Gelman, 2000). Cells were cultured in the presence and absence 
of Tc to induce c-Fos expression, and then treated for 24 hours with Z-VAD-fink 
(I OgM). They were then treated for a further 48 hours with Z-VAD-fink (10ýtND 
and complete growth medium, serum withdrawal, or serum withdrawal plus TNF-cc 
(Figure 5.4 Q. Interestingly, assessment of apoptosis demonstrated that using these 
conditions, Z-VAD-fink did not inhibit apoptosis induced either by c-Fos, serum 
withdrawal, or TNF-a. 
To further investigate whether Z-VAD-fink could inhibit apoptosis, the pre- 
treatment period was reduced to I or 6 hours. In the presence of ectopic c-Fos 
expression, pretreatment of cells with Z-VAD-fink for either I or 6 hours showed 
no protection from apoptosis induced by serum withdrawal (Figure 5.4 D). In the 
presence of Tc, there was a small and significant reduction in induction of apoptosis 
observed in cells treated with Z-VAD-fink. Overall, therefore, Z-VAD-fink showed 
no protection from apoptosis induced by ectopic c-Fos expression in KTI. 5 cells. 
To further investigate potential caspase pathways involved in c-Fos induced 
apoptosis, another caspase inhibitor, acetyl DEVI) aldehyde (DEVD-CHO) was 
used, which inhibits caspases-3,6,7 and 10. DEVD-CHO has been shown to inhibit 
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chemical and growth factor induced apoptosis in osteoblasts (Plotkin et al, 1999; 
Kawakami et al, 1998) and a variety of other cell types (e. g., Cohen, 1997; Schlegel 
et al, 1996). 
Cells were cultured as for previous apoptosis experiments and pretreated for I 
hour with DEVD-CHO, before apoptosis was induced by serum withdrawal. The 
apoptosis induced by ectopic c-Fos was slightly but significantly reduced from 1.5- 
fold stimulation to 1.3-fold stimulation in the presence of 30ýLM DEVD-CHO, with 
no effects on basal apoptosis levels (Figure 5.5). This inhibitory effect of DEVD- 
CHO also appeared to be dose-dependent, but further work using a wider concen- 
tration range of DEVD-CHO will be required. 
Cells were also pretreated with DEVD-CHO (30gM) as above before induction 
of apoptosis by serum withdrawal in the presence of TNF-a. DEVD-CHO signifi- 
cantly reduced the apoptosis induced by TNF-a in the absence of serum by 37% in 
cells cultured in the absence of c-Fos (Figure 5.6). However, no inhibition of 
apoptosis was observed in the presence of c-Fos. This suggests that only the apop- 
tosis induced by TNF-cc can be inhibited under these conditions and the presence of 
ectopic c-Fos is forcing the ceUs into a condition which cannot be overridden by 
caspase inhibitors. 
Overall, these results show that while a slight inhibition in c-Fos-induced 
apoptosis was observed using DEVD-CHO, the overall effects using both caspase 
inhibitors, Z-VAD-fink and DEVD-CHO, showed no marked inhibition, suggesting 
that the c-Fos effects on apoptosis may be caspase-independent. 
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Figure 5.4 - Effects of Z-VAD-fink on apoptosis induced by ectopic c-Fos 
expression in KT1.5 cells (previous page). (A) Schematic of methodology. 
KTI. 5 cells were cultured ±Tc for 48 hours, after which medium was replaced with 
complete growth medium (10%) or serurn-free medium (0% FCS), TNF-a 
(30ng/n-A), or a range of Z-VAD-fink (Z-VAD) concentrations as indicated. Cells 
were treated for the indicated times before cells were fixed and stained with PI as 
described in section 2.6.11. (B) Z-VAD-fink dose-response effects and (C) effects 
of 24 hour pretreatment with Z-VAD-fink on c-Fos and TNF-a-induccd apop- 
tosis. Ectopic c-fos expression produced a significant induction of apoptosis com- 
pared to cells grown in the absence of c-Fos (p<0.001) when cells were cultured in 
either 0% serum alone (* * *) or when also treated with Z-VAD (###). Furthermore, 
the apoptosis induced by serum withdrawal (+Tc only) was significantly enhanced 
(*, p<0.05) in the presence of Z-VAD. (D) 1 and 6 hour pretreatment with Z- 
VAD on c-Fos-induced apoptosis. Short term pretreatment with Z-VAD-fink only 
showed inhibition of apoptosis induced in the absence of c-Fos (##, p<0.01). Cells 
treated in 10% serum ± Z-VAD showed 0% apoptosis and have not been depicted. 
In all cases, apoptotic nuclei were quantified by counting at least 100 cells per field 
in 5 random fields per coverslip. The data represent the means (± S. D. ) of triplicate 
samples. 
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Figure 5.5 - Effect of the caspase-3 inhibitor DEVD-CHO on apoptosis induced by 
serum withdrawal and ectopic c-Fos in KTI. 5 cells. Cells were cultured in the presence 
and absence of Tc for 48 hours to induce c-Fos expression. Cells were pretreated for I hour 
with the DEVD-CHO as indicated, before medium was replaced with complete growth me- 
dium (10%), serum-free medium (0% FCS) plus DEVD-CHO, ± Tc. After 48 hours cells 
were stained with PI and apoptotic cells were quantified as in Figure 5.4. The means (± 
S. D. ) of triplicate samples are shown. Cells treated with 10% serum ± DEVD-CHO showed 
0% apoptosis and have not been depicted. (## p=0.01, compared to corresponding -Tc 
treatment at 0 and 3gM DEVD-CHO). 
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Figure 5.6 - Effect of DEVD-CHO on apoptosis induced by serum withdrawal, c- 
Fos and TNF-, a KTI. 5 cells. KTI. 5 cells were cultured ±Tc for 48 hours to induce c-Fos 
expression. Cells were pretreated for I hour with DEVD-CHO as indicated, before medium 
was replaced with serum-free medium (0% FCS) plus TNF-oc (30ng/mi), and ± DEVD- 
CHO as indicated. Cells were treated for further 48 hours before PI assessment and quanti- 
fication of apoptosis as above. The means (± S. D. ) of triplicate samples are shown which 
are representative of one experiment. (### p=0.001, compared to corresponding +Tc). 
ý TC *-ý; 
-c 
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5.2.2 Cell cycle inhibition by Roscovitine prevents c-Fos induced apoptosis 
To fin-ther understand the mechanisms of c-Fos-induced apoptosis, KTI. 5 cells were 
pretreated with Roscovitine, which is a potent inhibitor of the cyclin-dependent ki- 
nase, CDK2, and cell cycle progression (Alessi et al, 1998; Schutte et al, 1997; see 
also section 1.4). The rational for using this was three-fold: First, as described in the 
introduction, recent data clearly demonstrate a functional link between cell prolif- 
eration and programmed cell death. Second, Roscovitine was chosen since it has 
been shown to inhibit TGF-pi-induced apoptosis in FaO hepatorna cells (Choi et al, 
1999). Finally, data from our laboratory have shown that under reduced serum 
conditions, c-Fos can increase CDK2 activity and cause accelerated cell cycle pro- 
gression (Sunters et al, 2000). Dose-response experiments were performed initially 
to establish the optimal concentration of Roscovitine for inhibition of cell cycle pro- 
gression. KTI. 5 cells were cultured in standard medium, in the presence and ab- 
sence of Tc and Roscovitine for 48 hours and the cell density roughly estimated by 
methylene blue staining. Following a qualitative assessment after 24 hours, there 
appeared to be no difference in cell number, however, after 48 hours fewer cells 
could be observed in the cultures treated with 30ýM Roscovitine (pictures not 
shown). No obvious differences in cell density were apparent between ± Tc cul- 
tures. Thus, the cell growth in KTI. 5 cells was reduced by Roscovitine at approxi- 
mately 30pM. 
The effect of Roscovitine on apoptosis induced by serum withdrawal in the 
presence and absence of c-Fos expression was assessed using a range of Roscovitine 
concentrations. Cells were cultured in the presence and absence of Tc to induce c- 
Fos expression, before cells were pretreated for I hour with Roscovitine. Cells were 
then treated for 48 hours with Roscovitine and complete growth medium or serum 
withdrawal (Figure 5.7). Cells treated with Roscovitine in standard growth medium 
showed no induction of apoptosis (data not shown). Following serum withdrawal, 
c-Fos caused a 2.8-fold stimulation in the percentage of apoptotic cells (Figure 5.7). 
Treatment with Roscovitine significantly attenuated the apoptosis induce by serum 
deprivation in the presence of ectopic c-Fos expression, at all concentrations tested. 
This suggests that Roscovitine can inhibit c-Fos-induced apoptosis, possibly in a cell 
cycle-dependent way. 
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Figure 5.7 - Effects of Roscovitine on apoptosis induced by serum with- 
drawal and c-Fos in KT1.5 cells. Cells were cultured ± Tc for 48 hours to induce 
c-Fos expression. Cells were pretreated for I hour with Roscovitine as indicated, 
before apoptosis was induced by serum withdrawal (0% FCS) in the presence and 
absence of Roscovitine. Cells were treated for further 48 hours before PI assess- 
ment as described above. The means (± S. D. ) of triplicate samples are shown. Re- 
sults for 30ýiM are representative of at least three separate experiments. 
p: 0.001 and * p<0.05 compared to respective ±Tc; OýM Roscovitine control. 
The effect of exogenous c-Fos on Etoposide-induced apoptosis under normal 
serum conditions was investigated, and whether this could be inhibited by Roscovi- 
tine or Z-VAD-fink. Etoposide is known to induce apoptosis by forming a complex 
between DNA and DNA topoisomerase 11 (Lock et al, 1994), and is thus an apopto- 
sis inducing agent which acts through cell cycle mechanisms. Cells were pretreated 
for I hour with Roscovitine or Z-VAD-fink, before apoptosis was induced by Eto- 
poside in the presence and absence of Roscovitine or Z-VAD-fi-nk, all in the pres- 
ence and absence of Tc. Etoposide-induced apoptosis in KTI. 5 cells was signifi- 
cantly stimulated 2-fold by the presence of exogenous, c-Fos (Figure 5.8). Roscovi- 
tine abolished the apoptosis induced by both Etoposide alone and Etoposide in the 
presence of c-Fos to less than 1% apoptosis for both groups. However, treatment 
with Z-VAD-fi-nk showed no effects on inhibition of apoptosis either in the presence 
or absence of c-Fos (Figure 5.8). 
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Figure 5.8 - Roscovitine but not Z-VAD-fmk inhibits apoptosis induced 
by Etoposide. KTI. 5 cells were cultured in the presence and absence of Tc for 48 
hours to induce c-Fos expression. Cells were pretreated for I hour with DMSO 
vehicle control, Roscovitine (30pM) or Z-VAD-fink (10,30gM) as indicated, be- 
fore apoptosis was induced by Etoposide (I 0ORg/n-A) in the presence and absence of 
Roscovitine or Z-VAD-fink. Cells were treated for a further 24 hours before cells 
were fixed and stained with Pl. Apoptotic nuclei were quantified by counting at 
least 100 cells per field in 5 random fields per coverslip. The means ± S. D. of tripli- 
cate samples are shown from a representative experiment of two separate experi- 
ments. *p<0.05 compared to +Tc Etoposide control. 
To confirm that Roscovitine was reducing the apoptosis induced by c-Fos by 
cell cycle dependent mechanisms, KTI. 5 cells were made quiescent and synchro- 
nised by treatment in 0.5% serum before induction of apoptosis. In the presence of 
ectopic c-Fos there was a significant increase in the numbers of apoptotic nuclei in 
quiescent KI. 5 cells (Figure 5.9 A, left panel). Interestingly, pretreatment with 
Roscovitine not only inhibited this increase, but completely reversed the induction of 
apoptosis by c-Fos (Figure 5.9 A, left panel). A similar pattern of results was found 
when cells were made quiescent and induced to undergo apoptosis by serum with- 
drawal, although the overall level of apoptosis was much greater under these condi- 
tions. This pattern of inhibition by Roscovitine was slightly different to that ob- 
served when cells were not made quiescent before induction of apoptosis. Figure 
5.9 B shows the results from non-quiescent cells induced to undergo apoptosis as 
described previously for Figure 5.7. Under these conditions, Roscovitine inhibited 
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the c-Fos-induced increases in apoptosis to basal levels, but not further (Figure 5.9 
B), indicating different effects of this CDK2 inhibitor in cells arrested in Go when 
compared with non-quiescent cells. Taken together these results support the possi- 
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Figure 5.9 - Inhibition of apoptosis by Roscovitine in quiescent and syn- 
chronised KTI. 5 cells compared to non-quiescent cells. (A) Cells were cultured 
on glass coversfips in the presence and absence of Tc for 24 hours to induce c-Fos 
expression before cells were pretreated for 24 hours 0.5% serum, then 24 hours ± 
Roscovitine (30ýM) in 0.5% serum. Apoptosis was induced by serum withdrawal 
(0% FCS) or maintained in 0.5% serum, ± Roscovitine (30ýM), ± Tc. Cells were 
treated for a further 48 hours before being fixed and stained with Pl. (B) To control 
for previous observations with Roscovitine, cells were also treated as described for 
Figure 5.7, i. e. pretreatment ± Roscovitine (30ýM), ± Tc in 10% serum for 24 
hours, before induction of apoptosis by serum withdrawal ± Roscovitine, ± Tc. 
Apoptotic nuclei were quantified by counting at least 100 cells per field in 5 random 
fields per coverslip. The means ± S. D. of triplicate samples are shown. Data repre- 
sents only one experiment. *p: 50.05, **p<0.01, ***p ! ý0.001 compared to respec- 
tive +Tc treatment. 
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5.2.3 c-Fos mediated apoptosis is abrogated by ectopic expression of the 
CDK2 inhibitor, p2l, and Bcl-2 in KT1.5 cells 
To finther confirm that changes in cell cycle control and CDK2 activity may be 
contributing to c-Fos-induced apoptosis, and to further investigate the possible 
mechanisms of apoptosis, transient transfection. experiments were performed with 
the CDK2 inhibitor, p2l"F"C'P""", and the anti-apoptotic gene bcl-2. Expression 
ofp2l and p2; 1ý11 have been previously demonstrated to inhibit apoptosis, including 
in osteoblasts (Bellido et al, 1998; Hiromura et al, 1999). Additionally, the transient 
co-expression of the proto-oncogene bcl-2 was assessed to further delineate the 
apoptotic pathways involved in c-Fos induced apoptosis. 130-2 has been shown to 
inhibit chemical and growth factor withdrawal-induced apoptosis; in many in vitro 
cell systems (Wagner et al, 1993). 
Ectopic expression of the CDK2 inhibitor, p2l, or the anti-apoptotic gene, bcl- 
2, significantly inhibited c-Fos-induced apoptosis (Figure 5.10). In contrast, the 
level of apoptosis in control peDNA-transfected cells was not affected, with exoge- 
nous c-Fos causing -3-fold increase in the number of apoptotic cells (Figure 5.10). 
This data further suggest that c-Fos is inducing apoptosis through a cell cycle- 
dependent mechanism, perhaps by stimulating the cell cycle activity of cells in the 
absence of growth factors. This may also support the potential anti-proliferative 
effects of Bcl-2 during apoptosis that have been previously reported (Johnson et al, 
1999), especially since the Bcl-2 levels remain unchanged in KTI. 5 cells (see be- 
low). 
5.2.4 The expression of Bcl-2 and Bax following c-Fos expression 
The apoptotic response of a cell can vary depending on the relative levels of Bax and 
Bcl-2 present. The anti-apoptotic proto-oncogene M-2 has been shown to inhibit 
apoptosis in a variety of systems in vitro, and is expressed in osteoblasts in vivo 
during normal development as well as during bone tumour formation, in particular in 
c-Fos transgenic mice (EI-Emir et al, unpubfished/PhD thesis; see section 5.1 
above). To investigate whether the increased sensitivity of KTI. 5 cells to apoptosis 
following c-Fos expression may be a result of changes in the expression of Bcl-2 or 
Bax proteins, Western blot analysis was performed in KTI. 5 cells following c-Fos 
induction, and additionally in AT9.2 cells and control KT2.1 cells. The results 
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showed that Bel-2 protein levels were generally low and remained unchanged irre- 
spective of c-Fos induction, whereas Bax levels were generally higher (Figure 5.11). 
More importantly, the apparent ratio of Bax: Bcl-2 remained unchanged, possibly 
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Figure 5.10 - Ectopic expression of p2l and BcI-2 inhibits apoptosis induced 
by c-Fos following serum withdrawal in KT1.5 cells. Cells were transfected 
with pcDNA-3, p2l-HA and pBcl-2 vectors or in the absence of DNA as de- 
scribed in section 2.6.6.1, and cells were cultured for further 24 hours in standard 
medium ± Tc. Apoptosis was induced by serum withdrawal (0% FCS), ± Tc for 
24 hours before cells were fixed and stained with Pl. Apoptotic nuclei were 
quantified by counting cefls from 3 coverslips and at least 100 cells per field in 5 
random fields. The expression vector pCMV-SPAP (section 2.6.6.3) was used as 
an internal control for transfection efficiency. SPAP activity, assayed 48 hours 
after transfection is shown, and is expressed as SPAP units/ýLl culture medium. 
Cells that had been treated with Effectene alone or no transfection treatment at all 
were also assessed for apoptosis; simflar results were found as for cells trans- 
fected with pcDNA3 and have not been depicted. *** p< 0.001 and * p< 0.05 
compared to respective +Tc treatment. 
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Figure 5.11 - Western blot analysis of Bcl-2, Bax and c-Fos expression in 
the presence and absence of exogenous c-Fos in KTI. 5 cells. Cells (KTI. 5, 
KT2.1, and AT9.2) were cultured ± Tc for 48 hours to induce c-Fos expression, 
followed by either 0% or 10% serum (± Tc) for 3 days. Western blots were probed 
with specific antibodies to c-Fos, P-Actin, Bel-2 and Bax as described in section 2.9. 
The PI. 7 osteoblast like cefl fine, derived from the bone turnours of H2-c-fosLTR 
mice (Grigoriadis et al., 1993), was used as a positive control. 
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5.3 Discussion 
A number of in vitro and in vivo studies have demonstrated that apoptosis is an 
important physiological response in osteoblasts (Hill et al, 1997; Jilka et al, 1998; 
Kitajima et al, 1996). Utilising a Tc-inducible c-Fos construct in a clonal cell line of 
MC3T3-El osteoblast-like cells, the results of this chapter show for the first time 
that c-Fos induces programmed cell death in osteoblasts. Serum deprivation in the 
absence of exogenous c-Fos expression caused a marked increase in the number of 
apoptotic cells, and induction of exogenous c-Fos markedly increased this response. 
In contrast, when these cells were cultured in ftill serum conditions, apoptosis was 
scarcely detectable either in the presence or absence of c-Fos expression, suggesting 
that c-Fos induces apoptosis under conditions when cells are deprived of the survival 
signals and growth factors present in the serum. The stimulation of apoptosis was 
not merely due to the effects of Tc, since the level of apoptosis in the control lucif- 
erase clone (KT2.1), as well as in wild-type MC3 T3 -E I cells, was similar in both the 
presence or absence of Tc. The differences in maximal apoptosis observed in KTI. 5 
cells, especially in later experiments, is difficult to interpret, but was not as a result 
clonal drift since cells were always used from an early passage number. 
Previous studies have implicated c-Fos as a mediator of apoptosis: c-fos expres- 
sion has been observed to increase in cells undergoing apoptosis, and overexpression 
of a c-Fos-oestrogen receptor fusion protein induces apoptosis in colorectal ceus 
(Buttyan et al, 1988; Colotta et al, 1992; Gonzalez-Martin et al, 1992; Smeyne et 
al, 1993; Hafezi et al, 1997; Wenzel et al, 2000; Grimm et al, 2001; Preston et al, 
1996). In contrast, some studies have shown that in certain contexts, c-Fos can 
protect against apoptosis (Walker et al, 1993; Schreiber et al, 1995; He et al, 1998; 
Schreiber et al, 1999). Experiments using c-fos knockout mice have also yielded 
conflicting results. While some studies have demonstrated that c-fos is not required 
for apoptosis in normal mouse development, others have shown that it is essential 
for fight-induced photoreceptor apoptosis in the retina, an effect which could be 
rescued by expression of Fra-l (Roffler-Tarlov et al, 1996; Gajate et al, 1996; 
Hafezi et al, 1997; Fleischmann et al, 2000). Thus, the effects of c-Fos on apoptosis 
are clearly not equivalent in all systems; rather, it appears that c-Fos affects pro- 
grammed cell death in a cell- and tissue-specific manner. The data presented in this 
chapter using MC3T3-E1 subclones demonstrate that c-Fos is an inducer of apopto- 
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sis in osteoblasts in vitro. As explained in section 1.6.5 and 1.6.2, c-Fos is expressed 
during apoptosis in ossifying regions in late embryonic development and in growth 
regions during endochondral ossification (Smeyne et al, 1993). The physiological 
relevance of the c-Fos-induced apoptosis in osteoblasts in vivo compared with that 
observed in KTI. 5 cells needs to be investigated. Such experiments could compare 
apoptosis of cells derived from calvaria of c-Fos deficient mice with those of wild 
type mice. 
To study further the mechanisms of how c-Fos sensitises cells to apoptosis, key 
factors important for apoptotic signalling, such as caspases were investigated. 
These experiments found that c-Fos may sensitise cells to apoptosis independently of 
caspase activation. The c-Fos-induced apoptosis could not be blocked using the cell 
permeable caspase inhibitor, Z-VAD-fink, although apoptosis induced by serum 
withdrawal in the absence of c-Fos was partially inhibited. Furthermore, only the 
highest concentration of DEVD-CHO tested was seen to inhibit c-Fos-induced 
apoptosis and TNF-(x-induced apoptosis in the absence of c-Fos expression, and it 
remains possible that even higher concentrations may inhibit finther. DEVD-CHO is 
a specific inhibitor of caspase-3, which is an effector caspase rather than an initiator 
caspase and hence, fies fiwther downstream in the caspase cascade. Overall, this 
suggests that apoptosis induced by c-Fos may occur independently or downstream 
of the effector caspases, or at least independently of the caspases that are sensitive 
to Z-VAD-fink. Although most apoptotic processes require the activation of 
caspases as an effector mechanism of apoptosis (reviewed in Hengartner, 2000), 
many recent studies have reported caspase-independent apoptotic pathways 
(Maclaren et al, 2000; Nunez et al, 1998; Daugas et al, 2000; McCarthy et al, 1997; 
Susin et al, 1999,2000; Joza et al, 2001). Moreover, the presence of a novel 
caspase-independent death effector, the mitochondrial apoptosis inducing factor 
(AIF) has been reported (Susin et al, 1999,2000). This factor can stimulate mito- 
chondrial cytochrome c release (Susin et al, 1999), in addition to directly inducing 
chromatin condensation and DNA fragmentation (Daugas et al, 2000). 
Recently a role for cytochrome c release in c-Myc and v-Jun induced apoptosis 
has been described (Juin et al, 1999; Maclaren et al, 2000). This release of cyto- 
chrome c was not sufficient to drive apoptosis, but appeared to sensitise the cells to 
apoptotic stimuli and was independent of caspase activation. Furthermore, McCar- 
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thy et al (1997) reported how Z-VAD-fink could not inhibit the onset of apoptosis 
induced by c-Myc but was shown to delay or inhibit the completion of the program 
once initiated. Therefore, further studies in KTI. 5 cells are needed to address 
whether c-Fos-induced apoptosis involves direct stimulation of cytochrome c release 
from the mitochondria. In addition, if sustained stimulation of apoptosis is occurring 
over a 48 hour period, any inhibition of cell death by caspase inhibitors may be by- 
passed. Furthermore, some caspase inhibitors have been shown to only protect from 
apoptosis for a certain amount of time, for example DEVD-CHO Protection was 
decreased by 50% after 8hr and for Z-VAD-fink decreased after 15 hours (Boutillier 
et al, 2000). Clearly further experiments are required to confirm unequivocally 
whether c-Fos-induced apoptosis in osteoblasts is caspase-dependent or independ- 
ent. In view of the small window of time for protection, other markers of apoptosis 
in the presence of caspase inhibitors could be investigated, such as PARP cleavage, 
cytochrome c release, Annexin V binding and TUNEL. 
In KTI. 5 cells, Etoposide-induced apoptosis was also shown to be caspase- 
independent. Previous studies have found a similar result (Robertson et al, 2000; 
Sun et al, 1999; Yang et al, 1997), although this may also be concentration- 
dependent: Robertson et al (2000) found that whereas high concentrations of Eto- 
poside (5OgM) were shown to stimulate apoptosis via induction of cytochrome c, 
low concentrations (I OgM) were inhibited by Z-VAD-fink. Low concentrations of 
Etoposide induced apoptosis via a mechanism that involves the release of protein 
factors that are able to interact with the mitochondria, whereas, higher doses of 
Etoposide diminish the mitochondrial calcium buffering capacity. Similarly Sun et al 
(1999) showed that Z-VAD-fink did not inhibit Etoposide-induced cytochrome c 
release but was able to inhibit caspase-9 activity. The concentration of Etoposide 
used to induce apoptosis in KTI. 5 cells was greater than 50ýM and thus it cannot be 
ruled out that lower concentrations may have been inhibited by Z-VAD-fink. 
It is not uncommon for oncoproteins or transcription factors to have, in addi- 
tion to their mitogenic and transforming properties, proapoptotic effects. For exam- 
ple, c-Jun, c-Myc, EIA, E2F all stimulate apoptosis in the absence of rnitogens 
(Bossy-Wetzel et al, 1997; Shaulian and Karin, 2001; Evan, 1992; Qin et al, 1994; 
Wu and Levine, 1994). c-Myc sensitises cells to a variety of apoptotic signals such 
as Fas figand/CD95L and TNF-a, and this is thought to involve the release of cyto- 
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chrome c from the mitochondria (reviewed by Evan and Littlewood, 1998; Prender- 
gast, 1999). Moreover, c-Jun is a negative regulator of p53 expres- 
sion/transactivation, and is an important mediator of the pro-apoptotic effects of c- 
Jun N-tenninal kinase (JNK) activation (reviewed by Shaulian and Karin, 200 1). 
Similarly to c-Myc, v-Jun functions by promoting S phase entry but the cells are 
unable to accumulate in number in the absence of endogenous growth factors due to 
apoptotic cell death (Clark and Gillespie, 1997). It has been suggested that c-Fos 
may promote apoptosis in a similar way to v-Jun (Pandey and Wang, 1995). Indeed, 
recent work in our laboratory by Sunters et al (2000) has shown that induction of 
ectopic c-Fos in AT9.2 cells stimulates cell cycle entry by inducing cyclin A expres- 
sion and cycfinA/CDK2 kinase activity. Thus, it could be predicted that enhanced 
cell cycle progression is responsible for the increased apoptosis observed in this 
investigation. 
Experiments using cell cycle inhibitors clearly showed a link between the c-Fos 
effects on cell cycle progression and apoptosis. c-Fos-induced apoptosis was re- 
duced dose-dependently by Roscovitine, which is a specific inhibitor of cyclin- 
dependent kinase (CDK)-2 (Alessi et al, 1998; Schutte et al, 1997). When many of 
the cells in the population were arrested in the Go stage of cell cycle, the presence of 
ectopic c-Fos may have been forcing these cells to progress into cell cycle by in- 
creasing the available CDK2 in the cell, and thus predisposing them to apoptotic 
insult. Treatment with Roscovitine was then preventing the group of cells which 
tried to progress through the cell cycle by directly suppressing any CDK-2 activity. 
Apoptosis induced by Etoposide was abrogated completely by treatment of cells 
with Roscovitine. A number of studies suggest that cells progressing through the 
cell cycle appear more susceptible to apoptosis than quiescent cells, that is, inappro- 
priate induction of cell cycle progression may cause certain cell cycle effectors to 
promote apoptosis (reviewed in Evan, 1995; Evan and Littlewood, 1998). Cell 
cycle checkpoints have been shown to feature in some apoptotic pathways, with 
apoptotic cells often displaying abnormal levels of cell cycle components or the 
apoptosis has been induced by deregulation of cell cycle factors (e. g., Meikrantz et 
al, 1994). The stage in the cell cycle most sensitive to apoptosis appears to be be- 
tween late G, or early S phases. Cell cycle arrest in Go or early G, suppresses apop- 
tosis in response to a range of apoptotic stimuli. In contrast, arrest late in G, or in S 
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phase can accelerate or potentiate apoptosis, thus indicating that factors must be 
present in late G, and S phase whose activities facilitate the execution of apoptosis. 
In vivo apoptosis has been shown to occur primarily in proliferating tissue and is 
associated with induction of proliferation-associated genes, such as c-myc and c-fos 
(reviewed by Meikrantz and Schlegel, 1995). 
There are many lines of evidence from diverse systems suggesting that the in- 
duction of apoptosis is associated with activation of cyclin A-dependent kinases, i. e. 
CDK2 (Meikrantz and Schlegel, 1996). Overexpression of cyclin A and CDK2 
increased apoptosis in cells in which the BcI-2 gene is overexpressed (Bcl-2), that 
is, these factors can override the anti-apoptotic properties of Bcl-2 (Meikrantz and 
Schlegel, 1996). Gil-Gornez et al (1998) proposed that p53 and Bcl-2/Bax regula- 
tion was upstream of CDK2 activation in thymocyte apoptosis and that CDK2 acti- 
vation was the crucial point at which cell cycle and cell death pathways interact. 
Furthermore, caspase-3 has been shown to cleave or inactivate the CDK inhibitors, 
p2l. and p27, in cells undergoing apoptosis, leading to increased CDK2 activity in 
the early stages of apoptosis (Levkau et al, 1998; Jin et al, 2000). Thus, there are 
many fines of evidence implicating cyclin A and CDK2 as key players in apoptosis. 
Research by Harvey et al (1998) showed that changes in CDK activity during 
apoptosis are also downstream of effector caspases within a sequential and linear 
pathway. If CDK activation is downstream of caspase cascades, this helps to sup- 
port a caspase-independent mechanism for inducing apoptosis in KTI. 5 cells, such 
that c-Fos is increasing CDK activity which then has the ability to induce apoptosis 
when normal cell cycle control is being deregulated. By inappropriately bypassing 
mitotic checkpoints, such as in c-Fos-induced KTI. 5 cells, the deregulated CDK 
activity may then result in stimulating cell death. Alternatively, these CDKs may 
proceed to phosphorylate and activate other apoptotic proteins such as nucleases 
that are involved in apoptosis, or may alter nuclear envelope structure to allow dam- 
aging agents into the nucleus (King and Cidlowski, 1995). 
Further evidence that the cell cycle may be involved in c-Fos, induced apoptosis, 
comes from the observation that ectopic expression of the CDK inhibitor 
p21wAF"c'P"sD" reduced the c-Fos-induced apoptosis. Besides its well-characterised 
role as an inhibitor of CDK activity and cell cycle progression, p2l has also been 
shown to prevent apoptosis in various cells. For example, p2l has been shown to 
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mediate the anti-apoptotic effects of NF-icB and can bind to ASKI (apoptosis signal 
related kinase 1) to inhibit apoptosis (e. g., Wang and Walsh, 1996; Lu et al, 1998; 
Javelaud et al, 2000). The mechanisms through which p2l. inhibits c-Fos-induced 
apoptosis in KTI. 5 cells remains to be elucidated. Interestingly, while there are 
some parallels between c-fos and c-myc action, CDKs are not thought to be required 
for c-Myc-induced apoptosis, which is not inhibited by the CDK inhibitors Roscovi- 
tine, p2l, p27, and p16 (Rudolph et al, 1996). This suggests that c-fos and c-myc 
exert their apoptotic effects via different mechanisms. 
The apoptosis induced by c-Fos in KT1.5 cells was also inhibited by ectopic ex- 
pression of M-2. This suggests that the cells are undergoing a bonafide apoptosis 
following c-Fos-induction. The overexpression of Bcl-2 proto-oncogene has been 
shown to inhibit apoptosis in a number of different cell types including apoptosis 
induced by c-fos expression (reviewed in Reed, 1992; Korsmeyer, 1992; Preston et 
al, 1996). Indeed, the survival effects exerted by growth factors and cytokines are 
in many instances mediated by regulation of endogenous Bcl-2 levels (Oltvai et al, 
1993; Hoffinan and Liebermann, 1998). The rescue of apoptosis by transfected bcl- 
2 suggested that the expression of Bcl-2 family members may be altered in the pres- 
ence of c-Fos. However, Bcl-2 and Bax. protein levels were unaltered in the pres- 
ence or absence of exogenous c-Fos in all cell lines tested, suggesting that these 
genes were not directly regulated by c-Fos. It remains possible, however, that the 
expression of other members of the Bcl-2 family, for example, Bcl-xl and Bak may 
be altered. 
The mechanism of action of Bcl-2 is quite complex and not entirely understood, 
with many functions for Bcl-2 being postulated (see e. g., review by Tsujimoto and 
Shimizu, 2000). Of most relevance to this thesis, is the fact that the inhibition of 
apoptosis by Bcl-2 has also been linked to a reduction in cell cycle progression, in 
particular, in the prolongation of the G, phase of the cell cycle (Meikrantz and 
Schlegel, 1996; Borner, 1996; Mazel et al, 1996; Philips et al, 1999; Vairo et al, 
2000). Thus, it cannot be ruled out that the inhibition of apoptosis by ectopic Bcl-2 
expression in KTI. 5 cells may also be mediated through cell cycle mechanisms. 
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5.4 Conclusions 
Inducible overexpression of c-Fos in osteoblastic cells resulted in enhanced apopto- 
sis induced by different apoptotic stimulL Using specific inhibitors, this appeared to 
be independent of caspase activation but it did involve the cell cycle machinery. 
Taken together with previous work from our laboratory that c-Fos additionally in- 
creases cyclin A/CDK2 activity in these cells, the data presented provide a novel link 
between cell cycle control and programmed cell death in osteoblasts. 
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6.1 Introduction 
The Msx homeoproteins, MsxI and Msx2, have been shown to have a role in the 
development of mineralising tissues in craniofacial bones and teeth (Takahashi et al, 
1991; Jabs et al, 1993; MacKenzie et al, 1992; Jowett et al, 1993; see section 
1.7.1); where they act as transcriptional repressors of gene function in embryonic 
development. Furthermore, Msx2 may play a role in the differentiation of osteopro- 
genitor cells, preventing differentiation and promoting proliferation of cells specifi- 
cally at the osteogenic fronts of calvariae (Liu et al, 1995; Liu et al, 1999; see 
Chapter 1.7.1.1). Evidence is emerging of upstream regulatory processes of MSX 
genes. For example, BMPs (BMP-2, BMP-4 and BMP-7), FGFs, oestrogen, and 
retinoic acid have all been shown to induce ex vivo and in vitro Msx expression in 
various cellular systems (e. g., Bei and Maas, 1998; Lee et al, 1999; Wang et al, 
1998; Kim et al, 1998; Tucker et al, 1998; Kettunen et al, 1998; Phippard et al, 
1996; Abud et al, 1996; Wang and Sassoon, 1995; Sirard et al, 2000). 
Recent studies have shown that transcription factors, such as Cbfal, which are 
expressed in early development may also have a role in post-natal bone formation 
(Ducy et al, 1999). More specifically, Hodgkinson et al (1993) demonstrated a role 
for MSX2 in adult osteoblastic bone formation and its regulation of expression in 
vitro by 1,25401403. However, no vitamin D-response elements were found in 
DNA regulatory sequences up to 1.2kb upstream of Msx2, suggesting that the ef- 
fects of 1,25-(011)2D3 on Msx2 expression may be mediated indirectly through other 
mechanisms. Parathyroid Hormone (PTH) is another osteotropic; hormone, which 
acts in conjunction with 1,25-(OH)2D3 to co-ordinate the regulation of bone me- 
tabolism and calcium homeostasis (see section 1.3.3.2), and which may be involved 
in this signalling pathway. Similar to Msx2, PTH can also inhibit osteoblast differ- 
entiation and mineralisation, although these effects are dependent on the stage of 
differentiation and duration of administration (Dempster et al, 1993; Isogai et al, 
1996; see section 1.3.3.2). 
This study investigated whether Msx2 was involved in the signalling pathways 
for PTH in osteoblasts. This involved determining the regulation of both endogenous 
M=2 gene expression, as well as MW promoter activity by different hormones and 
growth factors, such as PTH in different osteoblastic cell lines. In addition, this 
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study explore further the in vivo expression of Msx genes in adult cells of the osteo- 
blast lineage using in situ hybridisation analysis of mouse bone and in particular, by 
utilising Msx]-lacZ knock-in transgenic mice. 
6.2 Endogenous MW expression in osteoblast-like cell lines 
following treatment with PTH 
To evaluate the endogenous expression of Msx2 in osteoblasts, Northern blot analy- 
sis was conducted on mRNA from SaOS-2 cells in culture, following treatment with 
PTH (1 -34). 





Figure 6.1 - Northern Blot analysis of MSX2 expression in SaOS-2 cells 
and regulation by PTH. SaOS-2 cells were treated for 24 hours with PTH or 
vehicle control before extraction of poly (A)+ RNA and Northern blot analysis. A 
radiolabelled probe containing Msx2 coding sequence was used to probe the mem- 
brane (see section 2.8.4). GAPDH transcripts were probed to control for RNA 
loading. Expression of alkaline phosphatase (ALP) was probed to assess for PTH 
functionality in these cells. Cells were also treated with 10 and lOOnM PTH for 
shorter periods (2 and 4 hours) but similar results were found (data not shown). 
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SaOS-2 cells were shown to express basal levels of MSX2. Furthermore, 
treatment of SaOS-2 cells with PTH showed that MSX2 was not regulated by PTH 
under the conditions used when standardised for GAPDH expression (Figure 6.1). 
The regulation of alkaline phosphatase was used as a positive control for PTH ac- 
tivity and demonstrated a small induction of alkaline phosphatase expression fol- 
lowing treatment with PTH (Figure 6.1). These results suggest that after 24 hour 
treatment, PTH has no effect on MW expression. 
6.3 The effects of osteotropic factors on the regulation of 1.2 and 
2kb Msx2 reporter gene constructs in osteoblast-like cell lines 
Factors known to be important in bone development, in particular PTH, were 
screened for their ability to induce the expression of two murine Msx2-CAT (Chlor- 
amphenicol acetyltransferase) reporter gene constructs. These constructs consisted 
of either 1.2kb (Jane Hodgkinson, PhD thesis 2000) or 2kb (Dr R. Maxson, pers 
comm; Liu et al 1994; Liu et al 1999) of the immediate 5' regulatory sequence of 
Msx2 gene. The osteoblastic cell fines mostly studied were murine osteoblastic 
MCM-El cells and the human osteosarcoma cell line SaOS-2. These were used to 
compare the regulation in cells types representative of cells either early or late in the 
osteoblastic: lineage, respectively. Initially, the SaOS-2 osteoblast cell line was cho- 
sen because of its well-characterised osteoblast phenotype with respect to its re- 
sponse to PTH and high levels of PTH receptors. In contrast, MCM-El cells are 
representative of preosteoblasts (Franceschi and Iyer, 1992) and were selected as a 
model for an earlier stage of osteoblast maturation. 
For SaOS-2 cells, the conditions for transfection with Lipofectamine were ini- 
tially optimised as described in section 2.6.6.2. Following this, cells were trans- 
fected with reporter constructs before treatment with a suitable range of concentra- 
tions of PTH, 1,25-(017I)A, BNT-2, BNIP-4, FGF-4, FGF-8, Sonic hedgehog and 
dexamethasone. These are factors known to be important in bone development and 
to influence the differentiation of osteoblasts. With the exception of PTH, cells were 
treated with the factors for 24 hours; treatment times for PTH were 1,3,6,24, and 
48 hours. Cell extracts were then prepared for assessment of CAT activity. 
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6.3.1 The effect of PTH on Msx2-CAT reporter gene activity 
SaOS-2 and MC3T3-El cells were transfected with Msx2-CAT reporter constructs 
and treated for various time points with a range of concentrations of PTH. PTH 
appeared to show no significant induction of reporter gene activity in the cell lines 
studied. Figure 6.2 shows the data summarised from at least three or more experi- 
ments whereby cells were treated with lOOnM PTH; similar results were observed 
with 48 hour treatment with PTH and for lower concentrations of PTH, but have 
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Figure 6.2 - Effect of PTH on Msx2-CAT reporter gene activity in SaOS- 
2 and MC3T3-EI cells. Msx2-CAT transfected cefls were treated for the indi- 
cated time points with I OOnM PTH, before extracts were prepared for assessment 
of CAT activity. Data represents mean relative CAT activity (treatment/control 
values) ± S. D. from three or more experiments. The counts per minute per ýtg 
protein extract were expressed as a ratio of treatment/control (T/0). 
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Following these experiments, additional cell lines were studied to determine 
whether the lack of regulation by PTH with these reporter constructs in SaOS-2 and 
MCM-El cells was a specific characteristic of the phenotype of these cells. Simi- 
lar results were obtained using rat ROS 17/2.8 osteoblasts, human MG63 osteoblas- 
tic cells and non-osteoblastic COS ceUs (data not shown). Furthermore, primary rat 
calvarial. osteoblasts were transfected with the 2kb Msx2-CAT construct and treated 
with PTH in one experiment. However, under these conditions, there was no 
stimulatory activity of the reporter gene construct with PTH when compared to 
vehicle control (Figure 6.3). Overall, these results suggest that Msx2 is not regu- 
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Figure 6.3 - Effect of PTH on 2kb Msx2-CAT reporter gene activity in 
primary rat osteoblasts. Msx2-CAT transfected cells were treated for the indi- 
cated time points with 100nM PTH, before extracts were prepared for assessment of 
CAT activity. Data represents mean relative CAT activity (treatment/control values) 
± S. D. from one experiment. The counts per minute per ýLg protein extract were 
expressed as a ratio of treatment/control J/0). 
The SV40-CAT vector was used as positive control for CAT activity in all ex- 
periments. In the cell lines studied, there was a strong regulation of SV40-CAT 
vector as deterniined by CAT activity, which was between 1.5 and 2.4-fold greater 
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than Msx2-CAT vectors in most experiments (Figure 6.4). Interestingly, there was a 
basal expression of the Msx2-CAT vectors in all of the osteoblastic cell fines as- 
sessed, which was significantly greater than that found with the pCAT-Basic vector 













Figure 6.4 - Basal regulation of Msx2-CAT vector in SaOS-2. CeRs were 
transfected with Msx2-CAT (1.2kb construct), pCAT-Basic or pSV40-CAT vec- 
tors. Following transfection, cells, were treated for 24 hours with PTH (10 and 
I OOrA4) or vehicle control (PBS), before extracts were prepared for assessment of 
CAT activity. Data represents mean (± S. D. ) CAT activity of triplicate samples 
from one representative experiment. 
Co-transfecting ceRs with constructs, such as CMV-SPAP, can result in a lower 
transfection efficiency and reporter gene response as a result of the plasmid of inter- 
est having to compete with the co-transfected DNA. Therefore, a comparison was 
made between Msx2-CAT-transfected and CMV-SPAP/Msx2-CAT co-transfected 
SaOS-2 cells in their response to PTH. This was done to confirm that the lack of 
response to PTH that was observed in SaOS-2 cells was not as a result of less DNA 
entering the cell and hence being available for modulation by mediators of PTH 
signalling. SaOS-2 cells were transfected with Msx2-CAT (1.2kb construct) alone 
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or Msx2-CAT plus CMV-SPAP vector. Following transfection, cells were treated 
for 24 hours with PTH, before extracts were prepared for assessment of CAT activ- 
ity. 
The response of transfected SaOS-2 cells to PTH was the same for cells trans- 
fected with Msx2-CAT alone as that for CMV-SPAP/Msx2-CAT co-transfected 
cells, with no significant regulation of Msx2-CAT activity for either group (Figure 
6.5). This confirms that co-transfecting the cells does not affect them in such a way 
that is detrimental to their response to PTH and ftirther confirms that the Msx2-CAT 








Figure 6.5 - Comparative response of SaOS-2 cells to PTH in MSX2-CAT- 
transfected and co-transfected cells. Cells were transfected with Msx2-CAT 
(1.2kb construct) alone or Msx2-CAT plus CMV-SPAP vector. Following trans- 
fection, cells were treated for 24 hours with PTH (0 and WOW), before extracts 
were prepared for assessment of CAT activity. Data represents mean (± S. D. ) CAT 
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6.3.2 Determination of the functionality of PTH in SaOS-2, MC3T3-E1 and 
ROS 17/2.8 cells 
The action of PTH is mediated by the peptide binding to its membrane-bound re- 
ceptor and subsequent activation of adenylate cyclase. This enzyme stimulates the 
increase in levels of cAW, thereby stimulating intracellular signalling cascades. To 
confirm whether PTH is functional in the cell lines under study, its ability to stimu- 
late cAMP was assessed. 
SaOS-2, MC3T3-EI and ROS 17/2.8 cells were found to respond to PTH as 
determined by the production of intraceflular cAMP. PTH produced a dose- 
dependent response in cAMP levels, with SaOS-2 cells showing the greatest re- 
sponse, followed by MC3T3-EI and then ROS 17/2.8 cells (Figure 6.6). Forskolin 
produced a similar response to PTH, which was greater in SaOS-2 cells; although 
ROS 17/2.8 cells showed a relatively poor response to Forskolin. As expected, the 
levels of cANV were relatively low in cells treated with DMSO or IBMX. These 
results suggest that the cell lines studied above are capable of responding to the 
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Figure 6.6 - PTH stimulation of cAMP production in SaOS-2, MC3T3-E1 
and ROS 17/2.8 cells. SaOS-2, MC3T3-El and ROS 17/2.8 cells were treated as 
indicated and cAMP was extracted and analysed as described in section 2.6.12. 
Data represents mean (± S. D. ) of triplicate samples from one experiment. 
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6.3.3 Regulation of Msx2 reporter gene constructs by other factors in bone 
development 
To confirm that the Msx2-CAT constructs could be regulated by other factors 
known to be important in osteoblast function, and reportedly the regulation of MSX2, 
SaOS-2 and MC3T3-El cells were transfected with Msx2-CAT constructs and 
treated with BNI? s, FGFs, 1,25-(OH)2D3, dexamethasone and Sonic hedgehog. 
The treatment of SaOS-2 cells with BNV-2 showed a marked 4 to 5-fold in- 
duction of the 2. Okb Msx2 reporter gene activity and a lesser 2-fold induction of the 
1.2kb construct (Figure 6.7 A). Similarly, BUT4 demonstrated stimulatory activity 
of the 1.2kb Msx2 reporter gene in SaOS-2 cells, with a 3.6-fold induction occurring 
at 20 pg/mI BMT-4 (Figure 6.7 B). There was only a marginal 1.5-fold stimulation 
of 1.2kb construct by BUT-4 observed in MC3T3-El cells (Figure 6.7 B). There 
was also a lack of stimulation of the 2kb construct in MC3T3-EI cells by both 
BNV2 and BNV-4 (data not shown). 
The growth factors FGF-8 and Sonic hedgehog (Shh), were shown to stimulate 
Msx2-CAT reporter gene activity but to a lesser extent than the induction observed 
with BNVs. Treatment of transfected MCM-El cells with FGF-8 was shown to 
dose-dependently stimulate the 1.2kb MW reporter gene (Figure 6.7 Q. However, 
2ýtg/ml FGF-8 was shown to be inhibitory (not depicted here). Furthermore, FGF-8 
inlulbited the basal activity of the 2kb construct in MC3T3-El cells (Figure 6.7 Q. 
When SaOS-2 cells were treated with FGF-8, a striking Mold stimulation was ob- 
served at 0.2 and 0.02ýtg/n-A FGF-8, but only 1.7-fold at 2Pg/ml FGF-8 (Figure 6.7 
D). However, these results are only based on one or two experiments and need to 
be reproduced. In addition, the 2. Okb MW construct was not studied under these 
conditions. FGF-4 treatment (0.002 to 2 ýtg/ml) of SaOS-2 and MCM-El cells 
showed no effect on the regulation of either of the MW constructs (data not shown 
for simplicity). 
SaOS-2 cells transfected with either the 1.2 or 2. Okb MW constructs were 
also treated with Shh. Shh (5 gg/n-d) produced a 1.6-fold stimulation of 1.2kb MSX2 
reporter gene activity (Figure 6.7 E) and a 2-fold stimulation of 2. Okb reporter gene 
activity for all concentrations of Shh. Once again these results are based on prelimi- 
nary work, consisting of only one experiment, and the regulation of Msx2 by Shh in 
MC3T3-E I cells needs to be investigated. 
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MSX2 expression has previously been shown to be induced by l, 25'(OI1)2D3 in 
normal human bone cells (Hodgkinson et al, 1993). However, no significant induc- 
tion of Msx2-CAT reporter gene activity was observed when SaOS-2 cells were 
treated with 1,25-(0102D3 following transfection with either the 1.2 or 2. Okb MSX2 
constructs (Figure 6.7 F). Similarly, when MC3T3-El cells were treated with 1,25- 
(OH)2D3 there was no induction of reporter gene activity above basal levels (data 
not shown). SaOS-2 cells were also treated with dexamethasone, which subse- 
quently reduced the regulation of the 2. Okb Msx2-CAT reporter gene activity; but 
had no effect on the 1.2kb sequence (Figure 6.7 F). Interestingly, this inhibition of 
reporter gene activity by dexamethasone was also observed for MC3T3-El (data not 
shown). 
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Figure 6.7 - Effect of osteotropic growth factors and hormones on MS_X2- 
CAT reporter gene activity in SaOS-2 and MC3T3-EI cells. Msx2-CAT 
transfected cells were treated at the indicated concentrations with BMP-2, BMP-4, 
FGF-8, Shh, 1,25-(OH)2D3, dexamethasone for 24 hours, before extracts were 
prepared for assessment of CAT activity. Data represents mean relative CAT ac- 
tivity (treatment/control values) ± S. D. from three experiments. The counts per 
minute per ýtg protein extract were expressed as a ratio of treatment/control J/0). 
Data is representative of at least three experiments except for data denoted by an 
absent error bar. 
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6.4 Investigation into the expression of Msx genes in adult murine 
osteoblasts 
6.4.1 Expression analysis of Msxl in post-natal bone in Msx1-1acZ knock-in 
transgenic mice 
The expression of Msx] in post-natal bone was investigated using the sensitive P- 
galactosidase assay on tissues from mice heterozygous for a n1acZ gene, which 
contains a nuclear localisation signal (n), inserted into the Msx] homeodomain (mice 
supplied from Benoit Robert; see Houzelstein et al, 1997). These heterozygous 
mice show no phenotypic abnormalities. The embryonic expression of Msxl has 
already been reported (MacKenzie et al, 1991; Houzlestein et al, 1997; Reginelli et 
al, 1995; Bidder et al, 1998; see review by Davidson, 1996). Thus, Msx] expres- 
sion was investigated in the growth plate region in bone of post-natal nice (days 1, 
8,15,22,28) and the expression in craniofacial and digit regions of embryonic (E) 
E16 and E18 embryos. 
Wild type ("') female mice (B6CBA strain) were mated with Msx-lacZ het- 
erozygous (") males. Heterozygous Msx]-lacZ mice were identified by assessing 
galactosidase (lacZ) activity in hernisected heads (E16,18, and day 1) or positive 
galactosidase staining in ear tissue which was removed from offspring after post- 
natal age day 8 (see section 2.5.6). 
A novel procedure was used to prepare tissue samples which helped to elimi- 
nate unnecessary background P-galactosidase staining observed with neonatal sam- 
ples when using this histochen-dcal method, or as a result of demineralisation (see 
section 2.5.6). Briefly, tissue was fixed (paraformaldehyde; 4%), deminerafised 
(formic acid/sodium citrate) and cryoprotected (30% sucrose), before freezing at - 
801C. Cryostat sections (5-7[im) were fixed and stained for P-galactosidase activity 
in X-gal solution and counter-stained using safranin. Adjacent sections were stained 
with haernatoxylin and eosin. 
In foetal tissue, lacZ expression was observed at high levels in developing tooth 
germs, hair follicles, ossifýring regions of the mandible, maxilla and cranium, and 
perichondrial. regions surrounding the developing digits (Figure 6.8 B, D, F). No P- 
galactosidase staining was observed in sections taken from wild-type bone (data not 
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shown). This expression correlates with the fundamental role for which MsxI plays 
in craniofacial skeletal development and limb formation (Robert et al, 1989; Hill et 
al, 1089; McKenzie et al, 1991). However, IacZ expression was only detected at 
day I in post-natal tissue; investigations at day 8 showed that IacZ expression had 
decreased by this time point in the post-natal skeletal tissue studied (Figure 6.9). At 
day I of post-natal development, Msx] continued to be expressed in the perichon- 
drial regions surrounding the developing digits and specific osteoblasts fining the 
trabecular bone of the growing long bones (Figure 6.9 A, B). Msxl expression was 
absent by day 8 of post-natal development (figure 6.9 C). Similarly no expression 
was observed in the long bones (Figure 6.9 E-F) or calvaria. (data not shown) of 
mice from post-natal stages day 15,22, and 28. 
6.5 In situ analysis of Msx gene expression during bone 
development 
To confmn the expression of MsxI, and that of Msx2, in post-natal bone tissue, non- 
transgenic mouse bone was analysed by in situ hybridisation using specific ribo- 
probes for these genes. 
Radioactive sense and anti-sense Msx] and MW riboprobes were synthesised 
using murine cDNA probes according to the method described in section 2.3.5 and 
2.10.1.2 (MacKenzie et al, 1991; Monaghan et al, 1991) and radioactive in situ 
hybridisation (see section 2.10.3) was performed on bone sections from herni-sected 
heads and long bones of CDI mice representative of various stages of bone devel- 
opment. Late stage embryonic (stage E17) and early post-natal (day 3) sections 
were included as a positive control for expression analysis based on results previ- 
ously reported (Monaghan et al, 1991; ReginellL et al, 1995; Bidder et al, 1998). 
Following hybridisation, sections were counterstained with haematoxylin and eosin, 
mounted and photographed. 
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Figure 6.8 - Expression of Msx] during late foetal development in MSXI- 
IacZ transgenic mice. Haernatoxylin and eosin staining (A, C, E) and P- 
galactosidase activity (13, D, F) in adjacent longitudinal cryostat sections of embry- 
onic stage 16 (E 16) limb digit (A, B), El 8 calvaria (C, D) and E 18 mandible (E, F) 
of Msx]-lacZ transgenic mice. LacZ expression was especially noticeable in the 
distal tip of the developing digit (B), occipital cartilage of calvaria. (arrows, D), 
tooth germs (arrowhead; F), hair follicles (arrow; F) and the surrounding ossiýýing 
regions of the mandible (F) and maxilla (not shown). Magnification xlOO A-D and 
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Figure 6.9 - Expression of Msx] during post-natal development in Msxi- 
I"Z transgenic mice. P-galactosidase activity (A, B, C, E, F) in longitudinal cry- 
ostat sections of post-natal day I limb digit (A), day I humerus (B), day 8 humerus 
(C), and day 22 and day 28 femur (E and F, respectively) of Msx]-lacZ transgenic 
mice. lacZ expression was especially noticeable in the distal tip of the developing 
digit (arrowhead in A), and the osteoblast fining the bony trabeculae (arrowhead; B) 
and developing growth plate (arrow; B). There was an absence of lacZ expression 
in the osteoblasts of long bone tissue following postnatal day I (C-F). An adjacent 
section of the day 8 humerus was stained with haernatoxylin and eosin (D) to aid 
identification of bone structure. Magnification xl 00. 
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As was observed above, Msx] expression was observed at high levels in devel- 
oping tooth germs in foetal tissue, and at post-natal day 3 (Figure 6.10 A, B), and 
day 6 (Figure 6.10 D), and in hair follicles (Figure 6.10 E). MsxI was weakly ex- 
pressed in osteoblasts of the mandible (Figure 6.10 F), maxilla and cranium (data not 
shown) as late as day 8 of development, and perichondrial regions surrounding the 
developing digits (data not shown). At post-natal day 1, radioactive in situ hybridi- 
sation analysis did not show Msx] expression in the osteoblasts lining the trabecular 
bone of the growing long bones (Figure 6.10 G) as observed in similar trabecular 
locations in Figure 6.9 B. This minor discrepancy may be as a result of strain differ- 
ences between Msx] -lacZ transgenie mice and non-transgenic CD I mice. Further- 
more, no expression of Msxl was observed in the osteoblasts of long bones of these 
mice after day 3 of post-natal bone development (Figure 6.10 H-J). 
Msx2 showed a similar pattern of expression to that of MsxI. Figure 6.11 de- 
picts an example of this expression pattern for Msx2 with noticeable expression 
observed in developing tooth germs and hair follicles both in foetal tissue and as late 
as day 8 of development (data not shown), in perichondrial regions surrounding the 
developing digits (Figure 6.11 A-C) and the osteoblasts of the mandible, maxilla and 
cranium (data not shown). Furthermore, ostcoblastic expression of Msx2 was not 
detected in growing long bones after day 3 of development up until day 21 (Figure 
6.11 F-I) or after day 3 in the suture region of the cranium (Figure 6.11 E). Inter- 
estingly, a small core of expression was observed in the cranium at day 21 which 
was not observed any earlier in development (figure 6.11 J). 
Hybridisation of sense riboprobes showed no positive signal of Msxl and Msx2 
in all cases, and have only been depicted once for simplicity (Figure 6.10 C, 6.11 D). 
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Figure 6.10 - Msx] gene expression during post-natal bone development. 
Radioactive anti-sense (A, B, D to 1) and sense (C) Msx] riboprobes were used to 
perform in situ hybridisation analysis on longitudinal bone sections from hemi-sected 
heads and long bones of mice representative of various stages of bone development. 
Following hybridisation, sections were counterstained with haematoxylin and eosin 
and mounted for photography. Early post-natal day 3 (A-C), day 6 (D, E), and day 
8 (F) show positive expression of MsxI in tooth germs (arrowheads in AB, D), hair 
follicles (arrowhead, E) and craniofacial bone (mandible; arrowhead in F). How- 
ever, expression was absent in the long bones from mice at day I (G), day 3 (H), day 
10 (1) and day 21 (J) of postnatal development. Hybridisation of sense probes gave 
negative results in all cases (only depicted in C for clarity). 
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Figure 6.11 - Msx2 gene expression during post-natal bone development. 
Radioactive anti-sense (A-C, E-J) and sense (D) Msx2 riboprobes were used to 
perform in situ hybridisation analysis on longitudinal bone sections from long 
bones and herni-sected heads of mice representative of various stages of bone de- 
velopment. Following hybridisation, sections were counterstained with haema- 
toxylin and eosin and mounted for photography. Embryonic expression at E17 
shows strong Msx2 expression in the distal perichondral regions of the developing 
digit (arrowheads, A-C). However, expression was diminished by post-natal day 3, 
in the suture (E) and was absent in the growing regions of the long bone (F). Fur- 
thermore, Msx2 expression could not be detected in the limbs of day 6 (G), day 10 
(H), or day 21 (1) mice. However, there was a small area of Msx2 expression in 
chondrogenic foci in cranial bone (J) of the day 21 mouse. Hybridisation of sense 
probes gave negative results in all cases (only depicted in D for clarity). 
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6.6 Discussion 
6.6.1 The in vitro assessment of MW expression in osteoblast differentiation 
Both Msxl and Msx2 are expressed in numerous tissues at many stages of embry- 
onic development (reviewed by Davidson, 1995). Several studies have suggested 
that Msx genes play a role in development of mineralised tissues such as teeth and 
skeleton. 
The expression of Msx2 reported in this chapter for SaOS-2 osteoblastic ceUs is 
similar to that reported for many primary and established osteoblast cell lines. For 
example, Msx2 expression has been observed in human bone cells (Hodgkinson et 
al, 1993), pre-osteoblasts (RCT-1) and osteoblastic cells (MBI. 8, RCT 3, and ROS 
17/2.8), as well as in cells from neonatal rat calvaria. (Towler et al, 1994). No ex- 
pression was detected in non-osteoblast like cells, such as ROS 25/1 or un- 
differentiated MC3T3-El cells (Towler et al, 1994). Collectively these findings 
suggest that Msx2 expression is a feature of determined or committed osteoblasts. 
Msx2 is expressed and regulated by the osteotropic hormone 1,25-(OH)2D3 in 
human osteoblasts (Hodgkinson et al, 1993) and inhibits expression of the COLIA] 
promoter, in ROS 17/2.8 cells (Dodig et al, 1996; Towler et al, 1994). Towler et al 
(1994) also showed that Msx2 inhibits the osteocalcin promoter in transfected 
MC3T3-El cells, but stimulates the same promoter in ROS 17/2.8 cells. Others 
have shown that Msx2 represses transcription of osteocalcin in neural crest-derived 
craniofacial odontoblasts and osteoblasts but not in the mesodermally derived osteo- 
blasts of long bones (Newberry et al, 1997; Towler et al, 1994; Liu et al, 1999; 
Dodig et al, 1996). Osteocalcin and Msx2 show a reciprocal pattern of expression 
during tooth development (Bidder et al, 1998). The binding of MINT, an Msx2 
binding protein, is thought to mediate both the repressor or stimulatory actions of 
Msx2 by organising the transcriptional complexes on the osteocalcin promoter dur- 
ing craniofacial. development (Newberry et al, 1999). Another Msx2 binding protein 
MizI (also known as ARIP3) has also been identified but its expression in craniofa- 
cial. osteoblasts and odontoblasts has not been reported (Wu et al, 1997). Further 
control of Msx2 repressor function at the transcriptional level, is shown with Dlx2, 
another homeodomain transcription factor expressed in calvarial. osteoblasts, which 
upregulates osteocalcin expression in osteoblasts by antagonising Msx2- 
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transcriptional repression (Zhang et al, 1997; Newberry et al, 1998). In addition, 
Msxl, but not Msx2, may down regulate CbfhI expression in the odontoblastic cell 
Une, M06-G3 (Bin-Wakkach et al, 200 1). 
Gain of function studies in transgenic mice and a dominant mutation in the hu- 
man gene for MSX2 result in a craniosynostotic condition in which the cranial suture 
closes early (Liu et al, 1995; Jabs et al, 1993; Ma et al, 1996; Winograd et al, 
1997). In contrast, studies in Msx2 deficient mice show defective proliferation of 
osteoprogenitor cells at the osteogenic front during calvarial development, a condi- 
tion found to resemble that associated with human MSX2 haplo insufficiency in pa- 
rietal foramina (Satokata et at, 2000). In vitro studies have confirmed that Msx2 
expression decreases as calvarial. osteoblasts differentiate, suggesting that Msx2 
prevents differentiation and increases proliferation of osteoblasts at the osteogenic 
front (Kim et at, 1998; Dodig et al, 1999; Liu et al, 1999). Thus, an understanding 
of the control of Msx2 expression by osteotropic factors may be useful in defining 
some of the molecular mechanisms involved in bone cell differentiation and may help 
to identify useful therapeutic targets for the treatment of bone diseases such as os- 
teoporosis. 
PTH is a well studied regulator of osteoblastic cells in vitro and in vivo. Its ac- 
tions can be either stimulatory or inhibitory depending a number of parameters. For 
example, in vivo the anabolic effect of PTH is markedly accentuated when the hor- 
mone is administered once daily, such that synthetic PTH fragments are now used 
for the treatment of osteoporosis (reviewed by Juppner, 1999). In post-menopausal 
osteoporosis daily subcutaneous injections of PTH is associated with dramatic in- 
creases in cancellous bone mass (Lane et al, 1998), and a marked reduction in the 
incidence of new bone fractures (e. g. Reeve et al, 1980; Hock et al, 1988; Kimmel 
et al, 1993; Hock and Gera, 1992), whereas continuous exposure causes an increase 
in osteoclast cell number and activity via affects on osteoblasts (Tam et al, 1982; 
McSheehy and Chambers, 1986). PTH can stimulate human osteoblast profferation 
in vitro (MacDonald et al, 1980), possibly via E217-dependent activation of cdc2 
(Onishi et al, 1997). PTH can either stimulate or repress osteoblast differentiation 
and bone-Eke nodule formation depending on the cell type under investigation (Yee 
et al, 1986; Bellows et al, 1990). Additionally, in some cases PTH inhibits collagen 
synthesis and decreases alkaline phosphatase activity (Kream et al, 1886; Majeska 
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and Rodan, 1982) whereas others the reverse has been found (Martin et al, 1985; 
Hakeda et al, 1985). Collectively, these findings suggest that the effects of PTH on 
cells, of the osteoblast lineage are dependant on their state of maturation (Bellows et 
al, 1990; Kim et al, 1998; Dodig et al, 1999; Liu et al, 1999). PTH also stimulated 
connexin-43 levels in proliferating and maturing osteoblasts but not in differentiated 
or non-dividing cells, in addition to reducing nodule formation, osteocalcin produc- 
tion, and calcium accumulation (Schiller et al, 1997). 
In this investigation, PTH displayed no regulatory control of either of the 1.2kb 
or 2kb Msx2-CAT reporter constructs or that of the endogenous gene in the osteo- 
blastic cell lines studied. Ile action of PTH is dependent on it binding to 
PT1"THrP receptors (PTHRI) and the subsequent stimulation of the adenylate 
cyclase/cAW/protein kinase A pathway and, to a lesser extent calcium/inositol 
triphosphate/PKC pathway. Some of the osteoblastic genes which are regulated via 
cAW/protein kinase A pathway include c-fos, c-jun, alkaline phosphatase, 
COLIA], Fgf-2 (partly mediated by AP-1 proteins), collagenase (in conjunction 
with Cbfal), IL-6, LIF, IGF-I, PGHS-2, TGFP-2, bone sialoprotein, inhibitory 
cAW response proteins (ICERs), vitamin D receptor (Pearman et al, 1996; Martin 
el al, 1985; Hakeda et al, 1985; Hurley et al, 1999; Selvarnurugan et al, 2000; Tet- 
radis el al, 1996; Wu and Kumar, 2000; Yang and Gerstenfeld, 1996; Tetradis et al, 
1998). 
Many PTH responsive genes are thought to be secondary targets for hormone 
action due to the delayed nature of their response and the requirement for ongoing 
protein synthesis. An example of a primary response gene that PTH transcriptionally 
regulates is c-fos. This is mediated via increased intracellular cAMP signalling 
which increases phosphorylation of cAMP response element (CRE) and binding of 
CRE binding protein (CBP) to consensus sequence 5' of the c-fos gene (Lee et al, 
1994; Onyia et A 1995). Analysis of the sequence data for the 1.2kb construct 
shows that there are no cAW response element binding sites in this 5' upstream 
sequence. Gonzalez et al (1998) also reported a lack of CBP sites in 4.9kb 5' 
flanking region of the mouse MW gene although there were important sites such as 
AP-1, AP-2, SPI, and RAR present. In the 1.2kb Msx2 sequence, there are also 
various AP-1, AP-2, E-box and TDFII binding sites present, which have the poten- 
tial to be regulated by early response genes, such as c-fos. Unfortunately, the se- 
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quence data for Maxson's 2kb 5' sequence used in the Msx2-CAT construct is as yet 
unpublished (see below). If the work in this chapter had shown some regulation of 
endogenous Msx2 by PTH then one could suppose that the 5'regulatory sequences 
used in the two MW-CAT constructs were of insufficient length to direct the tran- 
scriptional control by PTH signalling. Future work could involve using a 5.2kb 5' 
flanking sequence of MW which, when fused to a LacZ reporter to generate trans- 
genic mice, was shown to recapitulate the expression of the endogenous gene during 
embryonic development in craniofacial tissuc, limb mesenchyme, and apical ecto- 
derinal ridge (AER), and in early post-natal calvarial suture closure, but was not 
expressed in the tooth (Liu et al, 1994; Liu et al, 1999). Transgenic mice with 
fragments of this 5'sequence deleted showed that the -0.44 and -0.3kb 5' sequences 
could only drive cctopic expression in AER (Liu et al, 1994). 
Harris et al (1996) also showed a lack of PTH-induccd regulation of endoge- 
nous Msx2 using SV40 immortalised human fetal osteoblast cells. Similarly, 1,25- 
(OH)2D3, dexamethasone, retinoic acid, and prostaglandins had little effect on MSX2 
expression, whereas BMP2 and TGFP-I produced a modest 2-fold increase (Harris 
et al, 1996). This suggests that Msx2 is unaffected by regulation with osteotropic 
factors. More recently, Adams et al (1999) identified a novel paired class homeo- 
box protein induced by PTH following differential display, suggesting that PTII can 
regulate the expression of horneobox proteins. 
To confirm that the reporter constructs were functional, in the cell lines studied 
in this chapter, transfected cells were also treated with other factors previously 
shown to regulate Msx2 expression. In the preliminary experiments in this chapter, 
BNT-2, BUIP-4 and FGF-8 showed stimulatory activity of the Msx2 reporter con- 
structs. BNT are thought to be involved in regulating the balance between un- 
differentiated and differentiated states of osteogenic cells at the osteogenic front and 
Msx genes are involved in this signalling pathway (Kim et al, 1998). Furthermore, 
FGF may act later on in committed osteoblasts. Similarly FGFs have a significant 
role in bone development highlighted by the dominantly inherited skeletal disorders 
such as craniosynostosis (Shiang et al, 1994, Cohen et al, 1995) and FGF receptor 
(FGFR) mutations in Crouzon syndrome (Fragale et al, 1999). Also, signalling 
through FGFRs can upregulate the osteocalcin promoter (Newberry et al, 1996). 
BNTs and FGFs have been shown to be co-expressed with Msx genes at various 
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sites in the developing embryo, neonatal tooth and suture development, and many 
studies have suggested that Msx genes are downstream targets for these growth 
factors depending on the factor and tissue studied (Vanio et al, 1993; Watanabe and 
Ide, 1993; Fallon et al, 1994; Wang and Sassoon, 1995; Kostakopoulou et al, 1996; 
Kettunen and Thesleff, 1998; Bei and Maas, 1998; Niswander and Martin, 1992; 
Kim et al, 1998; Tucker et al, 1998; Graham et al, 1994; Shimeld et al, 1996; Wa- 
tanabe and LeDouarin, 1996; Barlow and Francis-West, 1997; reviewed in David- 
son, 1995). 
The regulatory Smad proteins are downstream mediators of BMP receptor sig- 
nalling in the cell, and are related to the Drosophild mothers against dpp (mad). 
Activation of BNT receptors leads to phosphorylation of Smadl and Smad5 by the 
type I receptor (previously transphosphorylated by its type II heteromeric partner) 
followed by their interaction with Smad4. These complexes are translocated to the 
nucleus where Smad4 functions as a transcriptional coactivator (Derynk et al, 1998; 
Yamaguchi et al, 2000). In particular, Smad4 has been demonstrated to be impor- 
tant in the BNT mediated control of MW expression in the differentiation of ES 
cells into ernbryoid bodies (Sirard et al, 2000). Most importantly, this work also 
involved studying the regulation of the larger 1.7kb upstream sequence of the mouse 
MW gene in a MW-Luc construct transfected into fibroblasts. This sequence was 
shown to be the most responsive to BMEP induction via Smad4 binding (R. Maxson's 
unpublished data). In the 1.2kb Msx2 construct studied in this chapter, there were 
four consensus sequences [AGAC] for Smad binding elements as reported by Zawel 
et al (1998). These sequence may be important for the regulation of the 1.2kb con- 
struct. Interestingly, Dr. P, Maxson has found inhibitory elements in the 2kb Msx- 
CAT construct which were shown to attenuate the BN11P responsiveness (pers. 
commun; unpublished data). BMP proteins have also been shown to complex with 
A FAST l transcription factors and interact with DNA at a 6bp and 7bp ARE repeat, 
however no potential repeat sites were identified in the 1.2kb Msx2 sequence. 
In this study, a preliminary experiment also showed that the Msx-CAT con- 
structs responded to stimulation by Sonic hedgehog (Shh), although this may be an 
indirect effect, mediated by the induction of BNT expression. Shh and Indian 
hedgehog (Ihh) arc involved in skeletal formation during development and during 
skeletal repair (reviewed by Yamaguchi et al, 2000). The regulation of osteoblast 
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differentiation is thought to involve the up-regulation of BUTs. Shh and Ihh exprcs- 
sion have been previously shown to correlate with BMP signalling at various sites in 
the mouse embryo and are reported to regulate BMP expression in various mesen- 
chymal sites and osteoblastic cells lines (Bitgood and McMahon, 1995; Yamaguchi 
et al, 2000). Indeed ectopic expression of Shh leads to bone formation. Recent 
studies have shown that Shh stimulates BMP expression through the Shh transcrip- 
tional mediators Gfil or GO (Kawai and Sugiura, 2001). In addition, the Shh pro- 
tein may interact with BMPs and lead to control of Msx expression at the osteogenic 
front through a patched-dependent pathway, which may be involved in the preven- 
tion of early sutural closure (Kim et al, 1998). In this work, expression patterns for 
Msx and BMPs were found to be discontinuous along the osteogenic fronts reflect- 
ing a patched pattern and thus resembling Shh and Ptc expression. In addition, 
studies in Drosophild have shown that the msh gene is also influenced by hedgehog 
signalling (D'Alessio and Frasch, 1996). Finally, in the mouse tooth germ, Msx1 has 
been demonstrated to be required for the induction of Patched (Ptc) by Shh (Zhang 
et al, 1999). Ptc is the Shh transmernbrane receptor, that functions as a negative 
regulator in the Shh signalling pathway. To further investigate the mechanism(s) by 
which Shh regulates Msx expression it will be necessary to monitor the levels of 
BMPs and Gli proteins following Shh stimulation. Alternatively, cells could be 
treated with Shh in the presence of BMP antagonists, such as Noggin proteins. 
The small effect of 1,25'(OM2D3was not significant in this chapter since there 
was a great deal of variability between experiments. From research previously car- 
ried out in our laboratory, no vitamin D response elements have been identified in 
the 1.2kb 5' regulatory sequence and this construct was not found to be regulated by 
1,25'(011)2D3 in the human MG-63 osteoblast cell line and ROS 17/2.8 cells 
(Hodgkinson, 2000; unpublished data from PhD thesis). In addition, Dr. R Max- 
son9s group have not reported any VDRE the 5.2kb regulatory sequence (Liu et al, 
1994). However, using RT-PCR techniques, Hodgkinson was able to show that 
1,2540H03 could regulate Msx2 expression in primary cultures of normal human 
bone cells (Hodgkinson et al, 1993). This stimulation may have been indirect 
through the signalling of other osteotropic pathways. The results of experiments in 
which cells were exposed to 1,25-(OH)2D3 in the presence of cyclohexamide, an 
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inhibitor of protein synthesis, are consitsent with this possibility (Brown, J. and 
Beresford, J. N., personal communication). 
6.6.2 Investigation into the expression of Msx genes in adult murine 
osteoblasts 
The ainis of this project were to investigate fiu-ther the expression of MsxI and Msx2 
genes during bone development and osteoblast differentiation by studying their ex- 
pression in post-natal bone. Using both LacZ reporter gene expression analysis and 
in situ hybridisation the postnatal expression of both MsxI and Msx2 could not be 
demonstrated. 
As mentioned above, before the work on this chapter was started, most of the 
research implicating Msx genes in the control of osteoblast differentiation and tissue 
mineralisation in osseous; tissues had suggested a role for these genes in cells derived 
from the neural crest but not in the mesodermaRy derived osteoblasts of long bones. 
This is in contrast to Cbfal which provides a global control of the osteoblast phe- 
notype of the entire skeleton, including the skull (Ducy et al, 1997, Komori et al, 
1997, Otto et al, 1997). 
In this investigation using bones from wild-type mice and Msxl-lacZ knock-in 
mice, there was no observable post-natal bone expression of either MSX1 or MSX2. 
In contrast, expression was detected in the calvaria, tooth and long bones of embry- 
onic or early post-natal mice (less than 3 days of age), as has been reported previ- 
ously (HUI et al, 1989; Robert et al, 1989; Davidson et al, 1991; Monaghan et al, 
1991; MacKenzie et al, 1992; Reginelli et al, 1995; Kim et al, 1998; Liu et al, 
1999). A minor discrepancy is that in Liu et al (1999), using a Msx2-lacZ knock-in 
mouse model, found that Msx2 continued to be expressed in the cranial sutures as 
late as P4. However, promoter activity was reduced by this stage and exhibited a 
punctuate pattern in undifferentiated osteoblasts in the outer margin of the osteo- 
genic fronts (a pattern which was similar to that found by Kim et al, 1998). Had the 
work described here looked at more serial sections of the calvaria, expression may 
have been observed at later time points. 
The results in this investigation are consistent with those of Nowroozi et al 
(1996), who found that in adult M=2-lacZ knock-in transgenic mice, Msx2 expres- 
sion was high in pre-osteoblasts and osteoblasts in calvarial sutures but not in neigh- 
bouring periostcal regions. MW expression was detected in the mandible and max- 
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Ula, but not in the periosteal areas of long bones, although some chance staining was 
observed in individual cells neighbouring the metaphysical cartilage (Nowroozi et al, 
1996). 
Recently, there has been a report that there is strong expression of Msx2 in the 
long bones of mice as late as post-natal day 30 (Satokata. el al, 2000). However, 
thcse mice had defective proliferation of osteoprogenitors at the osteogenic fronts 
during calvarial development (Satokata et al, 2000). In addition, they had defects in 
endochondral bone formation and in the axial and appendicular skeleton, there were 
post-natal defects in the PTR/PT1JrP receptor signalling and in the expression of 
osteoblast differentiation marker genes (Cbfal, alkaline phosphatase, bone sialopro- 
tein, and osteocalcin). This work suggests that Msx2 is required for both chondro- 
genesis and osteogenesis. Of particular relevance to the work presented here, these 
workers also found some MW expression in proliferating chondrocytes and in the 
osteoblasts of the periosteurn of wild type mice at post-riatal age 30 (Satokata et al, 
2000). 
Since the completion of this study, Orestes-Cardoso et al (2001) have reported 
adult expression of Msx] using the same strain of n1acZ knock-in transgcnic: mice. 
Their work suggests a role for Msx] in bone growth in the osteogenic fronts of su- 
tures, growth plate cartilage, and periosteum, as well as skeletal patterning of distal 
extensions of the mandible, limbs, sutures, and alveolar bone associated with the 
teeth. Furthermore, Msxl expression was found to be localised to chondrocytes and 
osteoclasts, in addition to ostcoblasts. When the work described here was initiated, 
bone samples were fixed and decalcified using standard histological procedures of 
fornialin fixation and EDTA decalcification (see section 2.5.6 for details). However, 
this procedure leads to an apparently high background level of X-gal staining in both 
transgene positive and transgene-negative samples. In the paper by Orestes-Cardoso 
et al (2001), the workers discuss the need to fix for a nfmimum. of 30 minutes and 
titrate the quantities of X-gal stain to ensure specific staining of positive tissue. This 
is something which was not investigated here and for this reason alone, it is difficult 
to interpret the discrepancies between the findings of the two studies. It should be 
noted, however, that Orestes-Cardoso et al did not substantiate their work with 
transgene negative samples or in situ hybridisation analysis. 
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6.7 Conclusions 
PTH showed no regulation of either endogenous; or exogenous Msx2 expression. 
However, BNVs were shown to stimulate the Msx2-CAT constructs. Using Msxl- 
IacZ transgenic mice, LacZ expression was only detected in mineralising tissues of 
the foetus and neonate, with no LacZ expression observed after birth. Similar re- 
sults were found when endogenous MsxI and Msx2 expression patterns were stud- 
ied. 
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The work described in this thesis has helped to elucidate further the roles of c-Fos 
and Msx transcription factors in bone cell differentiation and in health and disease. 
The role of c-Fos in osteoclast biology was investigated using an in vivo transgenic 
approach, and its potential function in regulating osteoblast diffierentiation and 
apoptosis was assessed using a tightly controlled gene induction system in vitro. 
Finally, the regulation of Msx. gene expression in osteoblasts was investigated in 
response to osteotropic hormones. 
That c-Fos plays a major role in bone biology came from earlier studies using c- 
Jos knockout mice in which it was found that c-Fos was essential for osteoclast de- 
velopment (Grigoriadis et al, 1994), as well as from studies demonstrating that c-fos 
is highly expressed in lesions from patients with Paget's disease. In this thesis, the in 
vivo effects of c-fos over-expression in osteoclasts, was addressed using TRAP-c- 
JbsLTR transgenic mice. Several founder mice developed bone lesions and turnours 
which contained a large numbers of multinucleated cells that expressed several os- 
teoclast-specific markers and were functional as evidenced by the presence of highly 
remodelled bone. However, the reasons for the apparent increase in the number of 
osteoclasts is not yet clear: One possibility could be because of increased osteoclast 
differentiation from circulating precursors, as a result of a positive feedback signal- 
ling from increased bone remodelling and a disruption of the balance between bone 
formation and resorption. Alternatively, it could be due to increased osteoclast 
survival as evidenced by the high levels of Bcl-2 expression in the transgenic osteo- 
clasts. c-fos has been demonstrated to be downstream of RANK/RANKL in the 
signalling pathway mediating osteoclast differentiation (Matsuo et al, 2000). Fu- 
ture studies should therefore investigate whether high c-Fos expression has had a 
positive feedback effect in modulating expression of these key osteoclast differentia- 
tion factors, in addition to changes in expression of Opg, which may help to ascer- 
tain any imbalance in bone formation versus bone resorption. 
An additional line of future experimentation should also include a comparison 
of the cffects of the TRAP-c-fosLTR construct with one in which the long terminal 
repeat (LTR) has been removed. As described in section 1.6.4, this LTR fragment is 
required for stable expression of the c-fos transgene in vivo, and is necessary for 
transformation of osteoblasts, as exemplified in H2-c-fosLTR mice (Grigoriadis et 
al, 1993). Although the TRAP promoter has been a useful system for targeting gene 
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expression to osteoclasts (e. g., Roodman et al, 1996), and we have achieved high 
levels of exogenous c-Fos protein in osteoclasts, we cannot completely rule out the 
possibility that the LTR fragment may be overriding the TRAP promoter specificity, 
leading to additional inappropriate expression in osteoblasts, and generation of a 
turnour phenotype. This can be addressed by generating additional mice using 
TRAP-c-fos constructs which lack the LTR but contain another suitable polyA sig- 
nal. Alternatively, as more promoter sequences become characterised and more 
information on osteoclast markers becomes available, an alternative promoter could 
be used for the targeting of c-fos to osteoclast at different stages of the differentia- 
tion sequence. For example, the RANK or MMIP-9 promoters could be used to 
target cells at early stages of osteoclast development, whereas the promoters for 
vacuolar-AT? ase, cathepsin K or carbonic anhydrase'II could be used for targeting 
to more mature osteoclasts. Enforced in vitro expression of c-fos in osteoclasts 
could be investigated using the RAW264.7 macrophage cell fine stably transfected 
with the inducible c-Fos construct utilised for the MC3T3-EI cell line (chapters 4 
and 5; see also Thomas et al, 2000). 
Clearly, further experiments are required to confirm unequivocally the appro- 
priate targeting of c-Fos in osteoclasts and assess the consequences for their func- 
tional activity. To achieve this more transgenic founder mice need to be generated 
which can be bred to give transgenic families, thereby allowing more in vivo and in 
vitro studies to be performed. In addition to studies mentioned above, in vitro stud- 
ies should, for example, investigate the osteoclastogenic capacity and function or 
altered gene expression of haernatopoietic spleen precursors, by culturing cells de- 
rived from turnours in the presence of RANKL. 
This thesis also identified an in vitro role for c-Fos in the proliferation, differen- 
tiation and apoptosis of osteoblasts in vitro, despite the fact that c-Fos has been 
shown to be dispensable for these processes in vivo (Field et al, 1992; Brusselbach 
et al, 1995; Johnson et al, 1992; Wang et al, 1992; Gajate et al, 1996, Roffler- 
Tarlov et al, 1996). Using in vitro systems, the overexpression of c-Fos in osteo- 
blasts may have resulted in the attenuation of the osteoblast phenotype, possibly 
through an increase in proliferation and decrease in maturation. Previous studies 
have shown that AP-1 proteins follow a sequential pattern of gene expression during 
osteoblast differentiation (McCabe et al, 1995; Banedee et al, 1996). The work 
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presented here has shown that this balance, in particular the regulation of BNT-2 
induced alkaline phosphatase activity, can be disrupted by the over-expression of c- 
fos. The inhibition of alkaline phosphatase activity may occur as a direct result of 
transcriptional control of alkaline phosphatase expression via AM binding sites in 
regulatory sequences (Owen et al, 1990; Slack et al, 1995) or through indirect 
regulation of BM[P downstream signalling molecules including SMAD6 and 
SMAD7, BNT receptors or other BNV target proteins. These possibilities remain 
to be investigated. 
One interesting line of future investigation would be to induce c-fos expression 
at various points in the differentiation sequence. This is possible only because of the 
tight control offered by the Tc-regulatable system. This may help to delineate the 
potential effects of c-Fos on the osteoblast mineralisation process, which may by 
overridden in the presence of c-Fos inducing a hyperproliferative advantage over the 
cells. In the normal ostcoblast differentiation sequence the proliferation period sup- 
ports the biosynthesis of a type-1 collagen extracellular matrix, which continues to 
mature and mineralisc. This matrix then suppresses osteoblast proliferation (Stein et 
al, 1990). During the process of extracellular matrix maturation and mineralisation, 
c-Fos is known to stimulate the production of collagenases (Angel et al, 1987; 
Schonthal et al, 1988; Gack et al, 1994; Winchester et al, 2000), which are neces- 
sary for the break down of this matrix during bone remodelling. Thus, one could 
speculate that in the KTI. 5 cell system ectopic c-Fos expression is affecting the 
formation of a competent extracellular matrix via transcriptional repression of the 
genes for extracellular matrix proteins and for collagenase. Future work should 
investigate the changes in levels of expression of additional osteoblast differentiation 
markers, such as collagen, BSP, osteocalcin and MW-13 in KT1.5 cells following 
ectopic c-fos expression. Furthermore the effect of c-Fos over-expression on the 
response of cells to osteotropic factors such as 1,25-(OH)2D3 and PTH needs to be 
investigated. Recently, Demiralp et al (2001) reported that c-Fos may have a role in 
the PTH induced mineralisation, since osteoblasts from c-fos dcficient mice showed 
decreased mineralisation compared to wild type cells. Based on the fact that cul- 
tures of KTI. 5 cells do not fully mineralise, primary osteoblasts derived from 112-c- 
fosLTR mice could be used for these studies. 
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The inducible overexpression of c-Fos in osteoblastic cells also resulted in in- 
creased apoptosis induced by diverse mechanisms. This is a highly significant find- 
ing, and involves a mechanism that is independent of caspase activation but depend- 
ent on specific cell cycle regulatory genes. Our laboratory has recently demonstrated 
that ectopic c-Fos perturbs osteoblast cell cycle progression (Sunters et al, 2000), 
and the work in this thesis provides a novel link between cell cycle control and pro- 
grammed cell death in osteoblasts. Many studies have demonstrated a link between 
proliferation and apoptosis following oncogene expression (reviewed Evan and Lit- 
tlewood, 1998), with c-Myc being a prime example (Prendergast, 1999). However, 
the results from this thesis suggest that c-Fos induces apoptosis through different 
mechanisms to that of c-Myc, potentially through the regulation of CDKs. Clearly, 
future experiments will be designed to elucidate the mechanisms of c-Fos-induced 
apoptosis as it relates to cell cycle regulation. These should include an analysis of 
CDK levels and cell cycle kinetics during the apoptosis program. Additionally, cell 
cycle regulatory factors may also be involved in the mechanisms of c-Fos-induced 
apoptosis, that may be stimulating CDK activity. For example, increased c-Fos 
expression may potentiate expression of the E2F transcription factor. Stimulated 
E2F may proceed to potentiate cell death by blocking anti-apoptotic signalling 
pathways including the down regulation of TRAF2 and inhibiting the activation of 
anti-apoptotic signals such as NF-0. c-Fos may also directly inhibit anti-apoptotic 
pathways such as NF-vJ3, and JNK/SAPK activation pathways. Furthermore, 
downstream targets of CDKs that may result in the progression of apoptosis need to 
be elucidated to confirm that the resulting apoptosis is either a direct effect of al- 
tered cell cycle machinery or indirect regulation of factors important for apoptosis 
such as BcI family proteins, nuclease activation, or p53 activation (King and Cidlow- 
ski, 1995). 
Future work could also investigate the regulation of other CDK inhibitors such 
as p27 in KT1.5 cells following ectopic c-Fos expression. In the normal environ- 
ment, p27 acts to constrain CDK2 activity and p27 levels have been shown to be 
down-regulated in ceHs undergoing apoptosis (Frost and Sinclair, 2000). Indeed, 
p27-/- fibroblasts show increased apoptosis (Hiromura et al, 1999). In addition, 
p16 and p57 have been reported to inhibit apoptosis through CDK-dependant 
mechanisms (Wang and Walsh et al, 1996; Yan et al, 1997). 
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Also, other apoptotic signalling pathways should be investigated to further un- 
derstand the mechanisms of c-Fos-induced apoptosis. Siegmund et al (2001) re- 
cently reported a role for c-Fos in a FasL- and TRAIL-mediated stimulation of pro- 
liferation. Here c-Fos was up-regulated via Fas-associated death domain protein 
(FADD), FADD-like interleukin-I -converting enzyme (FLICE) inhibitory protein 
(cFLIP) and caspase-8. However, caspase activity seemed to be dispensable in this 
process as Z-VAD-fink had no inhibitory effect. In contrast, Maclaren et al (2001) 
demonstrated recently that v-Jun induced apoptosis via a pathway that is dependant 
on cytochrome c, but independent of the p53 and FADD/caspase-8 signalling path- 
ways. PTH has been shown to inhibit osteoblast apoptosis induced by dexameth- 
asone and EtoPoside via a process that involved the activation of adenylate cyclase, 
but which could not inhibit apoptosis, induced by TNF-cc (Jilka et al, 1999). It will 
therefore be important to determine whether PTH can prevent the induction of 
apoptosis induced by ectopic c-Fos expression. 
A role of c-Fos in osteoblast apoptosis has not been shown previously. Re- 
search has suggested that c-Fos is not necessary for apoptosis in normal mouse de- 
velopment, based on the results from c-Fos deficient mice. However, the study of 
apoptosis in osteoblasts from mutant mice has not been reported, and thus it would 
be useful to investigate this process in primary osteoblast cultures derived from these 
mice. Work by Ethaar EI-Emir (PhD thesis) in our laboratory has suggested that 
osteoblasts derived from'tumours of c-fos transgenic mice (H2-c-fosLTR transgenic 
mice; Grigoriadis et al, 1993) are resistant to apoptosis, based on in situ TUNEL 
analyses in late-stage turnours, and in vitro studies on turnour-derived cell lines. 
However, her research did not include cells derived from mice early on during onco- 
genic transformation of osteoblasts. Thus future research should extend to studying 
apoptosis in osteoblast cells derived from these mice at early stages following c-Fos 
transgene expression; i. e. before the development of large tumours by which time 
other genetic changes will have surely taken place. This would also help to confirm 
the results observed in this thesis with respect to the KTI. 5 cells. A comparison of 
changes in gene expression between non-transformed and transformed cells follow- 
ing apoptosis could be used to elucidate mechanisms of the osteoblast's resistance to 
apoptosis, including an up regulation of BcI proteins and potential down regulation 
of p53 and CDK inhibitors such as p2l and p27. 
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The c-Fos induced apoptosis observed here may involve caspase-independent 
pathways. However, other caspase inhibitors and higher concentrations of DEVD- 
CHO need to be investigated. To further explore the potential importance of the 
caspase-independent signalling pathways it will be important to investigate the re- 
lease of factors such as AIF (Susin et al, 1999). However, this will also require the 
analysis of other earlier endpoint/markers of apoptosis such as cytochrome c release, 
to ensure other pathways have not bypassed the requirement for caspases. 
Finally, the work described here has helped to address the regulation of Msx 
horneobox containing proteins in osteoblasts. One of the original reasons for this 
research was to identify potential therapeutic targets for the treatment of bone dis- 
eases, such as osteoporosis. PTH is currently used for the treatment of osteoporo- 
sis, but as described previously, its effects vary according to the mode of admini- 
stration, and the ideal therapeutic agent needs to increase bone mass, without ef- 
fecting bone resorption. The results of this study suggest that Msx2 is not a candi- 
date protein, however, this does not eliminate the possibilities that other homeobox 
genes may exist which can be regulated by PTH. Indeed, a novel paired class ho- 
meobox protein was shown recently to be regulated by PTH (Adams et al, 1999). 
Thus, additional PTH-regulated homeobox proteins may be identified in the future, 
possibly by the use of DNA microarrays. 
This study has also assessed the regulation of two MW reporter gene con- 
structs in MC3T3-El cells and SaOS-2 cells, which are representative of cells early 
and late in the ostcoblast differentiation sequence. By using cells at these extremes, 
however, effects of PTH on MW expression in cells at intermediate stages of differ- 
entiation may have been missed. As described in chapters 4 and 5, the MC3T3-El 
cell fine can be used to study cells at different stages of osteoblast differentiation. 
An ideal experiment, therefore, would be to transiently transfect these cells with the 
1.2kb or 2kb Msx constructs or, better still, the longer 5.2kb construct of Maxson et 
al at various stages of differentiation. Unfortunately, at the time the studies de- 
scribed in this thesis were conducted the lattcr construct was not available. 
In conclusion, the work described in this thesis has provided several novel in- 
sights into the biological roles of c-Fos and Msx transcription factors in the control 
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Figure 9.1 - Diagram of the pMsx2-CAT reporter construct. (Adapted from 
Hodgkinson, 2000 PhD thesis). A. Representation of a 16kb genomic clone used to 
prepare the 1.2kb regulatory sequence (previously isolated by Bell et al, 1993), which 
contained the first and second exons of Msx2. The black boxes represent the two coding 
regions of each exon and hatched region of the homeobox. Open boxes represent tran- 
scribed but not translated regions. All HindII (10, BamIII (B) and EcoRl (E) sites are 
shown. The 1.2kb sequence used in the pMsx2-CAT reporter construct is in a region of 
a Barn. 111 fragment represented by a bar beneath the diagram. This diagram is not to 
scale. B. Linear representation (and not to scale) of the pMsx2-CAT reporter construct. 
The Msx2 fragment had been cloned into the Prornega pCATbasic vector and is shown 
upstream of the CAT coding sequence in this plasmid. 
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ABSTRACT 
The molecular mechanisms underlying Paget's disease and subsequent osteosarcoma fornlation are not well 
understood. In this study, we aim to delineate the function of the c-Fos oncogene in Paget's disease using transgenic 
mice, based on previous findings that c-Fos is highly expressed in Pagetic osteoclasts and that c-Fos is an essential 
gene for osteoclast differentiation and skeletal neoplasia. We have generated transgenic mice in which c-Fos is 
overexpressed specifically in osteoclasts using the tartrate-resistant acid phosphatase (TRAP) promoter, and rive 
founder mice have been identified. All transgene-expressing animals developed severe bone remodeling lesions, 
some of which progressed to large bone tumors. Histopathologic analysis indicated that the lesions contained a 
marked increase in the number of osteoclasts that contained a large number of nuclei. Osteoclasts were identified 
by histochemical staining for TRAP and by in situ hybridization for matrix metalloproteinase-9 (MMP-9) expres- 
sion. Moreover, transgenic osteoclasts, and in some cases, osteoblasts and chondrocytes, expressed high levels of 
c-Fos protein as judged by immunocytochemistry. This phenotype of increased osteoclast number and activity, 
together with an apparently high rate of bone turnover, resembles some characteristics of Paget's disease. These 
data therefore support an important function for c-Fos; in the Pagetic phenotype, and further support the notion 
that this gene is important in osteoclastogenesis and in bone remodeling disorders. U Bone Miner Res 1999; 14, 
suppl. 2: 21-28) 
INTRODUCTION 
P AGET'S DISEASE OF BONE is a chronic skeletal disorder 
that affects 4-8% of the elderly population worldwide 
and is characterized by areas of rapid turnover, deformity, 
and degeneration. 0) Furthermore, patients with the disease 
have an increased risk of malignant transformation and are 
30 times more likely to develop osteosarcomas. (') The pri- 
mary lesion in Paget's disease is thought to involve bone- 
resorbing osteoclasts, which are increased 50-100-fold both 
in number and multinuclearity, resulting in an increase in 
bone turnover. The specific causes of the apparent increase 
in osteoclast activity, in addition to the molecular mecha- 
nisms underlying cellular transformation and oncogenesis, 
are poorly understood. Despite this, several candidate 
genes have been. associated with Paget's disease. For ex- 
ample, the cytokine interleukin-6 (IL-6) is apparently up- 
regulated specifically in pagetic osteoclasts, which constitu- 
tively express IL-6 receptors and the transcription factor 
nuclear factor-IL-6 (NF-IL-6), suggesting a possible auto- 
crine role for IL, 6 . 
(1,3) There is also increasing evidence 
supporting a genetic component to Paget's disease, with 
both Paget's and the Paget's-related disease familial expan- 
sile osteolysis (FEO) being mapped to a susceptibility locus 
on chromosome 18q in some families. (4,5) Moreover, the 
anti-apoptotic gene Bcl-2 has also been mapped to 18q and 
recent preliminary data indicate that Bcl-2 expression is 
up-regulated in Paget's disease. (') Finally, as described be- 
low, earlier studies analyzing the expression of c-Fos have 
demonstrated that this proto-oncogene is apparently up- 
regulated in pagetic osteoclasts (7) providing an additional 
candidate molecule for explaining the possible molecular 
'Department of Orthodontics and Paediatric Dentistry, GKT Dental Institute, Guy's Hospital, London, United Kingdom. 2 Department of Craniofacial Development, GKT Dental Institute, Guy's Hospital, London, United Kingdom. 
3 Research Institute of Molecular Pathology (IMP), Vienna, Austria. 
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basis of Paget's disease, including the potential for cellular 
transformation and oncogenesis. 
We have focused extensively on identifying potential 
roles for c-Fos in bone development and bone disease using 
gain-of-function and loss-of-function approaches. (8) C_fOS is 
the cellular homolog of v-fos that was originally identified 
in the FBJ and FBR murine sarcoma viruses (MSVs). The 
c-Fos oncoprotein is a major component of activating pro- 
tein-1 (AP-1) transcription factor complex, and is part of a 
multigene family of nuclear proteins, including other c-Fos- 
related (FosB, Fra-1, Fra-2) and c-Jun-related (c-Jun, JunB, 
JunD) proteins. (') The function of c-Fos is dependent upon 
formation of heterodimers with specific JUN/ATF-2 family 
members and subsequent binding to AP-1 consensus se- 
quences of regulatory regions of specific genes. As an im- 
mediate early gene, c-Fos is associated with a variety of 
biological processes, ranging from transformation to cell 
cycle progression and differentiation. (') While the gene can 
be induced in a wide range of both embryonic and adult 
tissues and cell lines, the biological functions of c-Fos have 
been primarily delineated using transgenic and knock-out 
mice. (') Transgenic mice overexpressing c-fos using ubiqui- 
tous promoters develop remodeling osteosarcomas due to 
specific c-Fos-dependent oncogenic transformation of os- 
teoblasts. (") Moreover, histopathologic analysis revealed 
many features that resemble Paget's disease. (10-12) In con- 
trast, c-Fos knock-out mice lack osteoclasts and develop the 
bone remodeling disease osteopetrosis '(13,14) clearly 
dem- 
onstrating that c-Fos is an essential gene for osteoclast dif- 
ferentiation and bone remodeling in general . 
(8) Thus, the 
gain- and loss-of-function analyses have clearly implicated 
the c-Fos proto-oncogene and AP-1 transcription factor in 
both osteoclast differentiation and in bone cell transforma- 
tion and tumor formation, both processes hallmarks of Pag- 
et's disease. 
To further examine the role of c-Fos in Paget's disease, 
and consistent with the observations that osteoclasts in pag- 
etic bone express high levels of c-Fos, (7) we have generated 
mice in which c-fos is overexpressed specifically in osteo- 
clasts. To this end, we have used the promoter for tartrate- 
resistant acid phosphatase (TRAP), which is expressed 
at high levels in osteoclast precursors and differentiated 
osteoclasts, and which has been shown previously to func- 
tion reliably for targeting transgenes to osteoclasts in 
mice. (15-17) our results suggest that when high levels of 
c-Fos are expressed in osteoclasts, the mice develop a 
marked bone remodeling phenotype reminiscent of Paget's 
disease, such as the presence of large numbers of osteo- 
clasts containing many nuclei, and in some cases, the devel- 
opment of large tumors. 
MATERIALS AND METHODS 
Construction of TRAP-c-fosLTR and generation of 
transgenic mice 
The murine TRAP promoter (pBS-TRAP; obtained 
from Dr. G. D. Roodman, San Antonio, TX, U. S. A. (15)) was 
fused to a full-length genomic sequence for the murine c-fos 
gene in which the 3' mRNA destabilizing sequences have 
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FIG. 1. The DNA construct (TRAP-c-fosLTR) used for 
the generation of TRAP-c-fosLTR transgenic mice. The 
murine TRAP promoter (pBS-TRAP) was fused to a full- 
length genomic sequence for the murine c-fos gene in which 
the 3'mRNA destablizing sequences have been replaced by 
a YLTR from the FBJ-MSV. (") Two exogenous c-fos tran- 
scripts are synthesized as indicated. H, HindIII. 
been replaced by a 3' long-terminal repeat (LTR) from the 
FBJ-MSV (TRAP-c-fosLTR) (Fig. 1). (") The construct 
was microinjected (without plasmid sequences) into fertil- 
ized eggs according to standard procedures, followed by 
transfer into foster females. Founder animals were screened 
by Southern blot analysis of tail DNA for the presence of 
the transgene, and radiographs were taken on anesthetized 
mice. 
Northern blot analysis 
Northern blot analysis was performed on poly(A)+ RNA 
isolated from tissue samples of normal and tumor tissues. 
RNA isolation and hybridization using an 800-bp BamHI 
fragment from v-fos was performed as described previ- 
ously. (10) 
Histopathologic analysis 
Transgenic mice were killed by cervical dislocation and 
tissues were fixed immediately in 3.7% paraformaldehyde 
in phosphate-buffered saline (PBS) at room temperature 
for 24-48 h and decalcified in either 0.5 M EDTA or 5% 
formic acid. Material was paraffin embedded following de- 
hydration and vacuum infiltration, 5 Rm. sections were cut 
and mounted on 3-aminopropyltriethoxysilane (TESPA)- 
coated slides and stained by hematoxylin and eosin. For 
identification of osteoclasts, sections were stained for 
TRAP in the presence of 50 mM sodium tartrate as de- 
scribed previously. (14) 
In situ hybridization of bone from 
TRAP-c-fosLTR mice 
Sense and antisense matrix metalloproteinase-9 (MMp- 
9) riboprobes were synthesized using a murine MMP_q 
cDNA probe (323 bp Smal-EcoRI fragment(""")) and la- 
beled with digoxigenin (DIG) according to the manufactur- 
er's instructions (DIG RNA labeling kit, Roche Diagnostics 
Ltd., Lewes, U. K. ). Bone tissue was prepared as described 
above and 5 Rm sections were cut and mounted on polyly- 
sine-coated slides. Briefly, slides were deparaffinized in xy- 
lene, rehydrated, postfixed in PFA (Sigma Chemical Co., 
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Dorset, U. K. ), followed by digestion for 15 minutes at 37C 
with proteinase K (10 ýLg/ml in 20 mM Tris-HCL, pH 8,2 
mM CaC12). After a second fixation in PFA, sections were 
acetylated with freshly prepared 0.25 % v/v acetic anhydride 
in 0.1 M triethanolamine, pH 8. All sections were prehy- 
bridized for 2h at room temperature in 50% formamide, 1 
mg/ml BSA, 0.02% w/v Ficoll, 0.02% polyvinylpyrrolidine, 
5x SSC, 250 Rg/ml tRNA. Hybridization with a heat- 
denatured probe was carried out at 55"C overnight in pre- 
hybridization solution. Aliquots of 70 [d were applied to 
each section and covered with parafilm coverslips. After 
hybridization the tissue sections were washed with a series 
of washes; once for 5 minutes in 5x SSC at 55'C; 1h in 0.2x 
SSC at 55'C, followed by 10 minutes at room temperature 
in 0.2x SSC. The signal was detected according to manu- 
facturer's instructions using the Nitroblue tetrazolium, 
5-bromo-4-chloro-3-indoyl-phosphate substrate solution 
(Roche Diagnostics Ltd. ). Slides were mounted in Aqua- 
mount (BDFUMerck, Dorset, U. K. ) and coverslips applied. 
In situ hybridization of human pagetic bone 
A human c-fos cDNA probe consisting of the terminal 
500 bp of coding sequence and Y-untranslated sequence 
was random prime labeled with 35S-dCTP. The hybridiza- 
tion treatments were as previously described. ") Briefly, 
these included sequential immersion in 0.2 M HCl (20 min- 
utes); 2x SSC (10 minutes); 10 ýLg/ml of proteinase K in 50 
mM Tris-HC1, pH 7.5 (1 h, 37'C); 0.25% w/v glycine in PBS 
(2 minutes); and freshly prepared 0.25% v/v acetic anhy- 
dride in 0.1 M triethanolamine, pH 8. All sections were 
prehybridized for 1h at 37'C in 50% formamide, 1 mg/ml 
BSA, 0.02% w/v Ficoll, 0.02% polyvinylpyrrolidine, 0.6 M 
NaCl, 0.2 mg/ml of sheared salmon sperm DNA, 10 mM 
Tris (pH 7.4), 0.5 M EDTA, 10 mM dithiothreitol (DTT), 
and 10% w/v dextran sulfate. Hybridization with heat- 
denatured probe was carried out at 37C overnight in pre- 
hybridization solution. Aliquots of 50 pl were applied to 
each slide and covered with siliconized coverslips. After 
hybridization the tissue sections were washed with a series 
of high stringency washes; twice for 5 minutes in 0.5x SSC 
with 1 mM EDTA; 15 minutes in 50% formamide, 0.15 M 
NaCl, 5 mM Tris (pH 7.5), and 0.5 mM EDTA; and four 
times for 5 minutes in 0.5x SSC at 58'C, followed by 5 
minutes at room temperature in 0.5x SSC. Slides were de- 
hydrated in 70% and 95% ethanol with 0.3 M ammonium 
acetate and air dried. Autoradiography was performed with 
Ilford K5 emulsion (Ilford Imaging U. K. Ltd., Cheshire, 
U. K. ), melted at 40'C and diluted 1: 1 with distilled water. 
The slides were exposed at 40C for 14 days and then devel- 
oped for 5 minutes, rinsed, fixed for 5 minutes, and coun- 
terstained with hematoxylin and eosin. 
Immunohistochemistry 
The c-Fos antibody used in this study (c-Fos; sc52), was 
purchased from Santa Cruz Laboratories (Santa Cruz, CA, 
U. S. A. ). Bone tissue was prepared as detailed above, and 5 
pm sections were cut and mounted on TESPA-treated 
slides. Slides were deparaffinized in xylene and rehydrated. 
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Immunohistochernistry was performed following standard 
protocols following pretreatment in 3% H, O, in methanol 
and rehydration. Briefly, sections were permeabilized in 
I% w/v SDS in TBS (pH 8.0) for 5 minutes, rinsed twice in 
TBS and blocked for 1h in 50% normal rabbit serum 
(DAKO, Ely, U. K. ) in 2% BSAfTBS. Primary antibodies 
were used at a dilution of 1: 50 in 10% normal rabbit serum 
in TBST for 1h and washed 3x5 minutes in TBST. A 
biotinylated goat-anti-rabbit secondary antibody (DAKO) 
was used at a dilution of 1: 300 in TBST for 1 h. Negative 
controls consisted of either TBS or a nonspecific primary 
antibody (rabbit anti-FLAG epitope) (Santa Cruz Labs). 
Proteins were visualized using the ABC system (Vector 
Labs, Burlingame, CA, U. S. A. ) with a DAB substrate 
(Sigma). Slides were counterstained with hematoxylin and 
mounted in DePeX (BDH/Merck). 
RESULTS 
Skeletal abnormalities in TRAP-c-fosLTR 
transgenic mice 
The c-fos construct used to generate transgenic mice 
(TRAP-c-fosLTR) contains the murine genomic c-fos gene 
fused to the murine TRAP promoter (Fig. 1). In addition, 
the 3' destabilizing sequences and polyadenylation (polyA) 
site of c-fos have been deleted and replaced with a 3' LTR 
from the FBJ-MSV; this modification is essential for ensur- 
ing stability of the exogenous c-fos mRNA. (", 19) This vec- 
tor gives rise to two exogenous c-fos transcripts, a 3.0-kb 
transcript that terminates at the polyA site in the LTR and 
which encodes for the functional c-Fos protein, and a 
shorter 2.0-kb transcript that terminates at a cryptic polyA 
site present in the FBJ-derived sequence. A total of nine 
founder animals were obtained that contained between -5 
and 50 copies of the transgene as judged by Southern blot 
analysis of tail DNA. Of these, five developed noticeable 
swellings in the long bones between 3 and 6 weeks of age, 
and some mice were severely growth retarded. Radio- 
graphic analysis of all phenotypic founder animals indicated 
the presence of marked skeletal abnormalities in virtually 
all bones, in contrast to the normal skeletal development in 
transgene-negative littermates (Fig. 2). Of the five pheno- 
typic animals, three displayed a severe sclerotic phenotype 
over the entire skeleton with long bones, vertebrae, pelvis 
and skull being severely affected (Fig. 2A). In the remain- 
ing two founder animals, skeletal lesions were detected that 
developed rapidly into very large calcified tumors (Fig. 213). 
Again, these lesions were present in most bones of the skel- 
eton. All phenotypic mice developed these skeletal abnor- 
malities shortly after birth (3-6 weeks postnatally), prior to 
reaching sexual maturity, and together with the size and 
severity of the lesions, attempts to breed them and obtain 
transgenic offspring were not successful. Nevertheless, the 
generation of five independent founders that developed 
similar phenotypes (see below) clearly indicated that the 
defects were independent of the transgene integration site, 
and suggested that exogenous c-Fos expression was causal 
in generating the skeletal abnormalities. 
\111,44 
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FIG. 2. Skeletal abnormalities in TRAP-c-fosLTR trans- 
genic mice. Radiographic analysis of wild-type (left) and 
transgene positive (right) littermates, showing the severity 
of lesions in transgenic bone. (A) X-rays of a 5-week-old 
normal mouse (no. 228-2) and its age-matched transgenic 
littermate (no. 228-1) showing specific radio-dense lesions 
in all bones (arrows), including long bones, vertebrae, pel- 
vis, and skull. (B) X-rays of a 5-week-old normal mouse 
(no. 250-8) and its age-matched transgenic littermate (no. 
250-9) showing large calcified tumors (arrow). 
Expression of exogenous c-fos in transgenic tissues 
To investigate whether there was a relationship between 
the development of the skeletal phentoypes in the founder 
transgenic mice and expression of the c-fos transgene, we 
performed Northern blot analysis on tumor tissues as well 
as on unaffected tissues. In one particular transgenic found- 
er, exogenous c-fos was expressed in tumor-bearing bones 
and at lower levels in the heart, but not in any other tissues 
(Fig. 3). Intestine and muscle, and at lower levels brain and 
liver tissues, also expressed endogenous c-fos RNA. In a 
second independent founder, transgene expression was de- 
tected at high levels in lesional bone tissue, but also at lower 
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levels in liver, that did not develop any macroscopic abnor- 
malities (data not shown). Significantly, Northern blot 
analysis of tissues from the four founder animals that did 
not develop any bone abnormalities (see above) failed to 
demonstrate expression of the c-fos transgene in tissues 
analyzed. These data therefore suggest that the expression 
of exogenous c-fos was likely to be responsible for the de- 
velopment of the observed skeletal lesions. 
Histologic analysis of skeletal lesions 
Histopathologic analysis of sections from representative 
long bones of TRAP-c-fosLTR transgenic mice revealed an 
increase in bone trabeculae when compared to bones from 
nontransgenic littermates with a marked bone marrow fi- 
brosis (Figs. 4A and 413). Long bones in general also exhib- 
ited a poorly developed cortical bone (data not shown). 
Histochernical staining for the osteoclast marker TRAP 
demonstrated a marked increase in the number of osteo- 
clasts (Fig. 4C) compared to wild-type bones where only a 
few osteoclasts were observed primarily lining the distal 
endochondral growth plate (data not shown). The osteo- 
clasts in the transgenic bones were also larger than normal 
and contained a larger number of nuclei per osteoclast 
(Figs. 4D and 4E). The lesions appeared to undergo exten- 
sive bone remodeling as evidenced by the numerous rever- 
sal lines present in all trabeculae (Figs. 4D and 4E). In 
addition to osteoclasts and osteoblasts, occasional pockets 
of chondrocytes were observed suggesting that chondro- 
genic cells or specific precursors were also affected (data 
not shown). To confirm further the increase in number and 
activity of osteoclasts within these remodeling lesions, we 
performed nonradioactive in situ hybridization experiments 
on adjacent sections of transgenic bones for MMP-9, which 
is another specific marker for osteoclasts in ViVo. (14,19) The 
results suggested that all TRAP-positive cells were also ex- 
pressing high levels of MMP-9 (Fig. 4F), which were large 
and contained numerous nuclei (Figs. 4G and 4H), confirm- 
ing that these were bona fide osteoclasts. 
To investigate the cell-specific expression of c-Fos within 
these lesions, we performed immunocytochemical analysis 
on adjacent sections for c-Fos protein using a murine c-Fos 
polyclonal antibody. The results indicated that high levels 
of c-Fos protein were detected in almost all osteoclasts lin- 
ing the bone surfaces (Figs. 41 and 4J). In addition, we 
observed c-Fos protein expression in some, but not all, os- 
teoblasts and chondrocytes (Figs. 41 and 4J) and in many 
fibroblastic connective tissue cells within these lesions. It 
should be emphasized that the antibody we used detects 
both endogenous as well as exogenous c-Fos proteins, 
therefore it is perhaps not surprising that many cell types 
might be expressing c-Fos. Indeed, this is suggested by the 
Northern blot analyses where endogenous; c-fos RNA was 
also detected within the bone lesions (Fig. 3). Taken to- 
gether, the hallmarks of the phenotype that develops in 
c-fos-overexpressing transgenic mice are an increase in the 
number and multinuclearity of osteoclast-like cells that re- 
sult in the development of highly remodeling bone lesions. 
C-FOS AND PAGET'S DISEASE 
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FIG. 3. Northern blot analysis of c-fos transgene egression in different tissues of a TRAP-c-fosLTR transgenic mouse 
(no. 1766). The membrane was hybridized with a P-labeled v-fos probe which detects both exogenous (3.0 kb) and 
endogenous (2.2 kb) c-fos transcripts. The endogenous fox gene (0.6 kb) was used as a control for RNA loading. The 
exogenous; c-fos transcript was evident in tumor-bearing bones (+ T) like tibia and calvaria, compared with no signal in 
bones lacking tumors (-T). 
Expression of c-fos in bone cells of patients with 
Paget's disease 
To investigate whether high levels of c-Fos are also pre- 
sent in bone cells of patients with Paget's disease, and to 
assess cell specificity, we further analyzed the expression of 
c-fos by radioactive in situ hybridization techniques. Using 
paraffin sections of pagetic bone obtained from biopsies, 
the results indicated very high c-fos expression which was 
localized to multinucleated osteoclasts (Figs. 5A and 513), 
whereas c-fos expression in osteoclasts present in control 
osteophyte tissue was not detectable (see also(')). In addi- 
tion, the expression of c-fos mRNA was confirmed by im- 
munohistochernical staining for c-Fos protein on adjacent 
sections (see also (7) ) These data further implicate a role for 
c-Fos in the altered osteoclastic activity which is character- 
istic of Paget's disease, and confirms previous results using 
different pagetic bone samples. (7) More importantly, the 
basic similarities between the morphology and activity of 
the osteoclasts present in Paget's disease compared with 
those that develop in TRAP-c-fosLTR transgenic mice sug- 
gest that these mice might be useful for further delineating 
the molecular defects underlying the altered osteoclastic 
behavior, and perhaps also the subsequent events leading to 
osteosarcoma formation. 
DISCUSSION 
In this study we have investigated the consequences of 
ectopic c-Fos expression in mature osteoclasts in an attempt 
to mimic the high levels of c-Fos that are observed in pag- 
etic osteoclasts. (') While earlier c-Fos knock-out experi- 
ments have demonstrated unequivocally that c-Fos must be 
expressed in osteoclast progenitors for normal differentia- 
tion, (14) it was not possible in that study to discern whether 
c-Fos is also required for the fusion and activity of fully 
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differentiated, multinucleated osteoclasts. Here, we have 
shown that targeting c-fos expression to osteoclasts under 
the control of the osteoclast-specific TRAP promoter 
(TRAP-c-fosLTR mice) results in the rapid development of 
highly remodeling lesions and formation of bone tumors. 
Five independent transgenic founder mice were identified 
which expressed exogenous c-Fos but which could not be 
bred to generate individual families of transgenic mice due 
to the severity and early onset of the phenotype. Thus, 
while the absolute causal role of c-Fos in the development 
of these phenotypes is difficult to prove by analyzing only 
founder animals, it is clear that the observed skeletal de- 
fects were very specific to c-Fos overexpression and inde- 
pendent of the transgene integration site. 
The phenotypes among each affected animal, such as the 
time of onset, the histologic characteristics and cellular 
composition, were remarkably similar in all bones analyzed 
from all founder mice, suggesting that the defects were 
likely caused by ectopic c-Fos expression. Notably, all le- 
sions contained numerous osteoclasts, most of which con- 
tained a very large number of nuclei when compared to 
osteoclasts in wild-type littermates, and in this regard these 
lesions exhibit some similarities to Paget's disease. The os- 
teoclasts expressed high levels of TRAP activity in addition 
to MMP-9, which is a reliable specific marker for osteo- 
clasts in vivo. It is tempting to speculate that the conse- 
quences of this increased osteoclast number and activity in 
TRAP-c-fosLTR mice are the stimulation of a cascade in 
which there is an increase in the recruitment and differen- 
tiation of osteoblasts, which leads to a highly remodeling 
lesion in which osteoclastic bone resorption and osteoblas- 
tic bone formation are accelerated, causing bone deforma- 
tion. Despite the fact that the initial appearance of some of 
the skeletal defects (Figs. 1A and 4B) might suggest an 
apparent osteopetrotic phenotype implying that osteoclasts 
are inactive, the presence of abundant reversal lines and 
continued growth of these lesions suggests that this is not 
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FIG. 4. Histologic analysis of the lesions that develop in TRAP-c-fosLTR transgenic mice. Hematoxylin and eosin stained 
sections of a typical wild-type tibia (A) and a TRAP-c-fosLTR transgenic tibia (B), demonstrating the presence of 
increased bone trabeculac in transgenic mice compared to nontransgenic littermates. The bone marrow space is largely 
fibrotic with little hematopoietic cell activity (*). TRAP histochemistry and hematoxylin and eosin staining detected 
increased numbers of osteoclasts (C-E) compared to wild-type bone (data not shown). (C) Detection of TRAP-positive 
osteoclasts in adjacent sections to above, and (E) a high power view of multinucleated, TRAP-positive osteoclasts 
(counterstained with hematoxylin). DIG-labeled antisense riboprobes for MMP-9 detected high levels of expression of 
MMP-9 in TRAP-positive, multinucleated osteoclasts of TRAP-c-fosLTR transgenic mice (F-H). Control sense riboprobe 
hybridizations revealed no specific signal (data not shown). Immunolocalization of c-Fos protein using a murine polyclonal 
antibody confirms the expression of c-Fos in osteoclasts (U). Osteoblasts also express c-Fos in some areas, although clearly 
negative ostcoblasts are also observed (arrow in 1). Similarly, some chondrocytes express c-Fos (arrow in J). All sections 
are 5 ýLrn paraffin sections prepared and stained as described in Materials and Methods. Arrowheads in all panels indicate 
osteoclasts. gp. growth plate, b, trabecular bone. A, 13 100x; CY xffX)xý D, E. G-J 4(W. 




FIG. 5. Expression of c-figs in bone cells in Paget's disease. 
RNA in situ hybridization analysis shows that large multi- 
nucleated osteoclasts, (arrows) express high levels of c-fos 
(A, B). Hybridization of adjacent sections with a sense c-fos 
probe revealed no specific signal (data not shown). The 
micrographs are representative of the results obtained from 
six different Paget's patients (see also (7) ). 
the case and the osteoclasts are indeed active. This never- 
theless remains to be confirmed by examining in greater 
detail the morphology of the transgenic osteociasts and by 
measuring their resorptive activity in vitro. The fact that 
some of the transgenic mice developed very large bone 
tumors also suggests that additional events are occurring 
following expression of the transgene, such as activation of 
genes that are important in the growth control of specific 
bone cell populations! '") While this is a possible scenario, 
we cannot exclude the possibility that the early lesions 
would have eventually expanded extracortically to more 
closely resemble the tumor lesions (Fig. I B), which we 
would not have observed because the mice were sacrificed 
at a relatively early age. 
Assessing the possible causes of tumor formation in 
TRAP-c-fosLTR mice is very important in view of the fact 
that these tumors resemble in some ways the remodeling 
osteosarcomas that develop in other c-Fos transgenic mice 
(H2-c-fosLTR) that have been generated previously! "') In 
H2-c-fosLTR mice, chondroblastic osteosarcomas develop 
due to specific transformation of osteoblastic cells, and os- 
teoblasts express high levels of the transgene. The fact that 
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we have large numbers of osteoblasts (and in some cases 
chondrocytes) in TRAP-c-fosLTR lesions, a large propor- 
tion of which express c-Fos protein by immunocytochemi- 
cal analysis, raises several possible interpretations. First, 
since the antibody used cannot distinguish between endog- 
enous and exogenous c-Fos, it is possible that expression in 
osteoblasts reflects endogenous c-Fos protein; efficient ex- 
pression of the endogenous gene is confirmed by our 
Northern blot analyses. This may be possible since expres- 
sion of endogenous c-Fos in osteoclasts is normally very 
low (20) and activated osteoblasts during bone formation 
may indeed turn on endogenous c-Fos expression! " Sec- 
ond, it is possible that high c-Fos levels in osteoblasts could 
be interpreted as inappropriate expression of the transgene 
from the TRAP promoter; that is, we cannot rule out that 
"leaky" expression of the TRAP promoter in osteoblasts 
may have caused the observed tumor phenotype. Possible 
explanations for this scenario might be attributed to the 3' 
F13J-LTR which we have used in our construct. Although it 
has been demonstrated unequivocally that this fragment is 
necessary for efficient expression of c-Fos in bone tissue, it 
cannot be excluded that there exist sequences within this 
fragment which can override or alter the specificity of the 
selected promoter. The evidence that this could indeed oc- 
cur in transgenic mice has previously been discussed! 19,21) 
To address the issue of target cell specificity, we are cur- 
rently performing in situ hybridization analyses using a 
probe that is specific for the transgene (pB15) as described 
previously, ")) which will determine whether osteoclasts 
and/or osteoblasts are expressing exogenous c-fos. 
Taken together, the skeletal abnormalities that develop 
in TRAP-c-fosLTR transgenic founder mice share some 
properties with Paget's disease, namely, an increase in the 
number of large, active osteoclasts that express high levels 
of c-Fos, increased remodeling activity, and cellular trans- 
formation and tumor formation. Whether other character- 
istics are shared, for example, high BcI-2 levels in osteo- 
clasts, (") is not known for TRAP-c-fosLTR mice, but 
preliminary evidence suggests that in the remodeling osteo- 
sarcomas in H2-c-fosLTR mice, "') high levels of Bcl-2 
expression have been observed in osteoclasts (E. EI-Emir 
and A. E. Grigoriadis, unpublished observations). It is very 
clear that independent families of transgenic mice must be 
generated to determine unequivocally parameters such as 
the time of onset of transgene expression, the time of onset 
of microscopic phenotypic changes, the target cells for 
transformation in these mice, etc. Furthermore, estab- 
lishing lines of TRAP-c-fosLTR transgenic mice will also 
provide a useful tool for investigating osteoclast activity in 
vitro, for example the osteoclastogenic capacity of hemato- 
poietic spleen precursors, or by culturing cells derived 
from tumors in the presence of receptor activator of NF-KB 
ligand (RANKL) (also designated tumor necrosis factor- 
related activation-induced cytokine [TRANCE], osteopro- 
tegerin ligand [OPGLJ, osteoclast differentiation factor 
[ODF] ), (22-24) which is essential for osteoclast differentia- 
tion. It is also likely that immortalized osteoclastic cell lines 
can be established from these lesions, as has been shown for 
other oncogenes targeted to osteoclasts. (17 ) Finally, al- 
though TRAP-c-fosLTR transgenic mice cannot be consid- 
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ered as definitive models for Paget's disease, their useful- 
ness will become evident by investigating whether the 
increased osteoclast activity and remodeling defects can be 
inhibited using antiresorptive compounds such as bisphos- 
phonates, either in a preventive way, or to treat already 
formed skeletal lesions. It is becoming very clear that the 
causes of Paget's disease will be multifactorial. The genera- 
tion of TRAP-c-fosLTR mice will address only one com- 
ponent of the observed *abnormalities in Paget's disease, 
namely, the up-regulation of c-Fos, and will provide a well- 
defined, readily manipulatable system to test, the conse- 
quences of altered c-Fos expression in osteoclasts. 
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